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ABSTRACT
POLYMERSOMES: MULTI-FUNCTIONAL TOOLS FOR IN VIVO CANCER THERANOSTIC APPLICATIONS
Dalia Hope Levine
Dr. Daniel A. Hammer
Nanoparticles are currently being developed as delivery vehicles for therapeutic and contrast imaging
agents. Polymersomes (mesoscopic polymer vesicles) possess a number of attractive biomaterial
properties, including greater biocompatibility, prolonged circulation times, and increased mechanical
stability, that make them ideal for these applications. The polymersome architecture, with its large
hydrophilic reservoir and thick hydrophobic lamellar membrane, provides significant storage capacity for
water soluble and insoluble substances.
The primary thesis aims are to develop multi-functional polymersomes for combination therapeutic
applications, as well as simultaneous therapeutic and diagnostic applications. These multi-functional
vesicles are capable of simultaneously loading both therapeutic agents, such as doxorubicin and
combretastatin, and optical imaging agents, such as porphyrin-based near infrared (NIR) fluorophores,
into their hydrophobic and hydrophilic regions.
Doxorubicin, an anti-neoplastic agent, was encapsulated into PEO-b-PCL polymersomes and its release
was characterized in situ. In vitro and in vivo studies confirmed the therapeutic potential of doxorubicin
loaded polymersomes. Furthermore, the in vitro therapeutic efficacy of polymersomes loaded with
combretastatin, an anti-vascular agent, was established with and without co-doxorubicin loading. The coencapsulation of DOX and combretastatin into polymeric vesicles, generates a multi-functional drug
loaded polymersome with the potential to eliminate tumorigenic cells an endothelial cells, respectively.
The use of near infrared (NIR) emissive porphyrin polymersomes, loaded with porphyrin, for
biodistribution studies, to non-invasively track the location of the polymersomes in tumor bearing mice
was demonstrated using a noninvasive small animal optical imaging instrument which detects NIR
fluorescence signal. Passive accumulation of drug loaded NIR-emissive polymersomes in tumor tissues
of mice, as well as other organs, was observed. The study findings suggest the potential utility of NIRemissive porphyrin polymersome in clinical diagnostic applications. Furthermore, preliminary results
utilizing drug loaded porphyrin polymersomes to retard tumor growth and monitor vesicle location
suggest these vesicles may have great future clinical utility.
The ability to load components into the polymersome membrane and core shows enormous promise for
future dual modality polymersomes with potential to be nanostructured biomaterials for future
theranostic applications which provide both therapy and diagnosis.
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ABSTRACT
POLYMERSOMES: MULTI-FUNCTIONAL TOOLS FOR IN VIVO CANCER
THERANOSTIC APPLICATIONS
Dalia Hope Levine
Dr. Daniel A. Hammer
Nanoparticles are currently being developed as delivery vehicles for therapeutic
and contrast imaging agents. Polymersomes (mesoscopic polymer vesicles) possess a
number of attractive biomaterial properties, including greater biocompatibility, prolonged
circulation times, and increased mechanical stability, that make them ideal for these
applications. The polymersome architecture, with its large hydrophilic reservoir and thick
hydrophobic lamellar membrane, provides significant storage capacity for water soluble
and insoluble substances.
The primary thesis aims are to develop multi-functional polymersomes for
combination therapeutic applications, as well as simultaneous therapeutic and diagnostic
applications. These multi-functional vesicles are capable of simultaneously loading both
therapeutic agents, such as doxorubicin and combretastatin, and optical imaging agents,
such as porphyrin-based near infrared (NIR) fluorophores, into their hydrophobic and
hydrophilic regions.
Doxorubicin, an anti-neoplastic agent, was encapsulated into PEO-b-PCL
polymersomes and its release was characterized in situ. In vitro and in vivo studies
confirmed the therapeutic potential of doxorubicin loaded polymersomes. Furthermore,
ix

the in vitro therapeutic efficacy of polymersomes loaded with combretastatin, an antivascular agent, was established with and without co-doxorubicin loading.

The co-

encapsulation of DOX and combretastatin into polymeric vesicles, generates a multifunctional drug loaded polymersome with the potential to eliminate tumorigenic cells an
endothelial cells, respectively.
The use of near infrared (NIR) emissive porphyrin polymersomes, loaded with
porphyrin, for biodistribution studies, to non-invasively track the location of the
polymersomes in tumor bearing mice was demonstrated using a noninvasive small animal
optical imaging instrument which detects NIR fluorescence signal. Passive accumulation
of drug loaded NIR-emissive polymersomes in tumor tissues of mice, as well as other
organs, was observed. The study findings suggest the potential utility of NIR-emissive
porphyrin polymersome in clinical diagnostic applications.

Furthermore, preliminary

results utilizing drug loaded porphyrin polymersomes to retard tumor growth and monitor
vesicle location suggest these vesicles may have great future clinical utility.
The ability to load components into the polymersome membrane and core shows
enormous promise for future dual modality polymersomes with potential to be
nanostructured biomaterials for future theranostic applications which provide both
therapy and diagnosis.
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Chapter 1
AN INTRODUCTION TO AMPHIPHILIC VESICLES AS DELIVERY
VEHICLES AND IMAGING TOOLS AND SPECIFIC AIMS OF THE
THESIS DISSERTATION
ADAPTED FROM

Dalia Hope Levine, P. Peter Ghoroghchian, Jaclyn Freudenberg, Geng Zhang, Michael
J. Therien, Mark I. Greene, Daniel A. Hammer, and Ramachandran Murali, Methods,
2008, vol. 46, p. 25-32.
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1.1 BACKGROUND: INTRODUCTION TO POLYMERSOMES
Nanosized carriers are prime candidates for the delivery of highly toxic or
hydrophobic therapeutic agents. These delivery vehicles have the potential to augment
the pharmacodynamic and pharmacokinetic profiles of drug molecules, thereby
enhancing the therapeutic efficacy of the pharmaceutical agents [1].

Further,

encapsulating the drug molecule in a delivery system can increase in vivo stability, extend
its blood circulation time, and further provide a means for controlling the release of the
agent [1].

Moreover, the delivery system can alter the biodistribution of the drug

molecule by allowing the agent to accumulate at the tumor site, either passively or
actively with targeting [1]. In addition to their role in therapeutic drug delivery, by
serving as diagnostics tools, nanosized carriers can deliver imaging agents to detect and
non-invasively diagnose disease. Combining these two ideas, the marriage of the drug
delivery and imaging in one vehicle leads to the generation of a nanocarrier for
theranostics—therapeutics and diagnostics.
Polymersomes, polymer vesicles self-assembled from a diverse array of synthetic
amphiphilic block-copolymers containing hydrophilic and hydrophobic blocks [2-4],
have been shown to possess superior biomaterial properties, including greater stability
and storage capabilities [5-7], as well as prolonged circulation time, as compared to
liposomes (vesicles derived from phospholipids) [8]. A particularly attractive storage
feature, highlighted in Figure 1.1, is the large hydrophobic core of the polymersome
membrane, which follows from the membrane-forming amphiphilic polymers being
larger than conventional phospholipids [9]. Further, block copolymer chemistries can be
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tuned through polymer synthesis to yield polymersomes with diverse functionality [10].
A vast majority of vesicles made of synthetic copolymers have dense
polyethylene oxide (PEO) outer shells, which affords them “stealth” like character that
may lead to increased circulation times and in vivo biocompatibility [5]. Thus, although
liposomes are presently used in various biotechnological and pharmaceutical applications
to improve therapeutic indices and enhance cellular uptake [4], it appears that
polymersomes can offer superior advantages for future clinical therapeutic and diagnostic
imaging applications.
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Figure 1.1- Schematic representations of NIR-emissive polymersomes.
(A) In aqueous solution, amphiphilic diblock copolymers of polyethyleneoxide-1,2
polybutadiene (PEO30-PBD46) self-assemble into polymer vesicles (polymersomes)
with the hydrophobic PBD tails orienting end-to-end to form bilayer membranes.
The depicted unilamellar polymersome displays an excised cross-sectional slice
illustrating the bilayer PBD membrane (gray) containing the hydrophobic
(porphinato)zinc(II) (PZn)-based near-IR fluorophores (NIRFs, red). (B) CAChegenerated sectional schematic of the NIR-emissive polymersome membrane
indicating the molecular dimensions of: (i) the PBD component of the bilayer (9.6
nm); (ii) the large, dispersed PZn-based NIRFs (2.1-to-5.4 nm); and, (iii) a typical
liposome membrane (3-4 nm) comprised of phospholipids (1-stearoyl-2-oleoyl-snGlycero-3-Phosopho-choline – SOPC). (C) Chemical structures of NIR fluorophores
PZn2-PZn5. Copyright (2005) National Academy of Sciences, U.S.A. [9]
In aqueous solutions, amphiphilic block copolymers can self-assemble into
mesoscopic structures (≤200nm-50µm in diameter) [3].

The ratio of hydrophilic to

hydrophobic block volume fraction determines whether micelles (spherical, prolate, or
oblate), or vesicles (polymersomes) will form [2, 11-13]. As a general rule, however, a
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ratio of hydrophilic block to total polymer mass of approximately ≤ 35% ± 10% yields
membrane structures, while copolymers with ratios greater than 45% generally form
micelles; those with ratios less than 25% form inverted microstructures [14].

Micellar

structures have been used as intracellular and systemic delivery systems [15-18] but
present significant limitations when compared to polymersomes. In aqueous solutions,
they can only encapsulate hydrophobic molecules unless strong binding or covalent
linking strategies are incorporated for sequestering aqueous-soluble components.
In contrast to micelles, polymersomes can simultaneously encapsulate hydrophilic
components in their aqueous interior and hydrophobic molecules within their thick
lamellar membranes [10]. In addition, biologically active ligands, such as antibodies, can
be readily conjugated to the exterior brush surface to target the vesicles or to provide a
therapeutic response [19-22]. These properties of the vesicle architecture (Figure 1.2)
effectively create a multimodal platform, which can be used for therapeutic (drug
delivery) and/or diagnostic (imaging) applications.
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Figure 1.2- General application of polymersome architecture in theranostics.
Schematic representation of polymersome assembly illustrating three possible
applications, namely optical imaging, drug delivery, and targeted- therapy.
Although vesicles can be targeted to specific sites using biologically active
ligands, the anatomical and pathophysiological abnormalities of tumor tissue alone can be
utilized to aid in the localized delivery of macromolecules [23]. The tumor vasculature,
characterized by irregularly shaped, dilated, defective, and/or leaky blood vessels,
disorganized endothelial cells with fenestrations, as well as other abnormalities, allows
for the passive accumulation of macromolecules at the tumor site [24]. Further, due to
poor lymphatic drainage, nanoparticles can accumulate and remain at the tumor site even
in the absence of a targeting moiety [25]. This phenomenon is known as the enhanced
permeability and retention (EPR) effect and makes it possible to achieve high local
concentrations of macromolecules at the tumor site without specific targeting [24].
However, a question that has yet to be addressed with polymersomes is how much
6

additional accumulation is possible with targeting.

1.2 DIBLOCK CO-POLYMERS

AND

AMPHIPHILIC MOLECULES FORMING

VESICLES AND RELEASE MECHANISMS
In addition to yielding robust multi-compartment vesicles, some of block copolymer formulations that have demonstrated promise for controlled release of
pharmaceuticals.
Initial polymersome research by Hammer and Discher used poly(ethylene oxide)block-poly(ethylethylene) (PEO-b-PEE) diblock copolymers to demonstrate the
formation of polymersomes in aqueous solution, as well as to characterize the vesicle’s
material and physical properties [3]. Additional work in the field has led to the synthesis
of a number of biocompatible PEO-based amphiphilic block copolymers that form
aqueous vesicles dispersions, including poly(ethylene oxide)-block-poly(butadiene)
(PEO-b-PBD) [7].
A significant limitation of these polymers for in vivo therapeutics is that they are
not biodegradable and likely not fully biocompatible. In an effort to create vesicles that
degrade and release their contents in vivo, PEO-b-PBD polymers have been blended with
hydrolysable block copolymers, such as poly(ethylene oxide)-block-poly(lactic acid)
(PEO-b-PLA) or poly(ethylene oxide)-block-poly(caprolactone) (PEO-b-PCL); these
vesicles have been shown to undergo hydrolytic degradation intracellularly (in the acidic
environment of the endolysosomal compartment), leading to release of the
polymersomes’ encapsulates [26-28]. Cryo-TEM images and dynamic light scattering
measurements serve to demonstrate that nanoscale phase transitions occur in these blends
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as the polyester backbone of the vesicles’ hydrolytic components degrade over time; the
intact vesicle begins to form pores, which leads to the transition to worm-like micelles
and ultimately leads to the formation of spherical micelles [27]. Further, it has been
shown that the release rate of encapsulates in blended polymersomes increases linearly
with increasing mole ratio of hydrolysable polymer [26]. While these studies represent a
reasonable first step in the development of polymersomes for therapy, it is critical to
overcome the hurdle of in vivo toxicity presented by the residual PEO-b-PBD in these
structures.
Recently, efforts in our group have focused on the development of self-assembled
polymersomes from fully-biodegradable synthetic amphiphiles. The ability to generate
self-assembled, fully-bioresorbable vesicles comprised of an amphiphilic diblock
copolymer consisting of two previously FDA-approved building blocks, poly(ethylene
oxide) (PEO) and poly(caprolactone) (PCL), has been demonstrated by Ghoroghchian
and coworkers [10]. Unlike polymersomes formed from the blending of “bio-inert” and
hydrolysable block copolymers [26], these fully-bioresorbable PEO-b-PCL vesicles
undergo acid catalyzed hydrolysis of their ester linkages and degrade without leaving any
potentially toxic byproducts [10, 29]. We have demonstrated the release of doxorubicin
from these systems with time-constants of 18-24 hours, depending on pH; in vivo testing
of these polymersomes for delivery is underway as further discussed in Chapter 2.
In contrast to acid catalyzed hydrolysis of the polymer backbone, which occurs on
the order of hours to days, pH triggered contents release, using block copolymers whose
solubility in aqueous solutions is dependent upon solution pH, can occur much more
8

rapidly [30]. Borchert and colleagues generated polymersomes comprised of poly(2vinylpyridine)-block-poly(ethylene oxide) (P2VP-b-PEO) copolymers and showed that
the resultant vesicles disassemble in acidic solutions and quickly and completely release
their contents; this dissolution is due to the protonation of the P2VP block in acidic
solutions (below pH 5) which converts the previously hydrophobic block into a water
soluble polymer [30].
Cerritelli and colleagues have designed and characterized a diblock copolymer of
poly(ethylene glycol) (PEG) and poly(propylene sulfide) (PPS) with a reduction sensitive
disulfide link between the two blocks (PEG-SS-PSS); they demonstrated the ability of
this block copolymer to form polymer vesicles which burst within a few minutes of
endocytosis due to the reductive environment in the endosome [31]. In addition to
diblock copolymers, various other polymeric amphiphiles can form vesicles in aqueous
solutions. Napoli et al. synthesized a triblock copolymer of poly(ethylene glycol)-blockpoly(propylene sulfur)-block-poly(ethylene glycol) (PEG-b-PPS-b-PEG) [32], which at
dilute concentrations forms polymeric vesicles [33, 34]. Napoli and colleagues then
demonstrated that vesicles comprised of this triblock copolymer could be destabilized by
the oxidation of the hydrophobic PPS block; when oxidized, PPS is first converted to
poly(propylene sulphoxide) and subsequently converted to poly(propylene sulfone), both
of which are more hydrophilic than PPS [35]. This change in hydrophobicity of the
“hydrophobic” block alters the ratio of hydrophobic block to total polymer mass, leading
to changes in morphology of the self-assembled structures from vesicles, to worm-like
micelles, to spherical micelles, and finally to unimolecular micelles [35].
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These

polymers present the promise of biodegradability, due to oxidation of the hydrophobic
chain into small molecules solutes that can be readily cleared [32].
Another possibility to generate fully biodegradable vesicles is to utilize
polypeptides as their composite amphiphiles. Vesicles and micelles comprised of
polypeptide block copolymers can mimic the shape and biological performance of natural
vesicles and micelles [36]. Sun et al. synthesized various diblock copolypeptides of
poly(L-lysine)-block-poly(L-phenylalanine) (PLL-b-PPA) which spontaneously selfassemble into giant vesicles in aqueous solutions [36].
In addition to vesicle generation using block co-polymers, amphiphilic Janusdendrimers have demonstrated the ability to self-assembly into regular structures ranging
from dendritic spherical vesicles to cubosomes.

The mechanical stability of the

dendrosomes suggest they may be useful for in vivo applications.

1.3 THERAPEUTIC APPLICATIONS OF POLYMERSOMES
Currently, many compounds with toxic side effects or low bioavailability hold
extraordinary promise as potential therapeutic agents. However, limited bioavailability
of hydrophobic compounds and/or toxic side effects of these molecules can render their
therapeutic value ineffective. Further, the ability of the therapeutic agents to reach the
target site can be limited by the body’s clearance.

Thus, the development of a

polymeric delivery vehicle with specifically tuned pharmacokinetics, which can
encapsulate and release highly toxic therapeutic agents for concentrated local delivery,
should greatly increase therapeutic efficacy.
Doxorubicin (DOX) is an amphipathic anti-neoplastic agent that shows much
10

promise in cancer therapy, both alone and in conjunction with antibodies and peptides
[37] and other chemotherapeutics [27] and pharmaceuticals [38]. One of the major
limitations associated with administration of this chemotherapeutic agent is cardiac
myocyte toxicity [39].

However, utilizing drug carriers to deliver doxorubicin can

alleviate some of the associated cardio-toxicity by altering the pharmacodistribution of
the drug, thereby reducing the drug concentration in the heart [39].

Delivery of

doxorubicin in liposomes has been shown to extend the circulation time and alter the
pharmacodynamics of doxorubicin in such a way as to decrease its toxicity while still
maintaining its anticancer activity [39].

Using active loading methods originally

developed for liposomes, doxorubicin can be efficiently loaded into the aqueous center
[10, 26, 40] of polymer vesicles.
Paclitaxel (taxol), an anticancer agent, whose therapeutic efficacy is limited by its
poor aqueous solubility [41] is currently administered in a mixture of Cremophor EL
(polyoxyethylated castor oil) and dehydrated ethanol [42] to increase bioavailability.
Systemic administration of taxol is associated with several negative side effects in
patients including dyspnea, hypotension, bronchospasm, urticaria, and erythematous
rashes [42]. In addition, the formulation agent (Cremophor EL) used to solubilize the
hydrophobic taxol is believed to be responsible for inducing the hypersensitivity
reactions observed in patients [42]. As a result, various aqueous formulations of taxol
have been examined to decrease toxic side effects and increase water solubility. Li et al.
demonstrated the ability to load taxol into the hydrophobic bilayer of PEO-b-PBD
polymer vesicles and thus increase the water solubility of this drug while maintaining its
cytotoxic properties [43].
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Combination therapy involves the administration of different classes of
chemotherapeutics to a patient in order to treat the disease; this approach has been shown
to be generally effective and many cancer treatment regimes employ such multi-drug
therapy. A combination regime of DOX and TAX has been shown clinically to retard
tumor growth more effectively in comparison to the administration of a single agent
alone [44]. A reasonable hypothesis is that the synergistic effect of these two drugs
would be increased when both drugs are administered in the same delivery vehicle, as
this would ensure delivery of the drug molecules in prescribed ratios to a given target at
the same time; Ahmed et al. demonstrated the ability to co-encapsulate DOX and TAX
into polymer vesicles and showed the increased synergistic effect when DOX and TAX
are in the same polymersome [27, 28].

PEG-b-PLA/PEG-b-PBD blended polymer

vesicles were loaded with DOX in their hydrophilic reservoir and TAX in their
hydrophobic bilayer, and were administered in vivo; the results demonstrate a higher
maximum tolerated dose (MTD), as well as increased tumor shrinkage and maintenance,
when both agents are administered in vesicles rather than as free drugs [27]. Since there
are a wide variety of both hydrophilic and hydrophobic pharmaceuticals, this paradigm is
generally applicable to creating other polymersome-formulations for combination
therapy. Ultimately, as mentioned before, further work to combine these pharmaceuticals
within a safe and fully biodegradable formulation is necessary.
In addition to small molecules, peptides, proteins, and nucleic acids have been
encapsulated in block copolymer assemblies.

Lee et al. successfully encapsulated

myoglobin, hemoglobin, and albumin in PEO-b-PBD based polymer vesicles at varying
degrees of encapsulation efficiency [5]. Arifin and Palmer further demonstrated that
12

bovine hemoglobin (Hb) could be encapsulated inside PEO-b-PBD polymer vesicles with
oxygen affinities similar to those of human red blood cells; they demonstrated that these
“polymersomes-encapuslated hemoglobin” (PEH) dispersions could store and transport
Hb and potentially act as in vivo oxygen therapeutics [45]. The ability to encapsulate
proteins within polymersomes provides a promise for future protein therapies, which are
currently facing delivery obstacles.

1.4 DIANGNOSTIC APPLICATIONS FOR POLYMERSOMES
The ability to non-invasively image nanoparticles in vivo is a major advantage in
determining their biodistribution and developing these delivery vehicles for both
therapeutic and diagnostic applications. Biodistribution studies with polymersomes, in
particular, would be greatly aided by the encapsulation of an imaging agent in the
vesicles; this would enable non-invasive monitoring of the location of vesicles during
drug delivery without the need to sacrifice the animal. Although nanoparticles have been
used with a spectrum of different imaging modalities including PET [46, 47] and MRI
[48-50], here we will focus on polymersomes that encapsulate fluorescent agents for
optical imaging. Because light scattering decreases with increasing wavelength, and
hemoglobin and water absorption spectra have their nadir in the near infrared (NIR)
spectral region, much work has been focused on developing NIR contrast agents for in
vivo imaging studies [9]. To this end, Ghoroghchian et al. have successfully loaded
porphyrin-based near infrared fluorophores (NIRFs) into the hydrophobic bilayer
membranes of PEO-b-PBD [9, 10, 51, 52], PEO-b-PCL [52], PEO-b-PEE [52], and
poly(ethylene

oxide)-block-poly(methylcaprolactone)
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(PEO-b-PmCL)

[52]

polymersomes.
Studies using PEO-b-PBD polymersomes have shown that porphyrin-based
NIRFs, when encapsulated in polymersomes, are able to generate a signal with enough
intensity to penetrate through 1 cm of a solid tumor [9]. Further, when these NIRemissive nanopolymersomes are injected into the tail-vein of mice, the biodistribution of
the nanoparticles can be tracked in vivo via non-invasive NIR fluorescence-based optical
imaging [53]. Combining drug delivery with imaging will allow for the continuous noninvasive monitoring of drug-loaded nanopolymersomes in vivo, obviating the need to
sacrifice animals at each time point to determine basic pharmacokinetic and
biodistribution profiles, thereby greatly reducing animal load.
In addition to developing drug delivery applications, NIR-emissive polymersomes
have also been shown to be useful for ex vivo cellular labeling and in vivo cellular
tracking. Dendritic cells (DCs) play an important role in the immune response and have
shown potent anticancer activity, leading to DC-based vaccines research [54]. Current
progress in DC-based vaccines has been, however, limited by various factors [54], some
of which could be overcome by the development of imaging methods for in vivo DC
tracking [19]. Christian et al. have demonstrated the ability to label DCs ex vivo with
polymersomes encapsulating porphyrin-based NIRFs; the TAT peptide, as will be
discussed in greater detail below, was conjugated to these NIR-emissive polymersome to
facilitate efficient uptake of polymer vesicles by DCs [19]. Christian and colleagues
determined that DC surface-associated polymersomes shed over the first 24 to 48 hours;
but polymer vesicles that were fully internalized by the DCs remained stably incorporated
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over 3 days [19]. They further showed that the NIR-emissive-polymersome-labeled DCs,
when administered into the foot pad of mice, traffic to the nearest lymph node (popliteal
lymph node) and could be tracked in vivo via optical imaging over 33 days [55]. They
further showed that dendritic cells are sequestered in the liver when the cells are
delivered intravenously (42), indicating that the mode of dendritic cell delivery will be
critical for the effectiveness of cancer immunotherapy.

These results suggest that

polymer vesicles can be employed for cell tracking in longitudinal studies and could thus
assist in the further development of cell-based vaccines. Overall, the results in this
section demonstrate that the loading of imaging agents, such as porphyrin-based NIRFs,
into the polymersome bilayer creates soft matter optical imaging agents suitable for in
vitro

diagnosis

and

deep-tissue

imaging,

non-invasive

biodistribution

and

pharmacokinetic studies, as well as in vivo cellular tracking.
An alternative imaging modality that can be used to image polymer vesicles is
diagnostic ultrasound.

Zhou et al. prepared air-encapsulated polymersomes via

lyophilization and rehydration of previously formed polymer vesicles [56]. The polymer
bubbles were imaged using a Pie Medical Scanner 350 and were visualized as bright
spots, validating the acoustic activity of air-encapsulated polymersomes [56]. These
results show that polymer vesicles hold promise in the realm of ultrasound imaging as
well as optical imaging.

1.5 POLYMERSOME SURFACE MODIFICATIONS FOR ENHANCED DELIVERY
AND THERAPY

Biologically-active molecules conjugated to the surfaces of polymersomes can be
15

used to direct these nanoparticles to sites of disease and inflammation.

Modifying

polymer vesicles with biological ligands enables targeting of upregulated receptors and
molecules on affected cells in vitro and in vivo, thereby enhancing the nanoparticles’ EPR
effect and further mitigating the potential toxic side effects of systemic delivery.
Additionally, chemotherapeutics, when used in conjunction with molecular targeting
agents, can have a synergistic effect [57]. In addition to therapeutic applications, over the
past two decades the use of anticancer antibodies against molecular targets has been
developed for tumor imaging applications [37]. Polymer vesicles can be directed to
specific sites in vivo by conjugation of targeting moieties to the end group of their
hydrophilic polymer block (usually PEO).

It is important to recognize that the

conjugation of ligands to the polymersome surfaces can alter the composite polymer
amphiphiles’ hydrophilic-block-to-total-mass ratio leading to a change in structural
morphology (e.g. from vesicles to micelles).
Using a modular biotin-avidin chemistry, Lin and colleagues functionalized
polymer vesicles with anti-ICAM-1 antibody to target ICAM-1 (intercellular adhesion
molecule-1) [21], a molecule that is upregulated on endothelial cells during
inflammation. Using micropipette aspiration, they measured the adhesiveness of these
functionalized polymer vesicles to ICAM-1 immobilized on the surface of polystyrene
beads and determined that the adhesion strength is linearly proportional to the surface
density of the anti-ICAM-1 molecules on the polymersome [21]. This finding is in
contrast to their earlier adhesion experiments carried out with functionalized biotinylated
polymersomes and avidin coated beads [22], suggesting that the adhesiveness of
functionalized vesicles is not only dependent on surface density, but also upon the
16

presentation/orientation of the targeting molecules on the vesicle surface [21].
Additionally, sialyl lewisX (sLeX), a selectin ligand, has been conjugated to
polymer vesicles using similar biotin-avidin modular chemistry as previously described
(Hammer et al., in press, Faraday-Discussions 139). In addition to ICAM-1 molecules,
selectins are also upregulated at sites of inflammation [21].

In an effort to create

“leukopolymersomes,” i.e. polymersomes that mimic the adhesive properties of
leukocytes, dual functionalized vesicles of sLex and anti-ICAM-1 have been made by the
Hammer lab. The investigators were able to measure firm and rolling adhesion of antiICAM-1-, sLex-, and anti-ICAM-1/sLex conjugated polymersomes under flow along
ICAM-1, P-selectin, and ICAM-1/Pselectin coated surfaces, respectively, at venous shear
rates. It is believed that dual functionalized leukopolymersomes will be able to serve as
targeting agents to bring both therapeutics (drugs) and diagnostics (imaging agents) to
sites of inflammation [21].
Meng and co-workers functionalized polymersomes comprised of PEG-blockpoly(ester) and PEG-block-poly(carbonate) diblock copolymers with anti-human IgG (aHIgG) or anti-human serum albumin (a-HSA) [6].

a-HIgG and a-HSA were either

conjugated to the polymersome through covalent attachment to carboxyl groups on the
vesicle surface or by attachment to protein G, which was covalently attached to the
polymersome surface via the carboxyl groups; using imaging surface plasmon resonance
(iSPR), they determined that immobilization of antibodies on the vesicle surface through
protein G is preferred for targeting [6]. iSPR was further used to demonstrate the
potential of antibody functionalized vesicles for targeting antigens [6].
In addition to targeting, these biologically active ligands can aid in cellular uptake
17

[58]. As previously mentioned, Christian et al. demonstrated that the highly cationic
HIV-derived TAT peptide, when coupled to NIR-emissive polymersomes, enhances
cellular delivery of polymer vesicles to dendritic cells while moderately affecting cell
viability [19].

Intracellular uptake of polymersomes was dependent upon their

concentration and incubation time in solution; viability was affected by these factors as
well [19].
We have recently attempted to conjugate small anti-HER2/neu peptidomimetics,
designed by Murali and coworkers [57], to polymersomes in order to further develop
these

nanoparticles

for

both

clinical

breast

cancer

diagnosis

(NIR-emissive

polymersomes) and therapy (e.g. with and without doxorubicin incorporation).

In

comparison to normal epithelial tissues, over-expression of the HER2 protein, a member
of the epidermal growth factor (EGFR) or HER family, has been seen in approximately
30% of breast, ovarian, and colon cancers [37, 57]. A family of anti-HER2/neu peptides
(AHNPs) designed by Murali et al. has a potency on par with that of the full-length
monoclonal antibody (Herceptin®; Genentech, San Francisco, CA) and demonstrates
biochemical and biological properties predictive of clinical therapeutic response [57]. It
has been demonstrated that AHNP prevents tumor growth of transformed T6-17 cells, in
which HER2/neu is over-expressed, in vivo and in vitro [57]. However, the relatively
short half-life of peptides and proteins in vivo is one challenge that still remains to be
overcome when using such agents for therapeutic applications [59]. To overcome the
challenge of rapid clearance, “stealth” or “sterically stabilized” nanoparticles, such as
pegylated liposomes, have been employed to deliver peptides [60]. Thus, linking AHNP
to a nanoparticle surface can greatly improve the pharmacokinetics of the small peptide
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and allow for targeting as well as improved therapeutic efficacy.
Ghoroghchian et al. observed changes in polymersome morphology from vesicles
to micelles post-conjugation of the AHNP peptides to PEO-b-PBD vesicles [53].
Vesicles, as well as small spherical micelles, not present in aqueous suspensions of the
functionalized and unfunctionalized diblock copolymer without peptide, were observed in
the polymersome suspension post AHNP conjugation [53]. Since these micelles were not
seen in cryoTEM images of the pure or unfunctionalized polymer, it is probable that they
are comprised of peptide-conjugated polymer; furthermore, it is hypothesized that the
vesicles in the suspension consist of polymer not conjugated to AHNP peptide [53].
Peptide-conjugated vesicle generation with less hydrophobic AHNP peptide family
members were also attempted and again resulted in phase separation of the diblock
copolymer-peptide “triblock” from the diblocks [53]. Our interpretation of these results
is that the underlying polymer material needs to be redesigned to accommodate peptides
and preserve vesicular structure in order to develop AHNP polymersomes fit for clinical
diagnostic and therapeutic applications.

1.6 FUTURE DIRECTIONS
Polymersomes are new and valuable tools for both disease diagnosis and therapy.
Our view is that the enhanced stability and tunability of polymersomes will ultimately
lead to the development of effective carriers for in vivo drug delivery, molecular imaging,
and cellular mimicry that extend well beyond what has thus far been achieved with
phospholipid vesicles.
In pharmacodelivery, the potential to co-encapsulate two drug molecules in the
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same polymersome enables combination therapies and eliminates the need to individually
administer two separate drug formulations. As such, polymersome may not only be more
effective in treating recurrent, resistant, or residual tumors, but may also be more
convenient for patient administration and treatment tolerance. It is also possible to make
separate polymersome formulations, each with different drugs or with different dosing
that deliver drugs in a sequence, as needed for the particular type of disease that is being
treated. Additionally, localizing therapeutics to the site of intent, either through passive
accumulation (EPR effect) or with targeting ligands, can enable administration of higher
doses of drug while minimizing the toxic side effects of systemic delivery. Further, the
ability to image polymer vesicles during delivery will offer numerous advantages for
understanding the mechanisms of therapy as well as efficiently designing drug delivery
regimens in small animal models. Aside from the demonstration of the activity of multimodal polymersomes with existing block copolymers, we believe that further
developments in polymer design will extend the applicability of polymersomes to
different drugs and imaging modalities.
In addition to targeted therapeutic drug delivery, targeting ligands can be used to
direct diagnostic agents to tumors sites, assisting in in vivo diagnostic imaging. Airencapsulated polymeric vesicles facilitate nanodiagnostics using ultrasound. Further, the
encapsulation of both porphyrin-based near-infrared fluorophores and air into the same
vesicle should yield a multi-modal polymersome, where both ultrasound and optical
imaging can be performed concurrently thereby enhancing tumor imaging. Finally, we
have presented evidence that ultrasonics can be used as a delivery tool; and, thus, we see
promise for simultaneous clinical diagnostic imaging and in vivo therapeutic drug
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delivery with the correct polymer formulations.

1.7 SPECIFIC AIMS
1.7.1 Aim 1:

To load physiologically relevant therapeutic molecules and imaging

agents into the fully bioresorbable polymersome center and thick lamellar membrane
and characterize the kinetics of drug release from the polymersome
•

Aim 1.a) Load clinically relevant anti-cancer therapeutic into the hydrophilic
interior of the polymersome and characterize the kinetics of drug release from the
core.

•

Aim 1.b) Load clinically relevant anti-angiogenic therapeutic/vascular disrupting
agent (VDA) into the hydrophobic bilayer.

•

Aim 1.c) Co-load both therapeutic agents into one polymersome for the
simultaneous delivery of a vascular disrupting agent and chemotherapeutic.

•

Aim 1.d) Co-encapsulate a therapeutic agent, doxorubicin, into the vesicle core
and a near infrared imaging agent, porphyrin into the bilayer of the same
polymersome for biodistribution studies.

1.7.2 Aim 2: To demonstrate the potential use of amphiphilic Janus-dendrimers for in
vivo drug delivery applications
•

Aim 2.a) Load doxorubicin, an anti-neoplastic agent, into the aqueous core of
dendrosomes, vesicles self assembled from dendrimers and characterize the
release.

•

Aim 2.b) Determine the dendrosome effects on cell viability using Human Vein
Endothelial Cells (HUVECs).
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1.7.3 Aim 3. To use the drug loaded polymersome and porphyrin incorporated
polymersomes to study the in vitro effects of polymersomes using HUVECs and SKBR-3 tumorigenic cells
•

Aim 3.a) Determine the effects of unloaded polymersome on cell viability.

•

Aim 3.b) Determine the cellular uptake of polymersome by HUVECs and SKBR-3 Cells.

•

Aim 3.c) Determine the effects of drug loaded polymersomes on cell viability
when cultured separately and in co-culture.

1.7.4. Aim 4. To demonstrate the in vivo potential of polymersome for imaging and
drug delivery applications using athymic nude mice with xenograft tumors
•

Aim 4.a) Determine the biodistribution of polymersome and establish their in vivo
potential as imaging agents for in vivo deep tissue optical imaging.

•

Aim 4.b) Demonstrate the anti-tumor effect of drug loaded polymersomes on
tumor suppression in vivo.

•

Aim 4.c) Highlight the potential of drug and imaging agent loaded vesicles for
theranostic applications.

1.8 ORGANIZATION OF THE THESIS
1.8.1 Chapter 1
This chapter provides a brief introduction into the various vesicles self assembled
from diblock copolymers and other amphiphilic building blocks, such as dendrimers.
Particular detail is given to polymersomes self assembled from diblock copolymers. The
motivation for development and characterization of these vesicles is elaborated upon by
describing their potential for therapeutic applications through delivery of pharmaceutical
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agents within the core and bilayer and attachment of biologically active ligands to the
brush surface. Furthermore, the use of vesicles for diagnostic applications is discussed
and provides additional motivation for their development as biological tools. Lastly, the
potential for these vesicles to combine both therapy and diagnosis into one vesicles is
briefly discussed. These ideas will be further explored throughout the body of this thesis.
1.8.2 Chapter 2
The generation of a fully bioresorbable polymersome capable of simultaneously
delivering a vascular disrupting agent, combretastatin, and a chemotherapeutic,
doxorubicin, is described. Furthermore, the method of loading doxorubicin into vesicles
self-assembled from a variety of diblock copolymers and its release are discussed. The
ability to encapsulate each pharmaceutical agent separately as well as in concert is
highlights the enormous promise for using polymersomes as multi-drug delivery agents
for the eradication of tumorigenic cells and endothelial cells.
1.8.3 Chapter 3
The formation of self-assembled monodispersed vesicles from amphiphilic Janusdendrimers, dendrosomes, is introduced. In addition, the ability to load doxorubicin into
these vesicles is demonstrated and the release kinetics of the drug at various pHs is
established. Furthermore, the viability effects of these dendrosomes on HUVECs were
investigated and viability results demonstrate that the uptake of dendrosomes is well
tolerated by the HUVECs at short times.
1.8.4 Chapter 4
This chapter discusses the generation of a near infrared (NIR) emissive
polymersome, a self-assembled polymer vesicles loaded with porphyrin in its
23

hydrophobic compartment and highlights the special properties of these fluorophores that
render them useful for in vivo deep tissue optical imaging applications. Furthermore, the
loading of doxorubicin into porphyrin incorporated polymersomes is demonstrated and its
release is characterized.

Subsequent chapters will demonstrate the significance of

loading both an imaging agent and chemotherapeutic into one vesicles for in vivo
applications.
1.8.5.Chapter 5
Cellular studies carried out using Human Umbilical Vein Endothelial Cells
(HUVECs) and SK-BR-3 tumorigenic cells to determine the cytotoxic potential of drug
loaded vesicles are discussed in this chapter. In addition, the effects of unloaded vesicles
on cellular viability were investigated and results are presented. Furthermore, the cellular
uptake of vesicles was explored using porphyrin loaded polymersomes and the findings
are noted in this chapter.
1.8.6 Chapter 6
The use of porphyrin polymersome for biodistribution and diagnostic studies is
demonstrated using biocompatible and bioresorbable polymersomes. Initial studies over
12 hours to 9 days utilized the biocompatible polymersome comprised of PEO-b-PBD
due to its in vivo stability (i.e. does not degrade in vivo). More recent work showed the
ability to use bioresorbable polymersomes generated from PEO-b-PCL diblock
copolymer for imaging purposes. Furthermore, the use of drug loaded vesicles for in vivo
applications was investigated using doxorubicin loaded PEO-b-PCL polymersomes and is
described. Lastly, this chapter closes by marrying the two concepts—imaging and drug
delivery highlighting the promise for polymersomes as theranostic agents.
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1.8.7 Chapter 7
This final chapter summarizes and highlights many of the findings discussed
throughout the work presented in the previous chapters. Preliminary and promising
results presented are presented in further detail. Finally, this chapter offers suggestions
for improving and expanding upon the utility of polymersomes in vivo as drug delivery
vehicles and imaging agents with the final goal of obtaining multi-functional vesicles for
in vivo dual therapeutic and theranostic applications.
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2.1 SUMMARY
Polymersomes (polymer vesicles) have attractive biomaterial properties compared
to phospholipid vesicles, including prolonged circulation times, increased mechanical
stability, and the unique ability to incorporate hydrophobic molecules within their thick
lamellar membranes and hydrophilic molecules within their core [5-8]. The generation of
self-assembled nano-sized vesicles from various diblock copolymers has been
demonstrated.

The attractive biomaterial properties of these vesicles make the

polymersome a prime vehicle for the delivery of pharmaceutical agents to tumors.
Currently, new thought into cancer treatment suggests the use of combination
therapy as a method to improve the anti-tumor effects of chemotherapeutics. Such
combinations can include multiple chemotherapeutics, chemotherapeutics and peptides or
antibodies, or chemotherapeutics and anti-angiogenesis agents or vascular disrupting
agents (VDA).
Doxorubicin, an anthracycline antibiotic, is currently used in the treatment of a
variety of cancers ranging from solid tumor to leukemias. However, one of the major
therapeutic limitations of doxorubicin is its associated cardiotoxicity at cumulative doses.
Encapsulating doxorubicin in the aqueous core of vesicles, however, may decrease the
toxicity. The ability to load doxorubicin into biocompatible, bioresorbable, as well as
stabilized vesicles is demonstrated.
Combretastatin A4, a VDA, has been shown to cause vascular failure in new
vasculature around solid tumors, while not affecting healthy vasculatures. But, this
molecule is hydrophobic, limiting its bioavailability and creating challenges to delivery.
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The incorporation of combretastatin in the hydrophobic vesicle bilayer, however, can
assist with delivery.

Its incorporation into bioresorbable vesicles with and without

doxorubicin will be explored in this chapter.
Here, we demonstrate the ability to encapsulate each pharmaceutical agent
separately as well as in combination, thereby highlighting the enormous promise for
using polymersomes as multi-drug delivery agents for the eradication of tumorigenic
cells and endothelial cells.

2.2 INTRODUCTION
Currently, many compounds with toxic side effects or low bioavailability hold
extraordinary promise as potential therapeutic agents. However, limited bioavailability
of hydrophobic compounds and/or toxic side effects of these molecules can render their
therapeutic value ineffective. Further, the ability of the therapeutic agents to reach the
target site can be limited by the body’s clearance. Thus, the development of a polymeric
delivery vehicle with specifically tuned pharmacokinetics, which can encapsulate and
release highly toxic therapeutic agents for concentrated local delivery, should greatly
increase therapeutic efficacy.
As discussed in Chapter 1, presently liposomes, vesicles derived from
phospholipids, are used in a limited number of biotechnological and pharmaceutical
applications to improve therapeutic indices and enhance cellular uptake [4]. However, in
contrast to liposomes, polymersomes, polymer vesicles self-assembled from synthetic
amphiphilies, have been shown to possess superior biomaterial properties [5, 6, 8]. Selfassembled from amphiphilic polymers, with hydrophilic and hydrophobic blocks,
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polymersomes can encapsulate aqueous components in their interior and hydrophobic
molecules within their thick lamellar membranes.
The ability to load components into the membrane and interior of polymersomes
shows enormous promise for dual modality polymersomes that enable delivery of two
therapeutic agents as will be discussed in this chapter or a therapeutic agent and imaging
agent as will be discussed in Chapter 4. As a proof of concept, we have successfully
loaded various hydrophobic molecules, i.e. Nile Red, into the bilayer as well as various
hydrophilic molecules, i.e. Calcein, into the aqueous core[10]. Additionally, we have
successfully loaded both hydrophilic and hydrophobic molecules simultaneously into the
same polymersomes [10].
While the ability to load therapeutics into biocompatible polymeric vesicles, such
as those generated from PEO-b-PBD, is crucial for understanding and comparing the
loading and release kinetics of the drug from vesicles, the ability to load pharmaceutical
agents into bioresorbable polymers is paramount if these vesicles are to be used for in
vivo drug delivery.

Recently, much attention has been focused on developing

polymersomes composed of fully-bioresorbable polymers. The ability to generate selfassembled, fully-bioresorbable vesicles comprised of an amphiphilic diblock copolymer
consisting of two previously FDA-approved building blocks: poly(ethylene oxide) (PEO)
and polycaprolatone (PCL) has been demonstrated [10]. Unlike polymersomes formed
from the blending of “bio-inert” and hydrolysable block copolymers [26], these fullybioresorbable vesicles leave no potentially toxic byproducts upon degradation [29].
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In addition to generating vesicles that are biocompatible and biodegradable, the
ability to stabilize the membrane and control the release of the vesicles contents, is
imperative for the controlled release of many chemotherapeutics with a narrow
therapeutic window. While previous work has demonstrated the stabilization of
polymersome membranes [61-66] we aimed to design stabilized polymersomes that are
also biodegradable. To that end, a functional group (i.e. acrylate) was incorporated at the
PCL terminal end of PEO-b-PCL diblock polymers.
Doxorubicin (DOX) is an amphipathic anti-neoplastic agent that shows much
promise in cancer therapy, both alone and in conjunction with antibodies and peptides
[37]. Currently, DOX is widely administered for the treatment of various types of cancer
ranging from solid tumors to leukemias [67-70]. One of the major limitations associated
with administration of this chemotherapeutic agent, however, is cardiac myocyte toxicity
[39]. However, utilizing drug carriers to deliver doxorubicin can alleviate some of the
associated cardio-toxicity; drug carriers alter the pharmacodistribution of the drug and
thus reduce the drug’s concentration in the heart [39].

Delivery of doxorubicin in

liposomes has been shown to extend the circulation time and alter the pharmacodynamics
of doxorubicin in such a way as to decrease its toxicity while still maintaining its
anticancer activity [39].

Using active loading methods originally developed for

liposomes, doxorubicin can be efficiently loaded into the aqueous center [10, 26, 40] of
polymer vesicles.
Combination therapies, involving the combination of various chemotherapeutics
for cancer treatment, have proven very effective and in fact many cancer therapies now
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include a multi-drug regimen. However, therapies that use a Maximum Tolerated Dose
(MTD) approach, whereby the highest tolerated dose of chemotherapeutic is administered
as a single dose or over a short period followed by drug free periods, are aimed at
eliminating as many tumor cells as possible [71]. In addition to the toxic systemic side
effects associated with the MTD approach, during drug free cycles where the normal
tissue is allowed to recover, non-tumorigenic endothelial cells composing the vasculature
can continue to supply the small number of remaining tumor cells with the nutrients and
oxygen required for survival and remove waste products. Thus, although the initial
administration may be efficacious, these “drug free” periods can allow tumors to relapse
[71]. A new approach to administer chemotherapeutics over longer periods of time with
small doses is being considered as a way to reduce systemic toxicity and possibly
improve anti-tumor effects [71]; this slower more controlled dosing, termed ‘metronomic
chemotherapy’ has been shown to have an anti-angiogenesis effect as well [71]. This
bodes well for the polymersome as a potential delivery system, where the drug release
kinetics can be specifically tuned to release drug on both short time scales (hours) to
longer time scales (days). The ability to vary release kinetics using different polymer
backbones will be illustrated here; however the potential to vary the backbone and
ultimately the release kinetics is much greater than the limited number of examples which
are presented in this chapter.
In addition to administering chemotherapy in a slower more controlled manner as
a method of creating an anti-angiogenic effect, the combination of chemotherapeutics
with anti-angiogenic drugs has been examined. Studies have demonstrated the potential
of anti-angiogenic drugs to improve the cytotoxic chemotherapeutic effects which both
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drugs are administered in combination [71]. Since tumors require a network of blood
vessels to survive and grow, angiogenesis, the growth of new blood vessels is crucial for
tumor survival and metastasis. These newly formed blood vessels are required to provide
oxygen and nutrients to the tumor cells and remove carbon dioxide and waste. In fact, a
crucial step in tumor growth and subsequent invasion and metastasis of tumor cells is the
switch to the “angiogenic phenotype” [72].
These nascent blood vessels are immature and their walls are poorly developed
[73], distinguishing them from normal vasculature. Furthermore, while angiogenesis
occurs rapidly in tumor tissues, in normal healthy tissues the rate of angiogenesis is
minimal [74]. For these reasons, as well as others, targeting tumor endothelium is
advantageous in the treatment of cancer.

As a result, the combination of

chemotherapeutics with anti-angiogenesis agents, which suppress neovascularization, or
vascular disrupting agents (VDA), which result in rapid and selective disruption of the
tumor vasculature has emerged as a promising therapy [71, 73]. These agents target
genetically stable endothelial cells that constitute the blood vessels around tumors, rather
than the transformed tumor cells themselves [75].
However, this combination therapy is not without challenges which must be
overcome. First, if the tumor vasculature is destroyed by the VDA prior to administering
the chemotherapeutic, it can prevent the tumor from receiving the necessary amount of
chemotherapeutic required to destroy the tumor cells [38]. Furthermore, inhibiting blood
supply can lead to the upregulation of various cellular markers, for example, hypoxia
inducible factor (HIF1-α) which has been linked to increased tumor invasiveness and
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resistance to chemotherapy [38]. However, the use of polymer vesicles may solve some
of the challenges associated with anti-angiogenic drug/VDA delivery by simultaneously
delivering both chemotherapeutic and anti-angiogenic agent/VDA directly to the tumor
site. As discussed in Chapter 1, the polymersome architecture lends itself nicely to dual
drug loading.
Thus the addition of a VDA into the hydrophobic bilayer of doxorubicin loaded
vesicles can potentially create a multi-drug polymersome capable of destroying cancerous
tumors cells and their vasculature. Combretastatin A4, a hydrophobic vascular disrupting
agent, inhibits the polymerization of tubulin and causes “irreversible vascular shutdown
within solid tumors” while leaving the healthy vasculature intact [76].

Hence,

combretastatin A4, is a key candidate to incorporate into the bilayer of doxorubicin
loaded vesicles. Thus, the combination of combretastatin A4 and doxorubicin into one
vesicle will create a multi-modal platform for the eradication of tumor cells and the
endothelial cells which support them.
This chapter explores the challenges associated with loading DOX into the
aqueous core of polymersomes generated from biocompatible diblock copolymer,
poly(ethylene oxide)-b-polybutatdiene (PEO-b-PBD) as well as the bioresorbable diblock
copolymers, poly(ethylene oxide)-b-polycaprolactone (PEO-b-PCL) and poly(ethylene
oxide)-b-poly(methyl caprolactone) (PEO-b-PmCL). In addition, it discusses the release
of the drug from these vesicles.

Furthermore, the ability to load doxorubicin into

combretastatin incorporated vesicles is demonstrated, confirming the generation of a
multi-functional multidrug vesicles for the eradication of tumor cells and the endothelial
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cells which support them.

2.3 EXPERIMENTAL METHODS
2.3.1 Preparation of PEO-b-PCL Polymersomes for Doxorubicin Loading and Release
Studies
Self-assembly via thin-film hydration was employed in order to form the PEO
(2k)-b-PCL (12k) copolymers into their equilibrium morphologies. Film hydration has
been extensively utilized for preparing non-degradable polymersomes comprised of PEOb-PBD and PEO-b-PEE diblock copolymers [4, 9]. Briefly, 200 microliters of a 70
mg/ml (or 35mg/ml for development studies) PEO-b-PCL copolymer solution in
methylene chloride were uniformly deposited on the surface of a roughened Teflon plate
followed by evaporation of the solvent for >12h. Addition of aqueous solution, (~290
milliosmolar ammonium sulfate solution, pH ~5.4) and sonication for approximately 60
minutes at 65°C led to spontaneous budding of biodegradable polymersomes off the
Teflon-deposited thin-film, into the aqueous solution. The sonication procedure involved
placing the sample vial containing the aqueous based solution and dried thin-film
formulation (of polymer uniformly deposited on Teflon) into a sonicator bath (Branson;
Model 3510) at 60-65°C for 30 minutes followed by constant agitation for 60 minutes at
60-65°C. Subsequently, five cycles of freeze-thaw extraction followed by placing the
sample vials in liquid N2 and subsequently thawing in a water bath at ~55~65°C.
Extrusion using a pressure driven Lipex Thermobarrel Extruder (1.5 mL capacity) at
65°C was performed to yield small (<300-nm diameter) unilamellar polymersomes that
possess appropriately narrow size distributions. The size distribution of the PEO-b-PCL
suspension was determined by dynamic light scattering (Figure 2.5).
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Once vesicles of the appropriate size were formed, extruded samples were
dialyzed in iso-osmotic Sodium Acetate Solutions (50 mM Sodium Acetate, 100mM
Sodium Chloride, pH~5.5). Dialysis solutions were changed 3 times over approximately
30 hours. Post-dialysis, doxorubicin was actively loaded into the polymersomes through
an ammonium sulfate gradient. The polymersomes were incubated with doxorubicin in a
ratio of 1:0.2 polymer:drug (w/w) for 7 hours at a temperature above their main gel to
liquid-crystalline phase transition temperature [77-79]. Aggregation of DOX within the
polymersome core led to quenching of its fluorescence emission. For loading studies, to
demonstrate loading, fluorescence data was obtained at various time points over the
seven hour incubation (using a SPEX Fluorolog-3 fluorimeter; λex = 480nm, λem =
590nm). This incubation time was later extended to 9 hours.
Non-entrapped DOX was removed from the solution (using an Acta Basic 10
HPLC with Frac 950; the solution was passed through a C-1640 column with Sephacryl
S500-HR media. Subsequent studies employed a HiTrap desalting column instead of the
C-1640 column. The collected DOX-loaded polymersome suspension was centrifuged
and concentrated into an approximately 1 mL volume. The vesicles were then aliquoted
into various (290 mOsM) solutions buffered at pH ~5 (50 mM sodium acetate and 100
mM sodium chloride) and pH ~ 7.4 (PBS), with N = 4 samples for each buffer. Release
studies of DOX from the loaded polymersomes were initiated immediately following
aliquoting; DOX fluorescence was measured fluorometrically (using a SPEX Fluorolog-3
fluorimeter; λex = 480nm, λem = 590nm) at various intervals up to fourteen days. As
DOX was released from the polymersome core, and diluted into the surrounding solution,
its fluorescence emission increased over time. At the culmination of the study, the
43

samples were solubilized using Triton X-100.

The percent release over time was

calculated by comparing the measured fluorescence at each time point to final DOX
fluorescence, as determined upon solubilization of remaining intact polymersomes with
Triton X-100, at the completion of the study, as per Equation 2.1. Release rates were
calculated by comparing the fluorescence at two time points over the time period between
the time points as per Equation 2.2.
Equation 2.1:
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2.3.2 Preparation of PEO-b-PmCL Polymersomes for Doxorubicin Loading and
Release Studies
Similar to PEO-b-PCL and PEO-b-PCL-Ac doxorubicin loaded vesicles, PEO-bPmCL vesicles were prepared via thin film hydration. Briefly, a thin film of polymer was
deposited on a Teflon film, and the organic was allowed to dry. Following this step, the
film was hydrated with ammonium sulfate solution and sonicated at 65 C. Vesicles
spontaneously self-assembled and budded off the Teflon as a result of the energy
provided via sonication. Subsequent to sonication, vesicles were further processed as
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noted in Section 2.3.1and dialysis was performed. Samples were dialyzed however, into
iso-osmotic Sodium Chloride (NaCl) solution acidified with 12.1N HCl to yield a
solution with pH~5.5, osmolarity~290mOsM. Dialysis into sodium acetate buffer at pH
5.5, as performed with PEO-b-PCL vesicles, discussed in Section 2.3.1did not yield
stable loading as determined via fluorescence measurements; hence dialysis in various
buffers was attempted, as will be discussed in Section 2.4.2, and it was determined that
stable fluorescence counts were obtained for loading when acidified NaCl was used as
the dialysis media. Three exchanges were made over approximately 30 hours. Post DOX
loading, DOX was removed on two HiTrap desalting columns in series (GE Healthcare)
The vesicles were then aliquoted into various (290 mOsM) solutions buffered at
pH ~5 (50 mM sodium acetate and 100 mM sodium chloride) and pH ~ 7.4 (PBS), with
N = 4 samples for each buffer. Release studies of DOX from the loaded polymersomes
were initiated immediately following aliquoting; DOX fluorescence was measured
fluorometrically (using a SPEX Fluorolog-3 fluorimeter; λex = 480nm, λem = 590nm) at
various intervals up to fourteen days. As DOX was released from the polymersome core,
and diluted into the surrounding solution, its fluorescence emission increased over time.
At the culmination of the study, the samples were solubilized using Triton X-100. The
percent release and release rate over time was calculated by comparing the measured
fluorescence at each time point to final DOX fluorescence, as determined upon
solubilization of remaining intact polymersomes with Triton X-100, at the completion of
the study (Equation 2.1and Equation 2.2).
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2.3.3 Preparation of PEO-b-PBD Polymersomes for Doxorubicin Loading and Release
Studies
Doxorubicin loaded PEO-b-PBD vesicles were prepared via thin film hydration as
described above. Briefly, a thin film of polymer (35-70mg/ml in organic) was deposited
on a Teflon film, and the organic was allowed to dry. Following this step, the film was
hydrated with ammonium sulfate solution (pH ~5.3~5.5, ~290mOsM) and sonicated at
65 C. Vesicles spontaneously self-assembled and budded off the Teflon as a result of
the energy provided via sonication. Subsequent to sonication, vesicles were further
processed as noted in Section 2.3.1and dialysis was performed.
In order to determine the loading buffer which yields the most stable loading, for
development, samples were initially dialyzed, into either iso-osmotic Sodium Chloride
(NaCl) solution acidified with 12.1N HCl to yield a solution with pH~5.5 or iso-osmotic
Sodium Acetate/Sodium Chloride Buffer at a pH of 5.5. (Following this, studies were
carried out using Acidified NaCl Solution for the dialysis exchange.) Three exchanges
were made over approximately 30 hours.
The vesicles were then aliquoted into various (290 mOsM) solutions buffered at
pH ~5 (50 mM sodium acetate and 100 mM sodium chloride) and pH ~ 7.4 (PBS), with
N = 4 samples for each buffer. Release studies of DOX from the loaded polymersomes
were initiated immediately following aliquoting; DOX fluorescence was measured
fluorometrically (using a SPEX Fluorolog-3 fluorimeter; λex = 480nm, λem = 590nm) at
various intervals up to fourteen days. As DOX was released from the polymersome core,
and diluted into the surrounding solution, its fluorescence emission increased over time.
At the culmination of the study, the samples were solubilized using Triton X-100. The
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percent release over time was calculated by comparing the measured fluorescence at each
time point to final DOX fluorescence, as determined upon solubilization of remaining
intact polymersomes with Triton X-100, at the completion of the study.
2.3.4 Doxorubicin Release from Doxil (lipid vesicles)
Doxil®, the commercially available liposomal formulation of doxorubicin, was
obtained from the Hospital of the University of Pennsylvania Pharmacy for research
purposes only. Similar to the release studies performed on PEO-b-PCL and PEO-bPmCL vesicles, the 10ul of the concentrated Doxil (20mg/10ml) solution was placed in
2.95 mL of either phosphate buffered saline (PBS) (pH 7.4, 290mOsM), or sodium
acetate buffered solution (pH 5, 290mOsM) at a concentration below the quenching
concentration of the encapsulated doxorubicin as determined by absorbance
measurement.

The final concentration of doxorubicin was .0068mg/ml in buffer.

Release studies of DOX from the loaded liposomes were initiated immediately following
aliquoting; fluorescent measurements (using a SPEX Fluorolog-3 fluorimeter; λex =
480nm, λem = 590nm) were made at various intervals up to fourteen days post aliquoting.
As noted, as DOX was released from the polymersome core, and diluted into the
surrounding solution, its fluorescence emission increased over time. At the culmination
of the study, the samples were solubilized using Triton X-100 and heat. The percent
release over time was calculated by comparing the measured fluorescence at each time
point to final DOX fluorescence, as determined upon solubilization of remaining intact
polymersomes with Triton X-100, at the completion of the study.
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2.3.5 Preparation of PEO-b-PCL-Ac Polymersomes

for Doxorubicin Loading and

Release Studies
Prior to polymersome formation, the functionalize block copolymer was
synthesized by Joshua S. Katz via a two step process, as shown in Figure 2.1. Briefly, the
diblock copolymer was synthesized via a ring opening polymerization of the εcaprolactone using monomethoxy PEG as a macroinitiator and stannous octoate as the
catalyst. Once the block copolymer was synthesized, the terminal hydroxyl group on the
caprolactone block was acrylated using acryloyl chloride and dichloromethane.

Figure 2.1- Synthesis of Acrylate-Terminated PEO-b-PCL Copolymer
Polymersomes were generated by the self-assembly of polymer thin films on
roughened Teflon into aqueous medium (70-100 mg/mL solution of polymer in
methylene chloride, drying, immersion in aqueous solution), followed by sonication at
65 C, freeze-thaw cycling (five cycles liquid nitrogen to 65 C), and heated, automated
extrusion (400 and 200 nm membranes) [4, 9]. The photoinitiator DMPA (18 µg/mg
polymer for 1:1 mol polymer: mol photoinitiator, as determined by J.S. Katz) was co-cast
with the polymer on the Teflon for inclusion into the membrane prior to hydration. DOX
was encapsulated utilizing an ammonium sulfate gradient [77-79] (a 10 mg/mL DOX in
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water was added to the polymersome suspension at a ratio of 1:0.2 polymer: drug and
incubated at 65 C for 7-9 hours) [77], and free DOX was removed on two HiTrap
desalting columns in series (GE Healthcare). Post DOX loading and removal of free
DOX, UV light exposure was completed with an OmniCure Series 1000 spot-curing lamp
with a collimating lens (Exfo, Ontario, Canada; 365 nm, 55 mW/cm2). Release into
phosphate-buffered saline (PBS) was monitored by recording the fluorescence of
polymersome suspensions over time (SPEX Fluorolog-3 fluorimeter, λex = 480 nm, λem =
590 nm).

The amount of DOX encapsulated was determined by polymersome

dissociation with addition of 100 µL of 30% TritonX-100 and incubation for 60 min at
37 C.
2.3.6 Preparation of PEO-b-PCL Polymersomes for Combretastatin Incorporation
Studies
Self-assembly via thin-film hydration was used to assemble the PEO-b-PCL
copolymers into their equilibrium morphologies. Film hydration has been extensively
utilized for preparing non-degradable polymersomes comprised of PEO-b-PBD and PEOb-PEE diblock copolymers [4, 9]. Briefly, a 70mg/mL PEO-b-PCL copolymer solution
in methylene chloride was prepared and added to combretastatin at a 0.9:1 drug:polymer
molar ratio. Two hundred microliters of the polymer-drug solution were uniformly
deposited on the surface of a roughened Teflon plate followed by evaporation of the
solvent for >12h. Addition of aqueous solution, (~290mOsM Phosphate Buffered Saline,
PBS) and sonication at 65°C led to spontaneous budding of biodegradable
polymersomes, off the Teflon-deposited thin-film, into the aqueous solution.

The

sonication procedure involved placing the sample vial containing the aqueous based
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solution and dried thin-film formulation (of polymer-drug uniformly deposited on Teflon)
into a sonicator bath (Branson; Model 3510) @ 60-65°C for 30 minutes followed by
constant agitation for 60 minutes at 60-65°C. Subsequently, five cycles of freeze-thaw
extraction followed by placing the sample vials in liquid N2 and then thawing in a water
bath at 50-60°C. Extrusion using a pressure driven Lipex Thermobarrel Extruder (1.5
mL capacity) at 65°C was performed to yield small (<300-nm diameter) unilamellar
polymersomes that possess appropriately narrow size distributions. The size distribution
of the PEO-b-PCL suspension was determined by dynamic light scattering.

Post

extrusion, non-entrapped combretastatin was removed from the sample by concentrating
using a Centricon centrifugal device. The sample was centrifuged, filtrate removed, and
additional PBS buffer was added to the concentrated sample for a total of nine times.
The collected polymersome solution was centrifuged to concentrate the sample.
To determine the concentration, one hundred microliter sample aliquots were
removed and the combretastatin was extracted from the vesicles by adding the aliquot to
400 microliters of PBS and 500 microliters of methylene chloride, and subsequently
vortexing and centrifuging the sample.

The resulting aqueous layer was carefully

removed, and the remaining organic layer with drug was placed in a vacuum. The dried
powder resulting from evaporation of the methylene chloride was reconstituted in 1
milliliter of acetonitrile.

The concentration of combretastatin was determined by

measuring the absorbance (molar extinction coefficient 12,579M-1cm-1 in acetonitrile at
300nm). Polymer concentration was determined by a mathematical calculation.
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2.3.7 Preparation of Dual Drug PEO-b-PCL Polymersomes for Combretastatin
Incorporation and Doxorubicin Loading
Self-assembly via thin-film hydration was used to assemble the PEO-b-PCL
copolymers into their equilibrium morphologies. Film hydration has been extensively
utilized for preparing non-degradable polymersomes comprised of PEO-b-PBD and PEOb-PEE diblock copolymers [4, 9]. As described in section 2.3.670 mg/ml (or 35mg/ml or
for development studies) PEO-b-PCL copolymer solution in methylene chloride was
prepared and added to combretastatin at a 0.9:1 drug:polymer molar ratio and a thin film
of the polymer-drug solution was uniformly deposited on the surface of a roughened
Teflon plate.

The addition of aqueous solution, (~290mOsM Ammonium Sulfate

Solution, pH~5.4) and sonication for approximately 60 minutes at 65°C led to
spontaneous budding of biodegradable polymersomes, off the Teflon-deposited thin-film,
into the aqueous solution. As described, the sonication procedure involved placing the
sample vial into a sonicator bath (Branson; Model 3510) @ 60-65°C for 30 minutes to
equilibrate the sampled followed by constant agitation for 60 minutes at 60-65°C. Post
sonication, five cycles of freeze-thaw extraction followed by placing the sample vials in
liquid N2 and subsequently thawing in a water bath at 50-60°C. Extrusion using a
pressure driven Lipex Thermobarrel Extruder (1.5 mL capacity) at 65°C was performed
to yield small (<300-nm diameter) unilamellar polymersomes that possess appropriately
narrow size distributions.

The size distribution of the combretastatin PEO-b-PCL

suspension was determined by dynamic light scattering.
Once vesicles of the appropriate size were formed, samples were dialyzed in isoosmotic Sodium Acetate Solutions (50 mM Sodium Acetate, 100mM Sodium Chloride,
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and pH ~ 5.5). Dialysis solutions were changed 3 times over approximately 30 hours.
Post-dialysis, doxorubicin was actively loaded into the combretastatin incorporated
polymersomes through an ammonium sulfate gradient.

The polymersomes were

incubated with doxorubicin in a ratio of 1:0.2 polymer:drug (w/w) for 9 hours at a
temperature above their main gel to liquid-crystalline phase transition temperature [7779].

Aggregation of DOX within the polymersome core led to quenching of its

fluorescence emission. For loading studies, to demonstrate loading, fluorescence data
was obtained at various time points over the nine hour incubation (using a SPEX
Fluorolog-3 fluorimeter; λex = 480nm, λem = 590nm).
Non-entrapped DOX and combretastatin were removed from the solution (using
an Acta Basic 10 HPLC with Frac 950; the solution was passed through a HiTrap
desalting column. The collected dual drug polymersome suspension was centrifuged and
concentrated.

Samples were aliquoted and an absorbance spectrum of the resulting

vesicles was obtained from 190nm to 700nm. Furthermore, vesicles were solubilized
using Triton X-100 to demonstrate doxorubicin loading into the aqueous core. Once the
vesicles are solubilized, if DOX is in encapsulated in the aqueous core, there should be a
marked increase in fluorescence from the sample as DOX from aqueous core is freed into
the external media.

2.4 RESULTS AND DISCUSSION
2.4.1 Loading and Release of Doxorubicin in PEO-b-PCL Polymersomes
To assess the mechanism by which the PEO-b-PCL vesicles load a
physiologically relevant, the loading of Doxorubicin (DOX) was monitored
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spectrofluorometrically (λex=480nm, λem=590nm) over the course of 7 hours; this was
later followed through 9 hours. Since the aggregation of doxorubicin inside the core,
when loaded actively via ammonium sulfate gradient, results in quenching of the
fluorophore, a decrease in fluorescence over time was generally observed as drug
molecules load into the vesicles.

However, it should be noted, this decrease in

fluorescence was concentration dependent, and hence if the concentration outside the
vesicles was initially high (i.e. above the quenching concentration), loading was actually
seen as an increase in fluorescence as the DOX concentration in the external solution
decreased below the quenching concentration with loading. As such, in all loading
studies, the final determination of loading was thus made based on stabilization of the
fluorescence output over time.
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Figure 2.2- Schematic of remote DOX loading in vesicles
by an ammonium sulfate gradient created between the intravesicle aqueous phase
and the external solution [79].
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Figure 2.3- Characterizing the loading of doxorubicin into PEO-b-PCL
PEO
polymersomes.
A) Doxorubicin fluorescence spectra over time while loading into vesicles. B) The
normalized maximum fluorescence of doxorubicin over time, where all values are
normalized
lized back to the 0h fluorescence maxima. In both graphs, A) and b) he
decrease in fluorescence and the stabilization of the fluorescent signal after 3 hours
is clearly demonstrated
Using Cryotransmission electron microscopy (cryo
(cryo-TEM) we confirmed that the
remote loading of DOX did not adversely affect the structure of the membrane or
vesicular structure of the polymersome. DOX loaded polymersomes were observed via
cryo-TEM (Figure 2.1)) and demonstrate the vesicle like morphology seen with unloaded
polymersomes. However, in contrast to unloaded polymersomes, images of DOX loaded
vesicles have an electron
electron-opaque band in the aqueous core [79] (Figure
Figure 2.1, A-C)
resulting from the fibrous
fibrous-bundle aggregates formed when
n doxorubicin precipitates when
encapsulated in the presence of a pH gradient [80].
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Figure 2.4- Cryo-TEM
TEM Images of Doxorubicin loaded PEO
PEO-b-PCL
PCL vesicles.
Note the solid like aggregates in both circular and rod like form in the vesicle
center; this is the solgel
We assessed the mechanism bby which PEO-b-PCL
PCL vesicles load (See Section
2.4.1)) and release a physiologically relevant encapsulant.

As a model system,

Doxorubicin, an anti neoplastic agent which inhibits DNA replication, was actively
encapsulated into the aqueous
queous compartment of 200nm PEO
PEO-b-PCL
PCL vesicles (Figure
(
2.5)
though an ammonium sulfate gradient [77, 79, 81] (See Section 2.3.1).
).

in situ release
C)

where doxorubicin release was monitored fluorometrically (λex=480nm, λem=590nm)
over 14 days. Cumulative release and release rate were calculated according to equations
Equation 2.1and Equation 2.2, respectively.
While the kinetics of the release varied at the two pHs, an initial burst release
phase (where approximately
imately 20% of the initial payload within
hin the first 8 hrs) was
observed for both pH’s followed by a more controlled pH dependent release over the 14
day release study (Figure
Figure 2.6A). However, the dynamics of release varied at each
condition (Figure 2.6B).
B). At a pH of 5, one single release phase (β’)
’) is observed over the
entire 14 days; itt appears that the dominant mechanism of release at both short and long
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times at this pH is acid catalyzed hydrolysis of the PCL membrane (Figure 2.6C). In
contrast, at a pH of 7.4, two distinct phases (α, β) are observed. Kinetic release studies
suggest that initially (days 1-5, α phase) doxorubicin release from the polymersome core
is primarily dependent upon passive diffusion of the drug across the PCL membrane. At
subsequent times, (days 5-14, β phase) drug release is predominantly facilitated by
hydrolytic matrix degradation of the caprolactone backbone Figure 2.6C). The rate
constants of the β (pH 7.4) and β’ (pH 5) phases are similar further suggesting a similar
mechanism of release. Since acid catalyzed hydrolysis of the membrane occurs at both
short and long times at pH 5, DOX release at pH 5 is more rapid that at pH 7.4

Figure 2.5- Cumulative histogram of the size distribution of PEO(2k)-b-PCL(12k)based polymersomes as obtained via dynamic light scattering (DLS) at 25 C.
Vesicles were formed via thin film self- assembly upon aqueous hydration and
heating at 65 C for 1 hr. A mono-dispersed distribution of 200 nm diameter
polymersomes was subsequently obtained upon 5 cycles of freeze-thaw extraction
followed by extrusion through a thermo-barrel supported (5 passes at 65 C) 200 nm
pore cutoff membrane.
o

o

o
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Figure 2.6- in situ release of doxorubicin from PEO-b-PCL polymersomes
(A) Cumulative in situ release of doxorubicin, loaded within 200 nm diameter
PEO(2K)-b-PCL(12K)-based polymersomes, under various physiological conditions
(pH 5 and 7.4; T = 37 °C) as measured fluorometrically over 14 days. N = 4 samples
at each data point; individual data points for each sample varied by less than 10%
of the value displayed at each time interval. (B) Release rates of DOX (Vdox) from
200 nm diameter PEO(2K)-b-PCL(12K)-based polymersomes vs time. Dotted and
solid lines represent exponential fits obtained by regression analysis R = 0.99 for
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each curve), and the displayed equations correspond to the respective release
regimes (α, β, β’,). (C) Schematic illustrating differing regimes of DOX release via
(α) intrinsic drug permeation through intact vesicle membranes vs (β, β′′) release
predominantly by PCL matrix degradation.
2.4.2 Loading and Release of Doxorubicin into PEO-b-PmCL Vesicles
To determine whether the addition of a methyl group on the γ-carbon of the
caprolactone back bone alters the loading or release rate of doxorubicin from the vesicle
interior, Doxorubicin was actively encapsulated into the aqueous compartment of 200nm
PEO-b-PmCL vesicles (Figure 2.1) though an ammonium sulfate and pH gradient [77,
79, 81]

(See Section 2.3.2).

Figure 2.7A demonstrates that an increase in DOX

fluorescence occurs post vesicle destruction with Triton X-100; as explained above,
releasing the DOX from the vesicle core results in an increase in DOX fluorescence.
Figure 2.7B-D are cryo-TEM images of DOX loaded PEO-b-PmCL vesicles; the areas in
the center of the vesicle are due to the DOX-SO4-2 gel-like precipitate, and further
demonstrate encapsulation of DOX into the aqueous core; however, loading into each
vesicle appears variable and it appears that some vesicles may have loaded more or less
DOX than other vesicles.
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Figure 2.7- Doxorubicin loading in PEO
PEO-b-PmCL vesicles
A) Doxorubicin Fluorescence pre (PTX) and post (TX) treatment with Triton X-100.
X
The increase in fluorescence upon vesicle rupture due to Triton X
X-100
100 confirms the
loading of doxorubicin into the aqueous core of the vesicles. B
B-D)
D) CyroTEM images
of DOX loaded PEO-b-PmCL
PmCL vesicles where the DOX aggregates, circular and rodrod
like in form, appear as dark areas in the aqueous core.
In contrast to PEO
PEO-b-PCL
PCL vesicles, samples were dialyzed into unbuffered isoiso
osmotic Sodium Chloride (NaCl) solution (pH~5.5, os
osmolarity~290mOsM).
molarity~290mOsM).

While

dialysis into sodium acetate buffer at pH 5.5 yielded stable DOX loading for PEO-b-PCL
PEO
vesicles (Figure 2.3),
), dialysis in this buffer did nnot
ot yield stable loading (as determined via
fluorescence measurements) for PEO
PEO-b-PmCL vesicles (Figure 2.8).
). The pH of the spent
acetate buffer, when loading PEO
PEO-b-PCL
CL vesicles showed an increased in pH from acidic
conditions (starting) to basic conditions after dialysis, demonstrating the efflux of
ammonia and the establishment of an H+ gradient (Figure 2.2).
). This was not observed for
60

the loading of DOX in PEO
PEO-b-PmCL
PmCL vesicles, where the pH of the spent dialysis
solutions remained acidic. It was surmised that the methyl group in the PmCL block may
have increased the hydrophobicity of the block in comparison to PCL, hindering the
ammonia from crossing the bilayer and establishing the pH gradient. As such, dialysis in
various buffered and unbuffered solutions was attempted, and it was determined that
stable fluorescence counts (correlating to stable loading) were obtained for loading when
acidified NaCl was used as the dialysis media ((Figure 2.8).
).

Furthermore,
Furthermor when

examined, the pH of the spent acidified NaCl also increased from acidic to basic
conditions, suggesting that NH3 crossed the vesicle membrane and established a pH
gradient across the PmCL membrane.

Figure 2.8- Doxorubicin fluorescence over time while loading into PEO-b-PmCL
PEO
vesicles after dialysis in various iso
iso-osmotic
osmotic buffered and unbuffered solutions.
C. Note
te the fluorescence remains relatively stable after three hours of loading
for either of the samples dialyzed in sodium chloride solution.
NaOAc
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Buff.=Sodium Acetate/Sodium Chloride Buffered Solution at pH 5.5 (samples 1-3,
not stirred while loading, samples 4- 5- stirred while loading); NaCl Sol’n=Sodium
Chloride Solution, pH 5.5 (unbuffered); Sucr. Sol’n=Sucrose Solution, pH 5.5
(unbuffered)
in situ release studies were conducted at various physiological conditions (pH 5.5
and pH 7.4,@T=37 C) where doxorubicin release was monitored fluorometrically as
described above (λex=480nm, λem=590nm) over 14 days. Cumulative release and release
rate were calculated according to equations Equation 2.1and Equation 2.2, respectively.
Similar to release from PEO-b-PCL, we observed an initial burst phase release where
over 50% of the total amount of drug released was released during the first 12 hours.
This correlates well with the release rate where the initial release rate during the burst
phase is significantly higher than the release rate during the subsequent days. The dip
observed in the cumulative release of the drug in the pH 7.4 buffer could be the result of
drug degradation in pH 7.4 buffer at 37 C or the drug “reloading” in the vesicles post
release to establish an equilibrium across the non-hydrolyzed vesicle membrane. As is
evident from the cyro-TEM images in Figure 2.7, not all vesicles are loaded with the
same amount of DOX and hence some of the DOX may be redistributed upon release. In
both the pH 5.5 and the pH 7.4 buffers, the percent cumulative release of drug from the
vesicles is significantly less than observed for the PEO-b-PmCL vesicles (Figure 2.6).
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Figure 2.9- in situ release of doxorubicin from PEO
PEO-b-PmCL
PmCL polymersomes
A) Doxorubicin Cumulative Release and B) Release Rate from PEO-b-PmCL
PEO
vesicles at physiological pH's
2.4.3 Loading and Release of Doxorubicin in PEO
PEO-b-PBD
PBD Polymersomes
To examine the releas
release of Doxorubicin from biocompatible but nonnon
biodegradable vesicles, DOX was loaded actively into PEO
PEO-b-PBD
PBD vesicles through a
gradient. Similar to DOX loading in PEO
PEO-b-PmCL
PmCL vesicles, various dialysis media were
tested, and it was determined that the optim
optimal
al dialysis solution which leads to a stable
fluorescence within 7-99 hours was iso
iso-osmotic
osmotic acidified NaCl (pH 5.5). Successful
loading was confirmed by cryo
cryo-TEM
TEM microscopy and bursting of the vesicles using
Triton X-100 and heat.
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Figure 2.10- Doxorubicin loading into PEO
PEO-b-PBD polymersomes
A)Loading
Loading of doxorubicin in
into PEO-b-PBD vesicles over time and B) the
confirmation of doxorubicin loading in PEO
PEO-b-PBD vesicles.
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Figure 2.11- Cryo-TEM
TEM Images of DOX loaded PEO
PEO-b-PBD vesicles
A) Budding vesicles are observed, B) Not all vesicles are loaded with DOX, C) Fully
loaded DOX vesicle with not much space between the DOX aggregate and the
vesicle wall, D-E)
E) Pearlized structures resulting from DOX loading.
From Figure 2.11 it is evident that not every vesicle has DOX encapsulated within
it; furthermore, at timess there is very little (if any) separation between the DOX aggregate
and the bilayered membrane. Additionally, some of the vesicles have a cause of the
appearance of "stringed vesicles" but they are prevalent in the images.
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Figure 2.12- in situ release of DOX from PEO
PEO-b-PBD vesicles
A) Cumulative DOX release and B) DOX Release Rate from PEO-b-PBD vesicles at
pH 5 and pH 7.4
In situ DOX release studies were carried out fluorometrically for DOX loaded
PEO-b-PBD
PBD vesicles in physiologically simulated conditions.

Vesicles in pH 7.4

undergo a burst phase release where over 20% of the total DOX is released within the
first 12 to 24 hours (Figure
Figure 2.12A);
A); this burst phase at pH 7.4 is further evidenced by the
quick rate of DOX release over the first 24 hours ((Figure 2.12B,
B, closed boxes) which
quickly tapers off over the subsequent 13 days (Figure 2.12B,
B, open boxes).
boxes) It is surmised
that the
he drug released during this early time period is drug which was adhered to the PEO
brush or localized to the membrane, but not locked into the core. Following the burst
phase release,, a more controlled release is observed. It is interesting to note that,
that as in the
case of DOX loaded PEO
PEO-b-PmCL
PmCL vesicles, the cumulate DOX release decreases at later
time points; again, this may be the result of DOX degradation in the pH 7.4 solution as
DOX is known to degrade more rapidly in non
non-acidic solutions [82, 83].. Since not every
vesicle has DOX inside ((Figure 2.11B-D)
D) another possibility for the decrease in

66

cumulative DOX release at later times is that DOX is reentering unloaded vesicles
(Figure 2.11)) which are initially still intact at pH 7.4.
At a pH of 5.5, less than 10% of the drug is released from the PEO-b-PBD
PEO
vesicles within the first 24 hours, and it appears that the vesicles do not go through the
burst phase release, as evidenced by the slow and controlled cumulative release and
slower release rate, Figure 2.12A
A and B, respectively. Release rates do not reach over
ove
1.5% initial load/ hr even at early time points. Since it is unlikely that the PBD backbone
is degraded over the 14 days, in both conditions, it is believed that the drug release at
both pHs is due to permeation of DOX across the membrane and not vesicles
vesicl destruction.
2.4.4 Release of Doxorubicin from Doxil ® (Doxorubicin liposomal formulation)
Doxorubicin loaded liposomes were obtained and diluted to yield a .0068mg/ml
concentration of DOX in iso
iso-osmotic pH 7.4 PBS buffer or iso-osmotic
osmotic pH 5.5 Sodium
Acetate Buffer.

Figure 2.13-Release
Release of Doxorubicin from the clinically administered liposomal
formulation of doxorubicin
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A)Cumulative doxorubicin release from liposomes (Doxil ®) and (B) Doxorubicin
release rate from liposomes
Similar to the above release experiments, the release of DOX from lipid vesicles,
(DOXIL ®) was measured fluorometrically. Cumulative release and release rate were
calculated according to equations Equation 2.1and Equation 2.2, respectively. Release at
both pH’s demonstrates a characteristic burst phase over the first 12 hours followed by a
more controlled release over the subsequent days. However, the burst release is more
pronounced in the acid buffer as over 20% of the drug is released in the first 12 hours at a
pH of 5.5, whereas in PBS buffer (pH 7.4) only 10% of the total is released over the first
12 hours (Figure 2.13A). The burst phase is further demonstrated by examining the
release rate of the drug (%initial load/hr) which is greater than 1.0% initial load/hr for the
first 12 hour for the pH 5.5 condition, but quickly decreases post burst phase release to
less than 0.5% initial load/hr after the first day (B). At a pH of 7.4, it appears the DOX
fluorescence decreases over days 1-3; this may be due to a redistribution of drug back
into the vesicles, or the result of DOX degradation at pH 7.4 as discussed above; during
these days, the rate of degradation or re distribution is greater than the rate of release.
However, as the vesicles begin to breakdown due to hydrolysis of the lipid, the rate of
release surpasses the rate of degradation and/or drug redistribution, and the cumulative
release of drug slowly increases over the next 11 days (Figure 2.13A). The release rate
correlates with this observed cumulative release, as initially the %initial load/hr is 0.51.0, but decreases after the burst phase to approximately 0.1% (Figure 2.13B).
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2.4.5 Loading and Release of Doxorubicin into PEO-b-PCL-Ac Membrane Stabilized
Vesicles
As mentioned, one of the benefits of polymersomes over liposomes is the unique
ability to tune to degradation and release kinetics of the polymer backbone for enhanced
control of drug delivery rates. To that end, we sought to stabilize the membrane structure
and decrease the permeation of drug across the membrane prior to membrane hydrolysis
by forming biodegradable membrane stabilized vesicles through the use of a acryl group
on the terminal hydroxyl end of the PCL block, a photoiniator, and a light source. Once
assembled into polymersomes and in the presence of a photoinitiator, UV light exposure
induces a radical polymerization through the functional groups (Figure 2.14).

This

approach does not hinder hydrolysis of the PCL chain and yields oligo-caprolactone
units, PEG, and kinetic chains of poly(acrylic acid) as the degradation products [84].

Figure 2.14- Schematic of Hydrophobic End Group Polymerization for Stabilization
of Polymersome Membranes
Joshua S. Katz determined that only in the case where DMPA, the photoinitiator
was loaded into the bilayer and the polymersomes were exposed to UV irradiation was
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polymerization of thee acrylate groups observed (i.e., disappearance of acrylate peaks in
NMR spectra, Figure 2.15
15A).
A). Additionally, significant peak broadening can be seen in
the NMR spectrum
ectrum of the UV exposed polymersomes containing DMPA, indicative of an
increase in molecular weight that would be expected to accompany acrylate
polymerization. UV light alone or simply the presence of DMPA were both insufficient
to induce polymerization
polymerization.. Furthermore, the amount of DMPA necessary for complete
conversion of the acrylate groups was also investigated ((Figure 2.14, Figure 2.15B). A
1:1 mol/mol ratio of DMPA to polymer was necessary for complete conversion of
acrylates.

AcPCL
with
Figure 2.15- (A) NMR spectra of dehydrated polymersomes of AcPCL-b-PEG
or without DMPA loaded into the membrane before and after UV light exposure as
indicated. The -DMPA+UV
DMPA+UV sample received a 30min dose of UVlight, while the
+DMPA+UV sample received a 5 min dose
dose.. (B) NMR spectra of AcPCL-b-PEG
AcPCL
polymersomes with varying amounts of DMPA loaded into the membrane (reported
as molar ratio of polymer:DMPA). All samples received a 10 min dose of UV light.
Lowercase letters indicate assignment of peaks to the chemical structure shown.
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To demonstrate membrane stabilization as a method of controlling the release of
drug from the polymersome, doxorubicin was encapsulated in PEO-b-PCL-Ac
polymersomes loaded with DMPA in the membrane and the release was monitored via
fluorescence dequenching of the drug as discussed in Section 2.3 EXPERIMENTAL
METHODS. We compared formulations with and without 15 min exposure to UV light
(Figure 2.16A). As mentioned, as DOX releases from the polymersome and is diluted
into the surrounding solution, its fluorescence increases over a baseline level [85],
enabling tracking of the release from the polymersomes. Results are normalized to the
initial amount of DOX encapsulated (determined by membrane disruption through Triton
exposure to an additional sample for each group) less the baseline fluorescence.
Formulations were also highly stable, exhibiting negligible release (<1%) when stored at
4 C over the same period of time. The characteristic initial burst phase release, seen
with PEO-b-PCL vesicles, was seen for both stabilized and non-stabilized polymersomes;
however, the amount of drug released was slightly more when encapsulated in the nonstabilized polymersomes. The drug molecules released during this burst phase are likely
from the DOX that partitioned into the membrane prior to stabilization (DOX is
amphiphilic). However, following the burst phase release, the rate of release was much
slower for stabilized polymersomes compared to the non-stabilized polymersomes
(Figure 2.16B). By 7 days, only an additional ∼5% more of the drug from that released
during the burst phase was observed to be released for the stabilized vesicles, compared
to the additional ∼25% more being released for the non-stabilized samples, similar to
what was observed with PEO-b-PCL vesicles in Section 2.4.1. Due to degradation of
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DOX in aqueous solutions [82, 83], exact release profiles cannot be determined by this
method. However, from the two observed profiles ((Figure 2.16),
), it is evident that drug
release is significantly
antly retarded by stabilization of the membrane.

Figure 2.16- Doxorubicin Release from PEO
PEO-b-PCL-Ac vesicles
(a) Percent cumulative released and (b) release rates of DOX encapsulated in PEOPEO
b-PCL-Ac polymersomes
ersomes with 1:1 DMPA either without exposure (circles) or with
exposure to 15 min UV light (squares). The amount released was normalized to the
initial amount encapsulated and is reported as means ((n=3)
=3) and standard
deviations.
2.4.6 Incorporation of Combretastatin into PEO
PEO-b-PCL Vesicles
Combretastatin, an anti
anti-angiogenesis
angiogenesis drug, was incorporated into the hydrophobic
membrane of the PEO--b-PCL
PCL vesicles by dissolving it as well as the polymer in
methylene chloride prior to thin
thin-film hydration and vesicle
le formation. A relatively
monodispersed vesicle population of approximately 200nm drug incorporated vesicles
was obtained post vesicle formation and extrusion as determined by DLS. Incorporation
of combretastatin was determined by spectroscopy; absorban
absorbance
ce spectra were obtained and
compared for vesicles with and without drug as well as free drug Figure 2.17. These
spectra demonstrate that the combretastatin was inc
incorporated
orporated into the vesicles as a peak
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at approximately 345nm was observed for vesicles containing combretastatin, but not for
drug free vesicles. The red shift in the combretastatin spectra for combretastatin vesicles
in comparison to spectra of free comb
combretastatin
retastatin in ACN is probably due to the altered
environment inside the vesicle membrane.

Figure 2.17- Absorbance spectra of 1) combretastatin incorporated PEO-b-PCL
PEO
vesicles (closed triangle, closed squ
square), 2)PEO-b-PCL
PCL vesicles (circles), and 3) free
combretastatin in ACN (plus sign).
2.4.7 Dual Drug Vesicles:

The Incorporation of Combretastatin and Loading of

Doxorubicin in PEO-b-PCL
PCL Vesicles
As described, dual drug loaded polymersomes were generated by forming a thin
film of combretastatin and PEO
PEO-b-PCL
PCL and hydrating to form vesicles. Post vesicle
formation, vesicles were dialyzed to establish an ammonium sulfate gradient and
subsequently

loaded

with

doxorubicin.
73

Doxorubicin

loading

was

tracked

fluorometrically
etrically as described in sections 2.3.1and 2.4.1.

Figure 2.18A shows

fluorescence changes over time while loading DOX into combretastatin incorporated
vesicles. Again, fluorescence intensity stabilizes after the first three hours and remains
constant over
ver the entire loading study. In order to demonstrate both the incorporation of
combretastatin and the encapsulation of doxorubicin, absorbance spectra of the vesicles
were obtained. In Figure 2.19,, the peaks for both DOX (~480nm) and combretastatin
(~280nm) are clearly visible demonstrating the incorporation of both drugs into one
vesicle. Figure 2.18B
B clears shows an increase in fluorescence post treatment of Triton
T
X-100 and heat demonstrating release of doxorubicin into the external solution from its
initially quenched state inside vesicle aqueous core.

Figure 2.18- Doxorubicin loading in Combretastatin vesicles
A) Fluorescence intensity while loading over time B) Bursting of Sample 1 of DOX
loaded combretastatin vesicles; S1= Sample 1, etc.; PTX
PTX- prior to treatment with
Triton X; TX- after treatment with Triton X
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Figure 2.19- Absorbance Spectra of DOX loaded combretastatin incorporated
polymeric vesicles.
The top image shows the entire spectra with peaks for both DOX and
combretastatin, while the bottom image shows the spectra for combretastatin alone.
S1= sample 1, etc.; -11 is the first part of the sample, etc.

2.5 CONCLUSIONS
This study highlights the enormous potential of polymersomes as vehicles for
both single drugg and combination drug cancer therapy. Doxorubicin, an amphipathic
anti-neoplastic
neoplastic agent, was loaded into the aqueous core of both biocompatible (PEO-b(PEO
PBD) and bioresorbable (PEO
(PEO-b-PCL and PEO-b-PmCL) nano-polymersomes
polymersomes and the
release was characterized iin
n physiologically relevant buffers. Furthermore, doxorubicin
was loaded into the aqueous core of fully biodegradable stabilized polymersomes, and a
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decreased release rate was observed in comparison to non-stabilized vesicles.

This

reduced release rate is beneficial for high local delivery of chemotherapeutics over an
extended period.
Combretastatin, a VDA which binds tubulin and leads to vascular disruption in
tumors, was incorporated into the hydrophobic bilayer of PEO-b-PCL vesicles with and
without doxorubicin. Because of the enhanced permeation and retention (EPR) effect,
discussed in Chapter 1, vesicles naturally accumulate at the tumor site to do the leaky and
abnormal vasculature. Hence, vesicles loaded with combretastatin traffic to the tumor
site, even without targeting moieties, thereby further assisting with the elimination of
endothelial cells lining the tumor vasculature.
The ability to load both chemotherapeutics and vascular disrupting agents from
bioresorbable vesicles in a controlled fashion suggests that these vesicles may be useful
for clinical applications.
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3.1 SUMMARY
Biological membranes are complex molecular assemblies of phospholipids and
stabilized by cholesterol, proteins and carbohydrates [86]. Liposomes, vesicles selfassembled from natural or synthetic phospholipid amphiphiles [87], can mimic biological
membranes [88, 89], probe cell machinery[90], and be used to develop bio-inspired
materials for medical applications [91, 92]. The design of synthetic lipid amphiphiles for
vesicle self-assembly represents a formidable challenge since both natural and synthetic
amphiphiles generated by traditional methods can produce unstable liposomes that
require tedious separation and stabilization [91, 93-97].
Here we show that libraries of amphiphilic Janus-dendrimers self-assemble, by
simple injection of their ethanol solution into water, into monodisperse and stable
vesicles with excellent mechanical properties; these dendrimeric vesicles have been
termed dendrosomes. In contrast to polymersomes, polymeric vesicles self-assembled
from polydisperse block co-polymer amphiphiles[3, 4, 98, 99] with limited
bioresorbability, stable and monodisperse dendrosomes exhibit, in addition to the classic
spherical shape, the less encountered tubular[100], multilamellar vesicles[101],
polygonal[102], cubosome[103] and other complex architectures such as disc-like,
torroidal, rod-like, polygonal, spherical, ribbon-like and helical ribbon-like micelles[104].
Preliminary experiments demonstrate that dendrosomes are non-toxic to cells at
short times, and many produce pH-sensitive membranes that deliver cancer drugs, such as
doxorubicin, and incorporate pore forming proteins. Therefore, dendrosomes expand the
precise and monodisperse primary structure of dendritic building blocks into new
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functions[105-108]. Amphiphilic Janus-dendrimers self-assemble also in bulk and can be
used to elucidate the mechanism of self-assembly of amhiphiles in the absence and
presence of water[12]. We anticipate that dendrosomes will extend the capabilities of
synthetic amphiphiles, generating responsive membranes with permeability controllable
for desirable technological applications including novel pathways for targeted drug and
gene delivery, in vivo imaging, and mediation of the efficiency of enzymes[109] and
nucleic acids.

3.2 INTRODUCTION
The Perec Laboratory has designed twelve libraries containing 107 uncharged and
positively charged amphiphilic Janus-dendrimers (Figure 3.1). These Janus-dendrimers
were designed from natural AB3 and constitutional isomeric AB2 building blocks
containing both hydrophilic and hydrophobic segments that can be rapidly combined to
produce a large array of exact and monodispersed primary structures (Figure 3.1). These
dendrimeric structures were synthesized by a combination of convergent, for the
hydrophobic portion, and divergent or convergent methods for the hydrophilic portion.
Two hydrophobic segments (one aliphatic and one mixed aliphatic-aromatic) and six
hydrophilic segments (derived from oligoethylene oxide, dimethylolpropionic acid,
glycerol, thioglycerol, tert-butylcarbamate and quaternary ammonium salts) were
synthesized to generate the libraries of dendrimeric structures (Figure 3.1). This modular
concept allowed the weight fraction of hydrophilic to hydrophobic blocks to be
systematically varied.
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The monodispersity of the dendrimers sets them apart from polymers and block
copolymers which are polydisperse [3, 4, 98, 99]. Furthermore, while polymer chains
have only limited scope for additional functionalization since they contain only two chain
ends, the design of amphiphilic Janus-dendrimers, with their branched ends, allows a
higher concentration and larger diversity of functionalities to be incorporated at both the
hydrophilic and hydrophobic fragments of the molecule.

Figure 3.1- Library of Janus Dendrimers synthesized by the Perec Laboratory at
the University of Pennsylvania
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All amphiphilic Janus-dendrimers from Figure 3.1 self-assemble in both bulk and
in aqueous based solutions to form regular structures (Figure 3.2 and Figure 3.3). Vesicle
formation via injection of ethanol solutions of Janus-dendrimers into water (solvent
injection method) was monitored by dynamic light scattering (DLS) as a function of
concentration, temperature, and time. Formation of vesicles by injection of dendrimer in
ethanol and in a variety of other protic and polar aprotic solutions into water was
investigated as a function of temperature at a concentration of 0.5 mg/mL. Assemblies
with sizes from 55 nm to 732 nm with polydispersity ranging from 0.021 to 0.530 were
observed for the various concentrations, temperature, and time. These assemblies were
stable in aqueous solutions up to at least 300 days from 25 C-80 C. Surprisingly most
of the assemblies have low polydispersities of 0.021 to 0.200 via the solvent injection
method alone (i.e. no further processing); in the field of self-assembled vesicles, these
low values are considered monodisperse. For dendrimers from library 1, the size and
polydispersity depend on concentration. For example, the dendrimer (3,5)12G1-PEBMPA-G2(OH)8 exhibited polydispersities ranging from 0.106 to 0.44 and Z-average
sizes ranging from 84nm to 206 nm for concentrations ranging from 0.5 mg/mL to 4
mg/mL. In contrast, for dendrimers containing oligoethyleneoxide in the hydrophlic
portion, polydispersity and size are minimally dependent on concentration.
Small assemblies fabricated by injection of ethanol solutions of the amphiphilic
Janus-dendrimers into water were analyzed by cryo-TEM. 80 of these assemblies are
unilamelar spherical dendrosomes and 55 have a polydispersity lower than 0.2 (Figure
3a). In addition, dendrosomes within dendrosomes [101, 110], polygonal [102] and
tubular [100] dendrosomes, bicontinuous cubic particles (cubosomes [103]) and other
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complex architectures such as disc-like, toroidal, rod-like, polygonal, spherical, ribbonlike and helical ribbon-like micelles[104] were also observed by the analysis of the 3-D
intensity profiles of the optical micrographs and cryo-TEM images (Figures 2, 3). To our
knowledge this is the first example of dendrocubosome obtained in a two-phase non-ionic
surfactant system. The bilayer thickness of the dendrosomes was measured from cryoTEM and found to range from 5 to 8 nm. Liposomes from phospholipids exhibit
membrane thicknesses of 3 to 5 nm while the membrane thickness of polymersomes can
be varied between 8 to 20 nm or even greater. The mechanical properties in combination
with the measured thicknesses suggest that dendrosomes are excellent candidates for
models of biological membranes.
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Figure 3.2- CryoTEM of dendritic assmeblies in aqueous solutions
(a) Monodisperse dendrosomes from (3,4)12G1-PE-(3,5)-3EO-G1-(OCH3)4 in
ultrapure water (b) Dendrosomes contained inside a dendrosome bag from
(3,4,5)12G1-PE- (3,4,5)-3EO-G-(OH)6 in PBS (c) Polygonal dendrosomes from
(3,4)12G1-PE-(3,4)-3EO-G1-(OMe)4 (d) Bicontinuous cubic particles co-existing
with low concentration of spherical dendrosomes from (3,5)12G1-PE-(3,4,5)-2EO(OMe)6 (e) Disc-like micelles and toroids from (3,4,5)12G1-PE-(3,5)-3EO-(OMe)4
(f) Micelles from (3,4,5)12G1-PE-BMPA-G2-(OH)8 (g) Dendrosomes from
(3,5)12G1-PE-(3,4,5)-3EO-(OMe)6 (h) Rod-like, ribbon and helical micelles from
tris12-PE-BMPA-G2-(OH)8.
In addition to solvent injection method which yielded vesicles with little
polydispersity, dendrosomes were also prepared by thin film hydration.

In brief,

hydration experiments were performed on films drop cast onto a roughened Teflon
surface at a concentration of 2 mg dendrimer (in 200 µL solvent) per ~1 cm2. Samples
were dried under vacuum prior to hydration with 2 mL of ultra pure water or phosphate
buffered saline at 50°C. This method was used to generate giant dendrosomes ranging in
size from 2 to 50 µm in diameter, which were analyzed by either phase contrast or bright
field microscopy. Visualization of both vesicle wall and cavity was carried out using
fluorescence microscopy and a combination of hydrophobic (Nile Red) and hydrophilic
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(Calcein) dyes. The hydrophobic dye was mixed with the Janus-dendrimer by adding 10
µM Nile Red to a solution of amphiphile in dichloromethane or diethyl ether. Films were
prepared as described above and hydrated with 10 µM Calcein solution in saturated
sucrose. Following hydration, Calcein containing dendrosomes were isolated from the
free dye by repeated centrifugation washing cycles. Giant unilamellar dendrosomes were
visualized by fluorescence microscopy where the hydrophobic dye was observed to
concentrate exclusively in the wall whereas the hydrophilic dye was observed only in the
aqueous interior (Figure 3.3).

Figure 3.3- Optical Microscopy of giant dendrosomes
(a) Fluorescence microscopy image of dendrosome from (3,5)12G1-PE-(3,4)3EO(OH)4 encapsulating both hydrophobic Nile Red and hydrophilic Calcein dyes
(b)Dendrosome from (3,4)12G1-PE-BMPA-G2-(OH)8 visualized with Nile Red. (c)
Worm-like micelle from (3,4,5)12G1-PE-BMPA-G2-(OH)8 encapsulating Nile Red
(d) Spherical micelle from (3,4)12G1-PE-(3,4,5)3EO-(OH)6 encapsulating Nile Red.
(e), Dendrosome from (3,4,5)12G1-PE-(3,4,5)3EO-G1-(OH)6 visualized with Nile
Red and Calcein. Copyright (2009) Nature.
Micromanipulation

experiments

revealed

that

dendrosomes

are

more

mechanically stable than liposomes, possessing higher areal expansion moduli, Ka than

87

phospholipids, yet displaying lipid-like critical areal strains (Figure 3.4). For example,
dendrosomal materials 35-12-8 and 34-12-8 have area expansion moduli of
approximately 950 mN/m, well in excess of the 781 mN/m measured for a 50%
SOPC/50% cholesterol mixture [111].

Figure 3.4-Micropipette aspiration experiments on dendrosomes
(a) Micropipette aspiration assessment of mechanical strength by micro
deformation undernegative pressure of (3,5)12G1-PE-BMPA-G2(OH)8. f, The same
dendrosome under negative pressures howing small deformation of membrane. k,
Areal strain (〈〈c) determined from micropipette aspiration upon rupture. Copyright
(2009) Nature.
The stability of dendrosomes was investigated in biologically relevant media by
formation of membranes via ethanol injection into both phosphate buffered saline and
citrate buffer. Dendrosomes formed from compounds in library 1 showed poor stability
in phosphate buffered saline. However, stability in citrate buffer was maintained over a
period of two weeks. Dendrosomes formed from compounds from library 2 exhibited
excellent stability in ultrapure water as well as in phosphate and citrate buffers. Selected
dendrosomes were loaded with the anthracyclin drug, Doxorubicin, [92] used extensively
in the treatment of Hodgkins lymphoma, stomach, lung and breast cancers. This drug
shows activity as a DNA intercalator.

As mentioned, one major limitation of

Doxorubicin is cardiotoxicity at the therapeutic dosage. However, it is believed that
cardiotoxicity is mitigated though encapsulation of the drug in nanoparticles;
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encapsulated doxorubicin is commercially available in the liposomal preparation as Doxil
[92, 96]. However, synthetic liposomal drug formulations suffer from higher leakage and
reduced in vivo stability when compared to their natural counterparts.
Rapid growth and higher metabolic turnover exhibited by neoplastic cells result in
both leaky vasculature and a lower than physiological pH (~5.2). As a consequence of the
leaky vasculature and poor lymphatic drainage, nanoparticles, such as dendrosomes, tend
to aggregate at tumor sites rather than healthy tissue; this is know as the EPR effect [24,
25]. As a consequence, dendrosomes tend to passively target tumor cells rather than
healthy tissue. Janus-amphiphiles contain cleavable bonds which breakdown under acidic
conditions and destabilize the vesicle structure. Without special design, NMR analysis
showed that the cleavable bond in the Janus-dendrimer structure under identical pH
conditions is the aromatic-aliphatic ester bond. Engineering the dendrosome with
alternative pH-sensitive groups [92] is in progress in the Perec Laboratory. Selected
Janus-dendrimers tagged with Texas Red dye were shown to co-assemble into fluorescent
giant unilamelar liposomes with unlabelled Janus-dendrimers, block-copolymers and
phospholipids which demonstrate the potential utility of tagged Janus-dendrimers,
suggesting their use in theranotics (for detection and treatment of disease).
In order to determine their biocompatibility, unloaded dendrosomes were
incubated with HUVECs for a predetermined period and then subsequently Cell Titer
Blue assay was performed to determine the toxicity of the material on endothelial cells.
It was determined that the dendrosomes are relatively nontoxic to endothelial cells and
thus provide great promise as drug carriers.
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Several examples of liposomes assembled from positively charged polymerdendrimer block copolymers[112] and from charged amphiphilic dendrimers[108, 113]
are available. Nevertheless, the results demonstrate a simple and general strategy to the
design and synthesis of amphiphilic Janus-dendrimers that self-assemble into stable and
monodisperse dendrosomes and other complex architectures. Dendrosomes expand the
field of supramolecular dendrimer chemistry into new functions with possible
technological applications.

3.3 EXPERIMENTAL METHODS
3.3.1 Preparation of Doxorubicin Loaded Dendrisomes (dendrimeric vesicles) for
Loading and Release Studies
Self-assembly via thin-film hydration was used to assemble the dendrimers into
their equilibrium morphologies.

Film hydration has been extensively utilized for

preparing non-degradable polymer vesicles comprised of PEO-b-PBD and PEO-b-PEE
diblock copolymers [4, 9]. Briefly, 200 microliters of a 10mg/mL dendrimer solution in
methylene chloride were uniformly deposited on the surface of a roughened Teflon plate
followed by evaporation of the solvent for >12h under vacuum. Addition of aqueous
hydration solution, (~290 milliosmolar ammonium sulfate solution and doxorubicin
(DOX) (.2mg/ml), pH 7.3) followed by sonication led to spontaneous budding of drug
encapsulated nanosized dendrosomes dendrosomes, off the teflon-deposited thin-film,
into the aqueous solution. The sonication procedure involved placing the sample vial
containing the aqueous based solution and dried thin-film formulation (of dendrimer
uniformly deposited on Teflon) into a sonicator bath (Branson; Model 3510) @ 60-65°C
for 30min followed by constant agitation for 60 minutes at 60-65°C. Subsequently, five
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cycles of freeze-thaw extraction followed; freeze-thaw extraction was carried out by
placing the sample vials in liquid N2 and subsequently thawing in a water bath at 5060°C.
After hydration and sonication, samples were placed into dialysis cassettes and
dialyzed at 4°C in iso-osmotic citrate phosphate buffer (pH~7.4)

to remove non-

entrapped DOX. Dialysis solutions were changed 4 times over approximately 48 hours.
After the dialysis, the samples were removed from the dialysis cassette, and diluted in the
citrate phosphate buffer. Release studies of DOX from the loaded dendrosomes were
initiated immediately following dilution in buffer.
3.3.2 Doxorubicin Release from Dendrisomes Studies
Doxorubicin

release

from

the

dendrisome

core

was

was

measured

fluorometrically (using a SPEX Fluorolog-3 fluorimeter;λex = 480nm,λem = 590nm) at
various intervals up to fourteen days. The fluorescence was obtained at time zero for all
samples. Subsequently, a portion of the samples were acidified with 12.1N HCl to
reduce the pH down to approximately 5.2 and the fluorescence was remeasured, with this
new fluorescence being time zero for the acidified samples. Inside the aqueous core, the
DOX is aggregated and its fluorescence is quenched. As the drug is released from the
dendrosome core and diluted into the external solution its fluoreswcence is no longer
quenched and thus increases.

Thus, an increase in fluorescence over time can be

correlated to doxorubicin release.
At the culmination of the study, the samples were solubilized using Triton X-100
and heat. The percent of Dox release over time was calculated as the ratio between the
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fluorescence measured at each time point to the maximum final fluorescence obtained upon lysis
of the vesicles with TritonX-100 at the culmination of the study according to the equation:
P% = (It-It0)/(Imax(Tx)-It0)x100

Equation 3.1

where It = fluorescence at each time point t
It0 = fluorescence at time point 0
Imax(Tx) = maximum fluorescence upon lysis with Triton X

3.3.3 Cytotoxicity Studies of Various Dendrimers
Since endothelial cells are the first point of contact for intravenous drug formulations, the
toxicity of the dendrosomes was evaluated in vitro on human umbilical vein endothelial cells
(HUVECs). In order to estimate the toxicity of these dendrosomes, cell viability

experiments were carried out on human umbilical vein endothelial cells (HUVECs).
Dendrosomes from library 2 were incubated with HUVECs at varying concentrations for
a period of four hours. Cell viability assays with Cell Titer-BlueTM, a dye that becomes
fluorescent in the presence of living cells, were carried out at 1, 2 and 4 h intervals
Library 2 showed no discernable toxicity when compared to the control experiments
(Figure 5) indicating an excellent biocompatibility for dendrosomes..
HUVECs were cultured in EGM Endothelial Growth Media (LONZA) supplemented
with bovine brain extract (BBE) with heparin, h-EGF, hydrocortisone, gentamicin, amphotericin
B (GA-1000), and fetal bovine serum (FBS). Cells were maintained in plastic culture flasks at
37 C in a humidified atmosphere containing 5% CO2 and were further subcultured when the
flasks were 70% to 90% confluent. The passage number of the cells for the HUVECs in vitro
studies ranged from 5-8.

HUVECs were plated at a density of 3,200 cells per well (10,000cells/cm2) in 96
well tissue culture plates and allowed to adhere overnight. Culture media was removed
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from the wells and replaced with 250µL of either: 100% media, 94% media/6% PBS
buffer, 87.5% media/12.5% PBS buffer, 75% media/25% PBS buffer, 100% PBS buffer,
and various concentrations of sterile dendrosomes and PEO-b-PCL and PEO-b-PBD
polymersomes ranging from 0.0625mg to 0.25mg in the three concentrations of
media/PBS, and maintained at 37◦C in a humidified atmosphere of 5% CO2. The
dendrosomes and polymersomes were prepared by film the hydration method as
described in and manually extruded 25 times through 100 nm polycarbonate membrane.
Dendrosomes and polymersomes were sterilized by exposing them for 30min to UV
radiation.
The investigation of dendrosome toxicity and cell viability was assessed
fluorometrically using the indicator dye resazurin (CellTiter-Blue Cell Viability Assay,
Promega) which is reduced by viable cells from a non fluorescent form to a highly
fluorescent form, resorufin, according to Equation 3.2. The viable cells retain the
metabolic capacity to convert resazurin to resorufin while nonviable cells rapidly lose
metabolic capacity and are not able to reduce the indicator dye hence no fluorescent
signal is generated. As such, cell viability can be monitored by fluorescent changes.
Equation 3.2- Reduction of resazurin to resorufin in the presence of live cells.
-O

O
N

-O

O
[live cells]

O
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At various defined time points (1h, 2h, and 4h post vesicle administration), wells
were washed three times with 250µL of PBS and 100µL of fresh media was added. To
the fresh media, 20µL of Cell-Titer Blue (Promega) was added and cells were incubated
at 37◦C in a humidified atmosphere containing 5% CO2 for 2 hours. Subsequently,
100µL of media containing Cell-Titer Blue was removed from the cells and placed in the
wells of a 96 well black bottom plate. The fluorescence intensity at 590nm emanating
from the wells when excited at 560nm was then determined using a TECAN
Inifinite2000 plate reader.

3.4 RESULTS AND DISCUSSION
3.4.1 Doxorubicin Release from Dendrosomes
Selected dendrosomes from libraries 1 and 2 were loaded with the anthracyclin
drug, Doxorubicin, and its release was monitored fluorometrically at 37 C at
physiological pH (~7.2~7.4) and acidic pH (~5.2~5.4).

Figure 3.1 shows selected

experiments that illustrate a significantly higher release of drug at acidic pH than at
physiological pH.

As mentioned, Janus-amphiphiles contain cleavable bonds which

breakdown under acidic conditions leading to destabilization of the vesicle structure;
hence more drug is released at low pH. Since the vasculature surround the tumor has a
lower than physiological pH (~5.2), hence, this increased release at low pH is quite
beneficial for delivering drug to the tumor. For both conditions, the characteristic burst
phase release is seen where approximately 20% of the drug is released within the first
twelve hours. Subsequent release of the drug from dendrosomes at both pHs is slower.
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Figure 3.5- Characterization of the release of doxorubicin from dendrosomes
(a) Release of Doxorubicin from dendrosomes assembled from (3,5)12G1-PEBMPA-G2-(OH)8 showing excellent stability at physiological temperature and pH
7.4 and rapid release of the drug at physiological temperature and pH 5.2 (b)
Comparative of release of doxorubicin dendrosomes from different libraries.
3.4.2 Dendrosome Cytotoxicity Studies
Since endothelial cells are the first point of contact for intravenous drug formulations, the
toxicity of the unloaded dendrosomes was evaluated in vitro on human umbilical vein endothelial
cells (HUVECs) over the course of four hours. Dendrosomes from library 2 were incubated
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with HUVECs at varying concentrations for a period of four hours. Cell viability assays
with Cell Titer-BlueTM, a fluorometric agent that reports metabolic activity of cells, were
carried out at 1h, 2h and 4h intervals. Live cells undergo metabolism causing a change in
the fluorescence of the molecule, while dead cells do not undergo metabolism and hence
do not change the fluorescence of the molecule; this can be quantified via the
fluorescence of the CellTiter Blue substrate. Library 2 showed only slight toxicity when
compared to the polymersome control experiments (Figure 3.6) after one and four hours.
At 2 hours, the dendrosomes showed no discernable toxicity when compared to the
control experiments (Figure 3.6); these results indicated an excellent biocompatibility for
dendrosomes. Hence, the viability results demonstrate that the uptake of dendrosomes is
well tolerated by the HUVECs.
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Figure 3.6- Cell viability studies conducted using various dendrosomes from library
2
with human umbilical vein endothelial cells (HUVEC) and CellTiter-BlueTM cell
viability assay after 1h (top), 2h (middle) and 4h (bottom) from the moment the cell
were fed with dendrosomes. Control: EGM Endothelial Growth Media (LONZA)
Polymersome 1: hydrogenated polybutadiene-b-polyethyleneoxide; Polymersome 2:
polycaprolactone-b-polyethyleneoxide; Dendrosome 1: (3,4)12G1-PE-(3,4,5)3EO97

G1-(OMe)6; Dendrosome 2: (3,5)12G1-PE-(3,4,5)3EO-G1-(OMe)6; Dendrosome 3:
(3,4,5)12G1-PE-(3,4,5)3EO-G1-(OH)6

3.5 CONCLUSIONS
The results of studies described in this chapter demonstrate the potential use of
self-assembled dendrimeric vesicles for drug delivery purposes. Here we show that
libraries of amphiphilic Janus-dendrimers self-assemble into monodisperse and stable
vesicles, termed dendrosomes.

In addition to the classical spherical shape, these

dendrimers self-assemble into a variety of less encountered shapes.
Doxorubicin, a chemotherapeutic, was successfully loaded into the aqueous core
of vesicles self assembled from a variety of the amphiphilic Janus-dendrimers.

In

contrast to DOX loading in polymersomes (Chapter 2), DOX was not loaded actively
across the membrane with a gradient, but rather passively in the hydration solution. The
release of the drug from the vesicles was investigated at two physiologically relevant
pH’s and characterized. Furthermore, toxicity studies with these vesicles confirmed that
these vesicles are non-toxic to Human Umbilical Vein Endothelial Cells (HUVECs) at
short times.

Based on the performance of the dendrimeric vesicles in laboratory

experiments, it is expected that dendrosomes will extend the capabilities of synthetic
amphiphiles, generating responsive membranes with permeability controllable for
desirable drug delivery.
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Chapter 4
POLYMERSOMES: SELF-ASSEMBLED VESICLES FOR IMAGING
AND DRUG DELIVERY
ADAPTED FROM

Dalia Hope Levine, Nimil Sood, Julie Czupryna, Lanlan Zhou, Ramacharan Murali,
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4.1 SUMMARY
The bioresorbable poly(ethylene oxide)-b-poly(ε-caprolactone) polymersome,
with its thick lamellar hydrophobic membrane, of approximately 22nm, and large
aqueous core, holds great clinical promise for use in theranostic biomedical applications,
where both drug and imaging agent are simultaneously loaded into the same vesicle for
drug delivery and imaging purposes. This chapter discusses the generation of a near
infrared (NIR) emissive polymersome, a self-assembled polymer vesicle, loaded with the
NIR dye porphyrin in its hydrophobic compartment. Much of the seminal research
regarding NIR-emissive polymersomes was carried out by Ghoroghchian et al. Yet, the
ability to combine an imaging capability with drug delivery remained to be created and
characterized. The following chapter illustrates the design of a polymersome with the
capability to load both an imaging agent as well as a chemotherapeutic into one vesicle,
creating an optimal platform for both drug delivery and imaging.
This

chapter

chemotherapeutic,
polymersomes.

demonstrates

into

the

ability

to

encapsulate

doxorubicin,

poly(ethylene oxide)-b-poly(ε-caprolactone)

a

NIR-emissive

In addition to loading studies, the release of doxorubicin from the

vesicles was investigated.

The increase in fluorescence from doxorubicin, as it is

released from the vesicle, and the decrease in fluorescence from the porphyrin
chromophore, as the polymersome membrane degrades, were examined and will be
discussed in this chapter. Subsequent chapters will elaborate on the use of the NIRemissive polymeric vesicles for in vitro cellular uptake studies (Chapter 5) and in vivo
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imaging (Chapter 6). Furthermore, the use of the porphyrin-doxorubicin multi-modal
polymersome for imaging drug delivery will be explored in Chapter 6.

4.2 INTRODUCTION
The attractive biomaterial properties of polymersomes such as prolonged
circulation times [8], increased mechanical stability [7],and the ability to incorporate
numerous large hydrophobic molecules within their thick lamellar membranes and
hydrophilic molecules within their lumen [5, 6] render these vesicles useful in a variety
of clinical applications. One such application is in vivo deep tissue fluorescence based
optical imaging.
Currently, intravital microscopy (IVM), through the use of visible probes, has
enabled anatomical, functional and molecular imaging of live animals [114]; however,
due to light scattering and optical absorption by living tissue, the in vivo imaging
potential of these visible probes decreases substantially at tissue depths great than 500
µM to 1 mm [115]. Since light scattering decreases with increasing wavelength and the
absorbance spectra for hemoglobin and water reach their lowest values in the Near
Infrared (NIR) region of the spectra (Figure 4.1) [115], research efforts have been
focused on developing optical imaging probes in the NIR window for in vivo
applications.
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Figure 4.1- The absorbance spectra for water, hemoglobin, and water clearly
showing a nadir in their optical absorption over the NIR window.
Adapted from Weissleder [115].
A family of molecules which emit in the NIR has been developed by the Therien
Laboratory. The chemical structure and absorption spectra of these porphyrin based
fluorophores (PBF) is shown in Figure 4.2 and Figure 4.3A. These porphyrin molecules
are derived from the linkage of (porphinato) zinc (II) (PZn) macrocycles by meso-tomeso, beta-to-meso, and beta-to-beta ethynyl- and butadiynyl-bridges [116-118]. The
optical properties of these biologically inspired porphyrin molecules can be tuned over a
large window of the visible and NIR spectra by varying the number of macrocycles per
molecule, the bond type and location of the linkages between the macrocycles, and lastly
by changing the side groups [117]. These subtle changes in porphyrin chemical structure
can predictably change the optical properties of the fluorophores. The porphyrin trimer,
(PZn3), denoted as DDD in Figure 4.2, with its absorption maxima at 790nm and
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emission maxima at 809nm, is optimal for biologically based imaging applications for
reasons enumerated above. All NIR-emissive polymersome in situ, in vitro, and in vivo
work to be discussed therein utilized this particular porphyrin molecule.
These porphyrin molecules, however, are very large, ranging from 2.1nm
(monomer) to 5.3nm (pentamer) in length, and are highly hydrophobic, thus underscoring
the need for an appropriate amphipathic delivery system with a large hydrophobic region
[9]. Due to its large hydrophobic bilayer, the polymersome makes for a great delivery
vehicle for the porphyrin molecules. Recall the polymersome hydrophobic membrane
(~9nm-22nm), tuned by the length of the hydrophobic block of the copolymer, is at least
double the thickness of the liposome membrane (~3nm-4nm) [9]. As such, only the
monomeric or dimeric porphyrin molecules can be incorporated into liposomes, and only
at loading levels of ~1 mol%. In contrast, the incorporation of larger porphyrin structures
into the polymersome bilayer is easily obtained even at loading levels greater than 5
mol% (Figure 4.3B) with little effect on the spectral properties of the chromophore or the
structural properties of the polymersome membrane [51].

In addition to the large

hydrophobic membrane, which renders the polymersome ideal for the incorporation of
porphyrin fluorophores, the optimal biological properties of polymersomes previously
discussed, such as increased circulation due to the fully PEG-ylated brush [8] and
increased mechanical and thermodynamic stability [3], make the porphyrin loaded
polymersome quite useful for biological imaging applications.
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Figure 4.2-Some
Some of the porphyrin molecules ((PZn2 to PZn5)
whose macrocycles are linked by meso-to-meso
meso ethyne bridges. All in situ, in vitro,
and in vivo studies use the porphyrin trimer, DDD. Image adapted from Duncan
[118].

Figure 4.3- A) A subset of the family of porphyrin molecules
molecules, B) uniformly, stably,
and non-covalently
covalently incorporated into the hydrophobic bilayer of poly(ethylene
poly
oxide)-b-polybutadienee polymersomes. Adapted from Ghoroghchian (2005) [10].
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The NIR emissive polymersome soft matter complex, developed and extensively
characterized by Ghoroghchian et al [9, 51, 52, 119], is formed through the cooperative
self assembly of the diblock copolymer with the porphyrin molecules [9]. Following self
assembly, the vesicles maintain an aqueous core free of dye and there is no need for
further processing to remove unincorporated dye. Furthermore, no release of dye to the
internal or external aqueous solution is observed [51].

Figure

4.3B

depicts

the

stable, non-covalent, and uniform incorporation of multiple porphyrin molecules copies
into the polymersome bilayer. Incorporating the family of porphyrin molecules into
polymeric vesicles leads to a family of soft matter optical imaging agents with emission
maxima that span the window from approximately 575nm to 1000nm [51].
The incorporation of therapeutics into the aqueous core of the porphyrin
polymersome leads to the generation of multi-modal vesicles, with the capability to both
track vesicle location in vivo and locally deliver therapeutics.
The ability to incorporate numerous porphyrin molecules into one polymersome
creates an intensely bright fluorescent contrast agent with great promise for in vivo
imaging applications. The additional encapsulation of therapeutics into these contrast
agents lead to the creation of a multi-functional polymer vesicle with great theranostic
utility.

4.3 EXPERIMENTAL METHODS
4.3.1 Preparation of Porphyrin Loaded PEO-b-PBD and PEO-b-PCL Vesicles
Self-assembly via thin-film hydration was used to assemble the PEO-b-PCL and
PEO- b-PBD copolymers into their equilibrium morphologies. Film hydration has been
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extensively utilized for preparing non-degradable polymersomes comprised of PEO-bPBD and PEO-b-PEE diblock copolymers [4, 9]. Furthermore, Ghoroghchian, et al.
demonstrated the ability to load porphyrin molecules of various sizes into polymer
vesicles [9, 51, 52, 119].
Briefly, a PEO-b-PCL copolymer or PEO-b-PBD copolymer solution in
methylene chloride was prepared (35mg/ml-100mg/ml polymer) and added to porphyrin
at a 1:40 porphyrin:polymer molar ratio. Two hundred microliters of the polymerporphyrin solution were uniformly deposited on the surface of a roughened Teflon plate
followed by evaporation of the solvent for >12h.

Addition of aqueous solution,

(~290mOsM Phosphate Buffered Saline, PBS) and sonication at 65°C led to spontaneous
budding of polymersomes, off the Teflon-deposited thin-film, into the aqueous solution.
The sonication procedure involved placing the sample vial containing the aqueous based
solution and dried thin-film formulation (of polymer-drug uniformly deposited on Teflon)
into a sonicator bath (Branson; Model 3510) @ 60-65°C for 30min followed by constant
agitation for 60 minutes at 60-65°C. Subsequently, five cycles of freeze-thaw extraction,
which involved placing the sample vials in liquid N2 followed by thawing in a water bath
at 50-60°C. Extrusion using a pressure driven Lipex Thermobarrel Extruder (1.5 mL
capacity) at 65°C was performed to yield small (<300-nm diameter) unilamellar
polymersomes that possess appropriately narrow size distributions. The size distribution
of the vesicle suspensions was determined by dynamic light scattering. The sample was
centrifuged, filtrate removed, and additional PBS buffer was added to the concentrated
sample for a total of nine times. The collected polymersome solution was centrifuged to
concentrate the sample.
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Absorbance spectra of the NIR-emissive polymersomes were obtained using an
Ultrospec 2100pro Amersham Biosciences UV/Visible Spectrophotometer. Fluorescence
spectra of NIR-emissive polymersomes were obtained with a Spex Fluorolog-3
spectrophotometer (Jobin Yvon, Edison, NJ) The concentration of porphyrin in the
vesicles was determined by measuring the absorbance (molar extinction coefficient
1.29*105 cm-1M-1 in polymersomes at 794nm [9]).
4.3.2 Preparation of Porphyrin and Doxorubicin Loaded PEO-b-PCL Vesicles and the
Release of Doxorubicin and Porphyrin from PEO-b-PCL Vesicles
Similar to previous procedures, a PEO-b-PCL copolymer solution in methylene
chloride was prepared (35mg/ml-100mg/ml polymer) and added to porphyrin at a 1:40
porphyrin:polymer molar ratio. The solution was deposited on the surface of a roughened
Teflon plate followed by evaporation of the solvent for >12h. Hydration of the samples
in Ammonium Sulfate Solution (~290mOsM, pH~5.4), equilibration at 60-65 C for 30
minutes, and finally sonication at 60-65°C using a sonicator bath (Branson; Model 3510)
led to spontaneous budding of polymersomes, off the Teflon-deposited thin-film, into the
aqueous solution. Five cycles of freeze-thaw extraction as described in Section 4.3.1
followed the sonication. Extrusion using a pressure driven Lipex Thermobarrel Extruder
(1.5 mL capacity) at 65°C was performed to yield small (<300-nm diameter) unilamellar
polymersomes that possess appropriately narrow size distributions. The size distribution
of the vesicle suspensions was determined by dynamic light scattering.
Vesicles of the appropriate size were dialyzed against iso-osmotic acidified
sodium chloride solution (pH~5.5—acidified with 12.N HCl, ~290mOsM) to establish a
gradient across the vesicle membrane; three buffer exchanges were made in
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approximately 30 hours. Similar to the loading in PEO-b-PmCL, dialysis into sodium
acetate buffer at pH 5.5, as performed with PEO-b-PCL vesicles discussed in Chapter 2,
did not yield stable loading as determined via fluorescence measurements.

Hence,

dialysis in various buffers was attempted, as will be elaborated upon in Section 4.4.2, and
it was determined that stable fluorescence counts were obtained for loading when isoosmotic acidified NaCl (pH~5.5) was used as the dialysis media.
Post dialysis, vesicles were incubated with doxorubicin at a ratio of .2:1
(drug:polymer) at 65 C for greater than 7 hours [77-79]. Non-entrapped DOX was
removed from the multi-functional polymersome suspension using an HPLC (Acta Basic
10 HPLC with Frac 950) and the solution was passed through a HiTrap desalting column.
The fractions containing only multi-functional polymersomes were collected, centrifuged
and concentrated. Incorporation of porphyrin and encapsulation of DOX was confirmed
spectrophotometrically using an Ultrospec 2100pro Amersham Biosciences UV/Visible
Spectrophotometer.
The release of doxorubicin from the vesicles and the decrease in porphyrin
fluorescence over time was determined fluorometrically. Aliquots of the samples were
placed into either PBS buffer (290 mOsM at pH ~7.4) or sodium acetate buffer (50 mM
sodium acetate and 100 mM sodium chloride, at pH ~ 5, 290mOsM) with N = 4 samples
for each buffer. Release studies of DOX from the loaded polymersomes were initiated
immediately following aliquoting; DOX and Porphyrin fluorescence were measured
fluorometrically using a SPEX Fluorolog-3 fluorimeter (DOX: λex = 480nm, λem =
590nm; Porphyrin: λex = 480nm, λem = 800nm) at various intervals up to fourteen days.
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As DOX is released from the polymersome core and diluted into the surrounding
solution, its fluorescence emission increases over time.

In contrast, as the vesicle

membrane is hydrolyzed, the porphyrin fluorescence decreases upon membrane
degradation. At the culmination of the study, the samples were solubilized using Triton
X-100, which disrupts the vesicle membrane and releases the encapsulated DOX into the
external solution. The percent release over time and release rate were calculated by
comparing the measured DOX fluorescence at each time point to final DOX
fluorescence, as determined upon solubilization of remaining intact polymersomes with
TritonX-100, at the completion of the study.

4.4 RESULTS AND DISCUSSION
4.4.1 The Loading of Porphyrin into PEO-b-PCL and PEO-b-PBD Vesicles
Porphyrin trimer was successfully loaded into PEO-b-PCL and PEO-b-PBD
vesicles at a molar ratio of 1:40 (Porphyrin to polymer) as previously described by P.
Peter Ghoroghchian [9, 51]. In both cases, the incorporation of porphyrin was confirmed
using absorbance spectroscopy, where the spectra clearly demonstrate both scatter due to
the vesicles as well as the characteristic absorbance peaks of porphyrin (Figure 4.4).
Porphyrin PEO-b-PBD vesicles were used in the initial vesicle biodistribution studies
discussed in subsequent chapters.

Once the biodistrbution was determined,

biodegradable porphyrin PEO-b-PCL vesicles were used to further elucidate the
biodistribution and degradation of the vesicles in vivo.
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Figure 4.4- Absorbance spectra of porphyrin loaded vesicles
showing the incorporation of porph
porphyrin into A) PEO-b-PCL
PCL Vesicles and b) PEO-bPEO
PBD Vesicles. The characteristic absorbance peaks as well as the scatter from the
vesicles is clearly visible.
4.4.2 Loading and Release of Doxorubicin and Porphyrin in PEO-b-PCL
PEO
Polymersomes
Doxorubicin and porphy
porphyrin
rin were successfully loaded into polymersomes as per
the method described in section 4.3.2.. Successful loading of porphyrin and doxorubicin
was determined by obtaining
aining fluorescence spectra of the dual loaded vesicles and
confirming the existence of the characteristic emission peaks ((Figure
Figure 4.5).

The

encapsulation of doxorub
doxorubicin
icin was further confirmed by comparing fluorescence data pre
and post incubation with the nonionic surfactant, Triton X
X-100 (Figure 4..5).
Doxorubicin was actively encapsulated into the aqueous compartment of
porphyrin PEO-b-PCL
PCL vesicles (~200nm) though a gradient established by dialyzing
samples in acidified NaCl solution [77, 79, 81] (See Section 4.3.2). Recall, PEO-b-PCL
PEO
vesicles are dialyzed against sodium acetate buffer. When dialysis in this media was
attempted, however, similar to the case for PEO
PEO-b-PmCL and PEO-b-PBD
PBD vesicles, the
t
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fluorescence during loading did not stabilize. Hence, acidified sodium chloride solution
was tested as dialysis exchange media and deemed acceptable.
In situ release studies were conducted at various physiological conditions (pH 5
and pH 7.4,@T=37 C) where changes in doxorubicin and porphyrin were monitored
fluorometrically (λex=480nm, λem-DOX=590nm, λem-porphyrin=794nm) over 14 days. At both
pH’s, the characteristic initial burst phase release (where approximately 20% of the initial
payload within the first 12 hours) was observed followed by a more controlled pH
dependent release over the 14 day release study (Figure 4.4 B,C). At a pH of 5, the initial
release rate is significantly faster than the rate observed over the entire 14 days;
furthermore, similar to the findings for PEO-b-PCL vesicles alone, it appears that the
dominant mechanism of release at both short and long times at this pH is acid catalyzed
hydrolysis of the PCL membrane. At a pH of 7.4, two distinct phases (α, β) were
observed for DOX release from PEO-b-PCL vesicles. In contrast, when porphyrin is
incorporated into the hydrophobic membrane, it appears that the large porphyrin
molecules hinder extensive initial passive diffusion of the drug across the PCL
membrane, and thus significant doxorubicin release from the polymersome core at pH 7.4
occurs at later times. This suggests that DOX release from the porphyrin vesicles is
predominantly facilitated by hydrolytic matrix degradation of the caprolactone backbone
(Figure 4.6 B, C), even in non-acidic environments. Since acid catalyzed hydrolysis of
the membrane occurs at both short and long times at pH 5, DOX release at pH 5 is more
rapid and more drug is released than that at pH 7.4
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Figure 4.6A
A depicts the decrease in porphyrin fluorescence over the 14 day time
period. Porphyrin fluorescence is highly environmentally dependent and changes in the
environment are reflected as changes in the florescence. Thus, as the membrane breaks
down
wn and porphyrin is no longer in the hydrophobic environment of the PCL membrane,
its fluorescence decreases. As expected, the porphyrin fluorescence decrease over the 14
days, as the membrane degrades, correlates nicely with the increase in DOX fluorescence
fluoresce
(drug release).

Figure 4.5- Fluorescence spectra of DOX/porphyrin PEO
PEO-b-PCL
PCL vesicles.
The doxorubicin and porphyrin peaks are clearly visible. The inlay is a zoomed in
version of the curve from 70
700nm
0nm to 900nm to show the porphyrin peak.
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Figure 4.6- (A) Porphyrin decrease in fluorescence corresponds with (B)
doxorubicin cumulative release as determined by doxorubicin increase in
fluorescence and (C) rate of doxorubicin release from PEO
PEO-b-PCL
PCL polymeric
vesicles.

4.5 CONCLUSIONS
The findings discussed in this chapter highlight the potential of polymersomes to
be used simultaneously as contrast agents for imaging applications as well as drug
delivery vehicles for therapeutic applications. The results demonstrated the method used
to generate NIR-emissive
emissive polymersomes for imaging applications can be expanded upon
to encapsulate a chemotherapeutic, doxorubicin, into the aqueous core, creating a multifunctional polymersome. Extensive doxorubicin loading studies established the use of
both an ammonium sulfate and a pH gradient across the porphyrin incorporated
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hydrophobic bilayer of the polymersome as the optimal loading environment. Once the
loading parameters were determined, release studies were conducted and the release of
DOX from the vesicle and vesicle breakdown was characterized.
The theranostic applications of these polymer vesicles loaded with therapeutics
and imaging agents will be elaborated upon further in Chapter 7.
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Chapter 5
POLYMERSOMES: DISCOVERING THEIR IMAGING AND DRUG
DELIVERY POTENTIAL IN VITRO
ADAPTED FROM

D. H Levine, J. S. Katz, N. Dang, J. A. Burdick, J. Hadfield, and D. A. Hammer,
Manuscript in Preparation
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5.1 SUMMARY
Polymersomes (polymer vesicles) have been shown to possess a number of
attractive biomaterial properties compared to liposomes (phospholipid vesicles),
including prolonged circulation times, increased mechanical stability, as well as the
unique ability to incorporate numerous large hydrophobic molecules within their thick
lamellar membranes and hydrophilic molecules within their lumen. We have shown the
ability to generate fully-bioresorbable self-assembled nanovesicles, from two FDAapproved building blocks, poly(ethylene oxide) (PEO) and polycaprolactone (PCL). We
have successfully loaded imaging agents, such as porphyrin-based near infrared (NIR)
fluorophores, and therapeutics such as doxorubicin and combretastatin A-4 into these
polymersomes and tracked their release (See Chapters 2 and 4).
Tumors require a network of blood vessels to survive and grow; these blood
vessels are required to provide oxygen and nutrients to the tumor cells and remove carbon
dioxide and waste.

However, these tumor blood vessels are immature and poorly

developed. As a result, the combination of chemotherapeutics with anti-angiogenesis
drugs/vascular disrupting agents (VDA) has emerged as a promising therapy for
eradicating tumors. These agents target genetically stable endothelial cells that constitute
the blood vessels around tumors rather than the transformed tumor cells themselves.
Combretastatin A-4, a hydrophobic cytotoxic agent, inhibits the polymerization of tubulin
and is highly toxic to tumor vasculature, but is believed not to affect healthy vasculature.
Hence, in addition to delivering drug to tumorigenic cells, the ability to deliver
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therapeutics to the endothelial cells lining the newly formed vasculature would be
advantageous in cancer therapy.
Here, we determined the cytotoxic potential of combretastatin A-4 loaded
polymeric vesicles and doxorubicin loaded polymeric vesicles on human umbilical vein
endothelial cells (HUVECs) and SK-BR-3 tumorigenic cells both separately cultured, as
well as in co-cultured. For both cell lines and both therapeutic agents, toxicity was both
concentration

and

time dependent.

Furthermore,

we utilized

NIR-emissive

polymersomes formulated from PEO-b-PCL diblock copolymer and loaded with
porphyrin (a NIR emissive fluorophore) to assess cellular uptake of polymersomes.
Vesicle uptake by HUVECs was dependent on both concentration and incubation time.
A viability assay using CellTiter-Blue™ (Promega) demonstrated biocompatibility of the
unloaded polymersomes at short time for the SK-BR-3 cells and at extended time for the
HUVECs. Thus, this study highlights the feasibility of using polymersomes to deliver
vascular disrupting agents to endothelial cells simultaneously with treating tumors
directly.

5.2 INTRODUCTION
Polymersomes (polymer vesicles) have been shown to possess a number of
attractive biomaterial properties compared to liposomes (phospholipid vesicles),
including prolonged circulation times [8], increased mechanical stability [7], as well as
the unique ability to incorporate numerous large hydrophobic molecules within their
thick lamellar membranes and hydrophilic molecules within their lumen [5, 6]. We have
shown the ability to generate fully-bioresorbable self-assembled nanovesicles, from two
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FDA-approved building blocks, poly(ethylene oxide) (PEO) and polycaprolactone (PCL)
[10]. We have successfully loaded imaging agents, such as porphyrin-based near infrared
(NIR) fluorophores, and therapeutics such as doxorubicin and combretastatin A-4 into
these polymersomes and tracked their release (See Chapters 2 and 4).
Doxorubicin (DOX), an amphipathic antibiotic used to treat a wide array of
malignancies, from solid tumors to leukemias [67-70], has been known to cause
cardiotoxicity at cumulative doses [69, 120]. This has created a major therapeutic
limitation. However, as discussed, encapsulating the drug into a vesicle has been shown
to decrease cardiac toxicity thereby reducing the levels of DOX in heart muscle with
minimal effects on the therapeutic efficacy of the drug [69, 120].
As discussed in Chapter 2, tumors require a network of blood vessels to survive
and grow; these blood vessels are required to provide oxygen and nutrients to the tumor
cells and remove carbon dioxide and waste. However, these tumor blood vessels are
immature and poorly developed [73]. As a result, the combination of chemotherapeutics
with anti-angiogenesis drugs/vascular disrupting agents (VDA) has emerged as a
promising therapy for eradicating tumors [71, 73]. These agents target genetically stable
endothelial cells that constitute the blood vessels around tumors, rather than the
transformed tumor cells themselves [75]. Combretastatin A-4, a hydrophobic cytotoxic
agent, inhibits the polymerization of tubulin and is highly toxic to tumor vasculature, but
is believed not to affect healthy vasculature [76].
Hence, in addition to delivering drug to tumorigenic cells, the ability to deliver
therapeutics to the endothelial cells lining the newly formed vasculature is highly
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advantageous in cancer therapy. The therapeutic potential of the DOX/Combretastatin A4 co-drug combination vesicles, as well as the single drug -vesicle, on Human Umbilical
Vein Endothelial Cells (HUVECs) and the human breast cancer cells, SK-BR-3 cells,
cultured separately and in co-culture was investigated.
It should be noted that the HUVECs are a good "surrogate" for the new
endothelial cells making up the tumor vasculature since they are a well established cell
line that mimics the endothelial cells partially because the HUVECs express some of the
proteins upregulated on new endothelial near tumors [121].
The findings of the enumerated toxicity studies will be explored in this chapter.
First, however, the biocompatibility of non-drug loaded vesicles, as well as cellular
uptake of vesicles by HUVECs and SK-BR-3 cells, were examined and will be discussed.

5.3 EXPERIMENTAL METHODS
5.3.1 Preparation of Drug and Imaging Agent Loaded PEO-b-PCL Vesicles
Drug loaded vesicles were prepared as described in Chapter 2. Porphyrin loaded
PEO-b-PCL and Porphyrin/DOX Vesicles were prepared as described in Chapter 3.
Vesicles were concentrated post formation using Millipore Centricon Tubes.
To determine the concentration of combretastatin in the PEO-b-PCL vesicles, one
hundred microliter sample aliquots were removed and the combretastatin was extracted
from the vesicles by adding the aliquot to 400 microliters of PBS and 500 microliters of
methylene chloride, and subsequently vortexing and centrifuging the sample.

The

resulting aqueous layer was carefully removed, and the remaining organic layer with drug
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was placed in a vacuum. The dried powder resulting from evaporation of the methylene
chloride was reconstituted in 1 milliliter of acetonitrile.

The concentration of

combretastatin was determined by measuring the absorbance (molar extinction
coefficient 12, 579M-1cm-1 in acetonitrile at 300nm). Polymer concentration was
determined by a mathematical calculation, as the molar ratio of combretastatin to
polymer is known to be 0.9:1.
To determine the concentration of Doxorubicin in the PEO-b-PCL polymersomes,
sample aliquots were removed from the concentrated stock solution, and lyophilized to
destroy the vesicle structure and release the encapsulated DOX from the core of the
polymersome. The freeze-dried powder was reconstituted in tertiary butanol:water 9:1,
v/v containing 0.075N HCl or 90% isopropyl alcohol containing 0.075 M HCl. The
concentration of DOX was determined using Beer’s Law by measuring the absorbance at
480nm using a molar extinction coefficient of 12,500cm-1M-1 in either solvent [70, 122].
The concentration of the porphyrin vesicles in solution was determined by
measuring the absorbance at 794nm using a molar extinction coefficient of 1.29*105M1

cm-1 in THF[9]. Polymer concentration was determined by a mathematical calculation,

since the ratio of porphyrin to polymer was set at 1:40 (molar ratio).
For cell studies, 10x concentrations of the drug-polymer vesicles and
imaging agent-polymer vesicles were made by diluting the resulting concentrated sample
in PBS. The 10x samples were further diluted in sterile culture media to yield final
desired drug concentrations in a 90% media-10% PBS aqueous solution. The PBS-
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Media-vesicle suspension was sterilized under UV light in a cell culture hood for 30
minutes, yielding sterile drug loaded vesicles in media-PBS.
5.3.2 Cell Culture
Human umbilical vein endothelial cells (HUVECs) were cultured in EGM
Endothelia Growth Media (LONZA) supplemented with bovine brain extract (BBE) with
heparin, h-EGF, hydrocortisone, GA-1000 (gentamicin, amphotericin B), and fetal bovine
serum (FBS). Cells were maintained in plastic culture flasks at 37◦C in a humidified
atmosphere containing 5% CO2 in air and subcultured when the flasks were 70% to 90%
confluent. To subculture cells, growth media was removed from the HUVEC culture
flask via aspiration and the flask was washed with Hepes Buffered Saline Solution
(HBSS). The HBSS was removed and 0.025mg/ml trypsin-EDTA was added and the
flask was returned to the incubator for 5min at 37 C and 5% CO2 in air. Post trypsin
incubation, trypsin neutralizing solution (TNS, LONZA) was added to the flask and the
wall was washed in order to remove all cells. The cell suspension was then transferred to
a conical tube and centrifuged at 1000rpm for 5 minutes to pellet the cells.

The

supernatant was aspirated and the cells were resuspended in fresh growth media and a
cell count was performed with a hemocytometer for future culturing and well-plating.
HUVECs in vitro studies were conducted with cells between passages 4-8.
The human breast cancer cells, SK-BR-3 cells, were cultured in McCoy's 5a
Medium Modified (base media), 10% fetal bovine serum (FBS), and 1% Pen/Strep 100X
(10000u/ml P - 10mg/ml S). Cells were maintained in plastic culture flasks at 37◦C in a
humidified atmosphere containing 5% CO2 in air and subcultured at subcultivation ratio
of 1:3 when the flasks were 70% to 90% confluent. When cells were deemed 70%-90%
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confluent, growth media was removed from the culture flask via aspiration and the flask
was washed with Phosphate Buffered Saline (PBS). The PBS was removed and trypsinEDTA (0.25%)was added and the flask was returned to the incubator for 5min at 37 C
and 5% CO2 in air. Post trypsin incubation, media was added to the flask and the wall
was washed in order to remove all cells. The cell suspension was then transferred to a
conical tube and centrifuged at 1000rpm for 5 minutes to pellet the cells. The supernatant
was aspirated and the cells were resuspended in fresh growth media and a cell count was
performed with a hemocytometer for future culturing and well-plating. For in vitro
experiments, SK-BR-3 cells between passages 15 to 30 were used.
5.3.3 Determining Cellular Uptake of PEO-b-PCL Vesicles by HUVECs and SK-BR-3
Cells
In order to investigate the cellular uptake of PEO-b-PCL vesicles as a function of
cell number, vesicle concentration, and incubation time, HUVECs and SK-BR-3 cells
were plated at varying densities ranging from 3.0*104 cells/well to 0.7*104 cells/well in
96 well (black frame, clear well) cell culture plates (Isoplate-96 TC, Perkin Elmer) in
complete growth media and allowed to adhere overnight (~20-24hours). Culture media
was removed from the wells, wells were washed once with 250uL of PBS and replaced
with 250uL of either: 90% media/10% PBS without polymersomes, or 90% media/10%
PBS with various concentrations of porphyrin polymersomes and maintained at 37◦C in a
humidified atmosphere containing 5% CO2 in air. The suspensions were sterilized with
30 min exposure to a UV lamp in the culture hood prior to addition to cells. At various
defined time points (.75H, 1.5H, 3H, and 5H post vesicle administration), plates were
removed from the incubator, wells were washed three times with 250uL of PBS to
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remove free vesicles and 100uL of fresh media was added. The fluorescence intensity
emanating from the wells as a result of vesicles that had been taken up was then
determined using a LICOR Odyssey, an Infrared (IR) Imaging System.
5.3.4 Investigating the Biocompatibility and Viability of Unloaded PEO-b-PCL on
HUVECs and SK-BR-3 Cells
In addition to determining vesicle uptake, viability studies were carried out to
determine the biocompatibility of unloaded PEO-b-PCL polymersomes on HUVECs and
SK-BR-3 cells in vitro. HUVECs and SK-BR-3 cells were plated in 96 well plates in
complete growth media and allowed to adhere overnight (~20~24hours). Cells were
removed from the flasks as per the procedure described in Section 5.3.2.

When

examining the effects on HUVECs, HUVECs were plated at a density of 3,200 cells per
well; in separate plates, SK-BR-3 cells were plated at a density of 5,000 cells per well to
examine the effect on SK-BR-3 cells. In each case, cells were allowed to adhere for 20 to
24 hours. Culture media was removed from the wells, wells were washed once with
250uL of PBS and replaced with 250uL of either:

90% media/10% PBS without

polymersomes, or 90% media/10% PBS with various concentrations of unloaded
polymersomes and maintained at 37◦C in a humidified atmosphere containing 5% CO2 in
air. The suspensions were sterilized with 30 min exposure to a UV lamp in the culture
hood prior to addition to cells. At various defined time points (.12H, 24H, 48H, and 72H
post vesicle administration), plates were removed from the incubator, wells were washed
three times with 250uL of PBS to remove free vesicles, and 100uL of fresh media was
added. 20ul of CellTiter-Blue® (Promega) was added to each well and the plate was
returned to the incubator. After two hours of incubation, 20ul of the CellTiter-Blue™
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/Media from the wells was added to 80ul of PBS in a 96-well black bottom assay plate,
and the fluorescence emanating from the wells, which is a measure of cell viability, was
determined using a TECAN Infinite® 2000 Multimode microplate reader.
5.3.5 Investigating the Anti-vasculature Potential of Combretastatin PEO-b-PCL
Polymersomes on HUVECs and SK-BR-3 Cells Cultured Separately
In order to investigate the anti-vasculature potential of combretastatin loaded
PEO-b-PCL vesicles, HUVECs were plated at a density of 3,200 cells per well
(10,000cells/cm2) in 96 well cell culture plates and SK-BR-3 cells were plated in separate
96 well cell cultures plates at a density of 5,000 cells per well; in each instance, cells
were allowed to adhere overnight (~20-24hours). Culture media was removed from the
wells, wells were washed with 250uL of PBS, and replaced with 250uL of either: 100%
media, 90% media/10% PBS, 100% PBS, and various concentrations of drug in 90%
media/10% PBS, and maintained at 37◦C in a humidified atmosphere containing 5% CO2
in air. The suspensions were sterilized with 30 min exposure to a UV lamp in the culture
hood prior to addition to cells. At various defined time points (12H, 24H, 48H, and 72H
post drug administration), wells were washed with 250uL of PBS and 100uL of fresh
media was added. To the fresh media, 20uL of CellTiter-Blue® (Promega) was added to
each well and the cells and Titer Blue were incubated at 37◦C in a humidified atmosphere
containing 5% CO2 in air for 2 hours. Subsequently, 20uL of media containing CellTiterBlue™ was removed from the wells and diluted into 80uL of PBS in the wells of a 96well black bottom assay plate. The fluorescence intensity emanating from the wells,
which is a measure of cell viability, was then determined using a TECAN Infinite® 2000
Multimode microplate reader.
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5.3.6 Investigating the Cytotoxic Effects of Doxorubicin Loaded PEO-b-PCL Vesicles
on HUVECs and SK-BR-3 Cells Cultured Separately
Doxorubicin single culture cytotoxicity studies were carried out in a manner
similar to the previously discussed studies. HUVECs were plated at a density of 3,200
cells per well (10,000cells/cm2) in 96 well cell culture plates and SK-BR-3 cells were
plated in separate 96 well cell cultures plates at a density of 5,000 cells per well; in each
instance, cells were allowed to adhere overnight (~20-24hours). Culture media was
removed from the wells, wells were washed with 250uL of PBS, and replaced with
250uL of either:

100% media, 90% media/10% PBS, 100% PBS, and various

concentrations of drug in 90% media/10% PBS, and maintained at 37◦C in a humidified
atmosphere containing 5% CO2 in air. The suspensions were sterilized with 30 min
exposure to a UV lamp in the culture hood prior to addition to cells. At various defined
time points (12H, 24H, 48H, and 72H post drug administration), wells were washed with
250uL of PBS and 100uL of fresh media was added. To the fresh media, 20uL of
CellTiter-Blue® (Promega) was added to each well and the cells and Titer Blue were
incubated at 37◦C in a humidified atmosphere containing 5% CO2 in air for 2 hours.
Subsequently, 20uL of media containing CellTiter-Blue™ was removed from the wells
and diluted into 80uL of PBS in the wells of a 96-well black bottom assay plate. The
fluorescence intensity emanating from the wells, which is a measure of cell viability, was
then determined using a TECAN Infinite® 2000 Multimode microplate reader.
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5.3.7 Investigating the Anti-vasculature and Anti-tumor Potential of Combretastatin
and Doxorubicin Loaded PEO-b-PCL Polymersomes on HUVECs and SK-BR-3 Cells
in Co-Culture
In order to determine the cytotoxic effects of drug loaded vesicles in co-culture,
HUVECs and SK-BR-3 cells were stained using Cellvue ® NIR815(λEx max =786nm, λEm
max

=814nm) and Cellvue ® Burgundy (λEx

max

=683nm and λEm

max

=707nm) from

Molecular Targeting Technologies Inc.(MTTI), respectively. These dyes provide stable
labeling of the lipid regions of the cell membrane. Labeling was carried out as per
protocol obtained from MTTI, but scaled down for 2 million cells. Stained cells were
plated at a density of 3,200 cells per well (10,000cells/cm2) in 96 well (black frame, clear
well) cell culture plates (Isoplate-96 TC, Perkin Elmer) and were allowed to adhere
overnight (~20~24hours).

Culture media was removed from the wells, wells were

washed with 250uL of PBS, and replaced with 250uL of either: 100% media, 90%
media/10% PBS, 100% PBS, and various concentrations of drug loaded vesicles in 90%
media/10% PBS, and maintained at 37◦C in a humidified atmosphere containing 5% CO2
in air. The suspensions were sterilized with 30 minute exposure to a UV lamp in the
culture hood prior to incubation with cells. Immediately following addition of drug
loaded polymersomes, the fluorescence intensity was measured using a LICOR Odyssey,
an Infrared (IR) Imaging System and this fluorescence was deemed to be the initial
fluorescence per well. At various defined time points (12H, 24H, 48H, and 72H) post
drug administration, wells were washed with 250uL of PBS to removed dead cells and
250uL of fresh media was added to the wells. The fluorescence intensity emanating from
the washed wells, as a result of live stained cells in the wells, was then determined using
a LICOR Odyssey.
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5.4 RESULTS AND DISCUSSION
5.4.1 Cellular Uptake of Porphyrin Loaded PEO-b-PCL Vesicles by HUVECs and SKBR-3 Cells
To determine the cellular uptake of polymer vesicles by HUVECs and SK-BR-3
cells, we utilized ~200nm NIR-emissive polymersomes formulated from PEO-b-PCL
diblock copolymer and loaded with porphyrin (a NIR emissive fluorophore) and the
LICOR Odyssey, an Infrared (IR) Imaging System. Figure 5.1 shows the raw data
obtained for the uptake of ~200nm porphyrin polymersomes by HUVECs after 5 hours of
incubation; similar images were obtained for the other time points as well as for SK-BR-3
cells.

Figure 5.1- Raw HUVEC uptake data from the Odyssey.
Row A: 3*104 Cells/Well; Row B: 2.25*104 Cells/Well; Row C: 1.5*104 Cells/Well;
Row D: 0.75*104 Cells/Well Column 1-3: Media Only; Column 4-6: 9uM PEO-bPCL; Column 7-9: 4.5uM PEO-b-PCL; Column 10-12: 1.125uM PEO-b-PCL;
Porphyrin Vesicles=Green (800 channel)
The vesicle uptake by HUVECs was both concentration and incubation time
dependent. In general, as vesicle concentration in the media increased, cellular uptake
also increased, until the saturation capacity of the cell was reached, especially at low cell
numbers (Figure 5.2). Furthermore, increased incubation time or higher concentration of
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vesicles generally resulted in increas
increased uptake by both cell types (Figure
Figure 5.3). At higher
cell densities, uptake was seen as early as 45 minutes and increased with extended
incubation times. At lower vvesicle
esicle concentrations, extended time was necessary for
significant vesicle uptake.

number on polymersome uptake by
Figure 5.2- The effect of concentration and cell numb
HUVECs
(A) and SK-BR-33 cells (B) after 5 hours of incubation with porphyrin
polymersomes.. (n=3; error bars ± S.E.)
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Figure 5.3- The effect of concentration and incubation time on polymersome uptake
by HUVECs (A-B)
B) and SK-BR-3 cells (C-D).
D). (n=3; error bars ± S.E.)
5.4.2 Determination of the Viability and Biocompatibility of Unloaded PEO-b-PCL
PEO
Vesicles on HUVECs and SK
SK-BR-3 Cells in vitro
A viability assay using CellTiter-Blue™ was used to demonstrate the
biocompatibility of the PEO
PEO-b-PCL nanoparticles without drug or imaging agent on cells
in culture. HUVECs and SK
SK-BR-3
3 cells were cultured with ~200nm unloaded PEO-bPEO
PCL polymer vesicles at varying concentrations for up to 72 hours. A moderate drop in
viability (∼55-75%)
75%) was observed wi
with
th the HUVECs, which did not appear to be
concentration or time dependent ((Figure 5.4A). For the case of SK-BR
BR-3 cells, toxicity
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appeared to be both concentration aand
nd time dependent. After 12 hours of incubation with
vesicles, the viability dropped to approximately 50%, and after 24 hours, the viability
decreased to ~35-40% Figure 5.4B.
B. At the 48 hour time point and beyond, there appears
to be a great loss in viability at the high concentrations of PEO
PEO-b-PCL
PCL vesicles, however
the cells cultured with .28uM of vesicles appear to be 50% viable ((Figure
Figure 5.4B).

Figure 5.4- The viability of HUVECs (A
(A) SK-BR-3 cells (B) when cultured with
PEO-b-PCL
PCL vesicles at varying concentrations for 12hours to 72 hours.
hours
Each bar represents the mean of four samples and error bars are standard
deviation.
All conditions are normalized to cultures grown in
Media(90%)/PBS(10%) without vesicl
vesicles present.
5.4.3 Determination of the Anti
Anti-vasculature Potential of Combretastatin
tastatin PEO-b-PCL
PEO
Polymersomes on HUVECs and Cytotoxic Effect on SK
SK-BR-3
3 Cells Cultured
Separately
Anti-vasculature
vasculature potential of combretastatin A
A-4
4 loaded polymeric vesicles on
HUVECs and SK-BR-33 tumorigenic cells was determined over 72 hours. Both cell lines
were separately cultured in the presence of ~200nm combretastatin loaded PEO-b-PCL
PEO
vesicles at varying concentrations and for up to 72 hours. For both cell lines incubated
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with combretastatin vesicles, viability decreased over the 72 hours in both a time and
dose dependent manner (Figure 5.5).
For HUVECs cultured with combretastatin vesicles for 12 hours, viability appears
to be highly concentration dependent and ranged from ~40% viable at 9uM concentration
of combretastatin to ~100% viable for the 0.25uM combretastatin condition. At later
times however, while viability still appears to be concentration dependent, the viability
has significantly decreased and by 72 h, viability dropped to less than ~35% for all
doses of combretastatin (Figure 5.5A).
For SK-BR-3 cells, cell growth for drug treated cells was arrested, and at
extended times cells appeared to be dying. After the first 24 hours, the cellular viability
decreased to 50% or less for all concentrations, and by 72 hours, viability was less than
~25% for all concentrations of combretastatin in polymersomes (Figure 5.5B). Recall
however, that a portion of the toxic effects are due to the vesicles themselves as
evidenced in Figure 5.4B and thus some of the toxic effects seen may be due to the
vesicles and not only the drug.
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Figure 5.5- The effect of varying concentration
concentrationss of combretastatin loaded
polymersomes on HUVECs (A) and SK-BR-3 cells (B) viability over 72 hours.
Each bar represents the mean of four samples and error bars are standard
deviation.
All conditions are normalized to cultures grown in
Media(90%)/PBS(10%)
%) without vesicles
vesicles.
5.4.4 Determination of the Cytotoxic Potential of Doxorubicin Loaded PEO-b-PCL
PEO
Polymersomes on HUVECs and SK
SK-BR-3 Cells Cultured Separately
The cytotoxic potential of doxorubicin loaded PEO
PEO-b-PCL
PCL polymeric vesicles on
HUVECs and SK-BR-33 tu
tumorigenic
morigenic cells was examined for both concentration and
incubation time dependence. Both cell lines were separately cultured in the presence of
~200nm doxorubicin loaded PEO
PEO-b-PCL
PCL polymersomes at varying concentrations and
for up to 72 hours. For both ce
cell
ll lines incubated with doxorubicin vesicles, viability
decreased over the 72 hours in both a time and concentration dependent manner (Figure
(
5.6).
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Figure 5.6- The effect of varying concentrations of doxorubicin loaded
polymersomes on HUVECs (A) and SK-BR-3 cells (B) viability over 72 hours.
Each bar represents the mean of four samples and error bars are standard
deviation.
All conditions are normalized to cultures grown in
Media(90%)/PBS(10%) without vesicles
vesicles.
After 24 hours of incubation, HUVEC viability does not appear to be effected by
doxorubicin vesicles, even at high concentration.

However, the cellular viability

decreased sharply after the first 48 hours, where the viability is less than ~10% for cells
incubated with doxorubicin at concentrations greater than 2.5uM.

After 72 hours,

cellular viability is less than ~25% for all concentrations of DOX greater
grea than .025uM
(Figure 5.6A).
A). While one might expect to observe a less dramatic effect on HUVEC
viability after incubation with the chemotherapeutic, one must cons
consider
ider that nearly all
chemotherapeutics have anti
anti-angiogenesis
angiogenesis or antivascular effects; this has been show
both in vitro and in vivo [71]
[71].
For SK-BR-33 tumorigenic cells, the cytotoxic effect of doxorubicin was more
prevalent after 24hours. In fact, viability is less than ~75% in for all concentration, and
less than ~50% for most concentrations of DOX. Similar to the HUVEC response, by 48
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hours, the cellular viability dropped to less than ~25% for DOX concentrations greater
than 2.5uM and after 72 hours, only cells incubated with concentrations less than 0.25uM
were greater than ~25% viable (Figure 5.6B).
5.4.5 Investigating the Anti-vasculature and Anti-tumor Potential of Combretastatin
and Doxorubicin Loaded PEO-b-PCL Polymersomes on HUVECs and SK-BR-3 Cells
in Co-culture
HUVECs and SK-BR-3 cells were each stained using MTTI’s Cellvue ®
Burgundy and Cellvue ® NIR815, respectively. Post staining, cells were plated in 96
well (black frame, clear well) cell culture plates (Isoplate-96 TC, Perkin Elmer) for
further examination of the effects of drug loaded vesicles on HUVECs and SK-BR-3
cells in co-culture. Figure 5.7 shows the initial fluorescence emanating from the wells of
the 96 well plates, post plating with stained HUVECs and SK-BR-3 cells. In order to
determine cell viability, cells incubated with drug loaded vesicles were washed to remove
non-adherent cells and then assayed for fluorescence. Specifically, the fluorescence
emanating from each well post incubation with drug vesicles was normalized against its
original fluorescence intensity, post initial wash and prior to incubation with drug.
Subsequent to that normalization step, intensity per well was normalized against the
normalized value for wells without drug. This double normalization accounted for the
fact that the washing step can remove some viable loosely adherent cells.
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Figure 5.7- Image of stained co-cultured HUVECs and SK-BR-3 cells using the
LICOR Odyssey prior to incubation with drug loaded vesicles.
Green=HUVECs (700 Channel); Red= SK-BR-3 (800 Channel)
When combretastatin loaded PEO-b-PCL polymersomes are administered to
HUVECs and SK-BR-3 cells in co-culture, the anti-vasculature effect of the drug on
HUVECs appears to be less pronounced than when the drug is administered to cells in
single culture; however, viability of cells cultured with drug loaded polymersomes is
compared to the viability of cells cultured in PBS only (negative control as all cells will
be dead), there is a noticeable effect after 12 hours (Figure 5.8A). Noting that the
viability of the PBS only cells is quite high, a CellTiter-Blue™ Cell Viability Assay
(Promega) was carried out to determine if the PBS only wells still contained viable cells.
Though this assay, it was confirmed that these wells were devoid of living cells. From
this, it is believed that the non-viable stained HUVECs stick to the wells even post
washing and this sticking increases with increased incubation time in the wells. Hence,
the fluorescence from the PBS only wells increases over time, even though it was
confirmed that the cells were dead after culturing in PBS for 72 hours. Data not shown.
Post 12 hour incubation with combretastatin polymersomes, SK-BR-3 cell
viability appeared to be adversely effected by the administration of combretastatin loaded
polymersomes as well (Figure 5.8B). After 24 hours, the viability drops to ~75% or less,
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and 48 hours post administra
administration
tion of drug loaded vesicles the cellular viability is less than
~50%. For the SK-BR-33 cells, the toxicity in co
co-culture
culture appears to be less than when the
cells are cultured separately; this may be the result of having the same concentration of
polymer and drug, but 1.25 times more cells.

Figure 5.8- The effect of combretastatin loaded polym
polymersomes
ersomes on HUVECs (A) SKSK
BR-3 cells (B) in co-culture.
culture. Each bar represents the mean of four samples and
error bars are standard deviation. All conditions are normalized to the initial
fluorescence and then to cultures grown in Media(90%)/PBS(10%) without vesicles.
Twenty four hours post iincubation
ncubation with doxorubicin vesicles, the cellular viability
of HUVECs appears to decrease to about 60% (when the viability is compared against
that of the cells cultured in PBS only).

When comparing against the fluorescence

emanating from PBS cultured cel
cells
ls against the fluorescence from cells cultured with drug
loaded vesicles, it appears that the viability drops greatly after a 72 hour incubation with
drug loaded vesicles. Again however, it must be noted, that sticking of the non-viable
non
cells cultured in PBS only was observed and from this we can surmise that cells cultured
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with drug at high concentrations over extended periods of time are also sticking to the
wells yielding a false positive reading for the fluorescence.
The effect of doxorubicin loade
loaded polymersomes on SK-BR-3
3 cells in co-culture
with HUVECs is apparent after 24 hours, when cellular viability decreased to less than
~80% after administration of drug loaded polymersomes. For concentrations of drug
2.5uM and greater, the decrease in SK
SK-BR-3 viability over time at a single drug
concentration is demonstrated by cellular viability decreasing from ~100% at 12 hours to
less than 20% after 72 hours at the higher concentrations. At 48 and 72 hours post
incubation with drug loaded polymersomes, tthe
he time and concentration dependence
becomes apparent as decreasing concentration of drug at a particular time point leads to
an increase in viability.. In contrast to the combretastatin co
co-culture
culture studies, here we see
that although there are more cells in culture with the same amount of polymer and drug,
the SK-BR-33 cells are still adversely affected by incubation with doxorubicin.

Figure 5.9- The effect of doxorubicin lloaded PEO-b-PCL
PCL polymersomes on
HUVECs (A) SK-BR-33 cells (B) in co-culture.
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Each bar represents the mean of four samples and error bars are standard
deviation. All conditions are normalized to the initial fluorescence and then to
cultures grown in Media(90%)/PBS(10%) without vesicles.
As a final proof of concept, the following preliminary studies were carried out to
investigate the effect of dual drug (DOX and combretastatin) loaded polymersomes on
co-cultures of SK-BR-3 cells and HUVECs. Similar to the single drug loaded vesicles,
we see a strong dependence on both concentration and time for the SK-BR-3 cells,
especially at the higher drug concentrations where viability decreases with each time
point after the first 24 hours. In addition, at the 72 hour time point, a clear drug
concentration dependence is exhibited where the viability ranges from ~100% at the
lowest concentration to ~20% at the highest concentration of drug (Figure 5.10B). The
HUVEC response to the dual drug loaded vesicles is not nearly as strong as what is
observed for the SK-BR-3 cells. A loose dependence on concentration and time is
observed (Figure 5.10A), however, additional studies are required to precisely determine
the effect of the dual drug vesicles on HUVECs in co-culture. Follow up studies will be
described in Chapter 7.
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Figure 5.10- The effect of doxorubicin
doxorubicin-combretastatin
combretastatin dual loaded PEO-b-PCL
PEO
polymersomes on HUVECs (A) and SK
SK-BR-3 cells (B) in co culture.
Each bar represents the mean of four samples and error bars are standard
deviation. All conditio
conditions
ns are normalized to the initial fluorescence and then to
cultures grown in Media(90%)/PBS(10%) without vesicles.

5.5 CONCLUSIONS
Wee successfully utilized nano
nano-polymersomes
polymersomes formulated from PEO-b-PCL
PEO
diblock copolymer for in vitro delivery of both imaging agents as well as therapeutics.
NIR-emissive
emissive polymersomes were used to determine uptake of polymersomes in human
umbilical vein endothelial cells (HUVECs) and SK
SK-BR3
BR3 tumorigenic cells. Vesicle
uptake for both cell lines was dependent on concentration and incubation time. As
vesicle concentration in the media increased, cellular uptake also increased. Furthermore,
increased incubation time generally resulted in increased uptake. At higher HUVEC
densities and/or high vesicle concentration
concentration, uptake was seen as early as 45 minutes and
increased with extended incubation times. At lower concentration
concentrations,, extended time was
necessary for significant vesicle uptake.
Toxicity studies on drug loaded as well as empty vesicles were carried out using
CellTiter-Blue™
Blue™ Cell Viability Assay (Promega). A viability assay demonstrated
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biocompatibility of the nanoparticles without drug or imaging agent at all concentrations
with HUVECs. The SK-BR-3 cells demonstrate a 50% loss in viability after 12 hour
incubation with empty vesicles at high and intermediate concentrations of polymer. At
low concentration of polymer, SK-BR-3 viability does not appear to be effected. The
cytotoxic potential of combretastatin A-4 loaded polymeric vesicles and doxorubicin
loaded polymeric vesicles on HUVECs and SK-BR3 tumorigenic cells were determined.
For both cell lines, toxicity was generally both concentration and time dependent. For
HUVECs, a 50% reduction in viability is seen within 12 hours at high concentrations of
combretastatin A-4; at longer times, cellular viability is decreased to approximately 25%
viable even at low concentrations of combretastatin A-4. For SK-BR3 cells, cell growth
for drug treated cells was arrested, and at extended times cells appeared to be dying.
Similar results were observed for HUVECs and SK-BR-3 cells treated with doxorubicin
loaded vesicles. When co-cultured, the effect of the drug is less pronounced then when
the cells are treated separately, but at high concentrations of drug and/or extended
incubation times, the cytotoxic effect of the drug loaded vesicles is observed.
Thus, this study highlights the feasibility of using polymersomes to deliver
vascular disrupting agents to endothelial cells simultaneously with treating tumors.
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J. Therien, Mark I. Greene, Daniel A. Hammer, and Ramachandran Murali, Methods,
2008, vol. 46, p. 25-32.
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6.1 SUMMARY
Polymersomes (polymer vesicles) have been shown to possess a number of
attractive biomaterial properties compared to liposomes (phospholipid vesicles),
including prolonged circulation times, increased mechanical stability, as well as the
unique ability to incorporate numerous large hydrophobic molecules within their thick
lamellar membranes and hydrophilic molecules within their core. We have previously
shown the ability to generate two types of self-assembled nano-sized vesicles ranging in
size from 100’s of nanometers to 10’s of microns; one type comprised of a biocompatible
diblock copolymer consisting of polyethyleneoxide (PEO) and polybutadine (PBD) and a
second fully-bioresorbable vesicle consisting of two FDA-approved building blocks:
polyethyleneoxide (PEO) and polycaprolactone (PCL). In addition, we have successfully
loaded imaging agents, such as porphyrin-based near infrared (NIR) fluorophores, and
therapeutics such as doxorubicin, an anti-neoplastic agent, into these polymersomes and
tracked their release in situ and in vivo.
NIR-emissive polymersomes, loaded with porphyrin, can be used for
biodistribution studies, to track the location of the polymersomes, and potentially for
diagnostic studies.

Here, we utilize NIR-emissive polymersomes to determine

polymersome biodistribution in tumor bearing mice using a noninvasive small animal
optical imaging instrument which detects the NIR fluorescence signal.

Passive

accumulation of NIR-emissive polymersomes in tumor tissues of mice, as well as other
organs, is evidenced. Using porphyrin polymersomes for biodistribution studies will
greatly decrease the number of animals required for such studies since the location of the
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polymersomes can be determined without sacrificing animals at multiple time points to
perform histology on the excised organs.
Doxorubicin, an anti-neoplastic agent, was encapsulated to serve as a model
system for the release of a physiologically relevant compound from the PEO-b-PCL
polymersomes. The therapeutic potential of doxorubicin loaded polymersomes is shown;
drug loaded bioresorbable polymersomes were administered in vivo and their capability
to retard tumor growth was assessed using such metrics as tumor size and body weight.
Doxorubicin loaded polymersomes were able to retard tumor growth in a live animal on a
par with the commercially available DOXIL, liposomal doxorubicin.

Furthermore,

mouse weights remained within +/-1.5g, for all treatment groups throughout the study.
Lastly, the marriage of the porphyrin polymersome with the doxorubicin
polymersome was attempted in vivo. Results are promising suggesting with further work
that the multi-functional polymersome for theranostic applications could be a reality.

6.2 INTRODUCTION
The fully PEG-ylated polymersome, with its thick hydrophobic membrane and
large aqueous core, posses a number of superior biomaterial properties [4-6, 8] which
make it ideally suited to facilitate biomedical applications such as deep tissue optical
imaging and drug delivery.
Chapter 4 discusses the basis and rationale for using near infrared imaging (NIR)
agents in contrast to visible probes for in vivo imaging applications and the tunable
spectral properties of the porphyrin fluorophores used in the in vivo imaging studies
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discussed in this chapter. This chapter will build upon those concepts highlight in the
previous chapters and discuss some of the principles of in vivo fluorescence based
imaging.
In vivo deep tissue fluorescence based imaging characterizes the interaction of
photons with tissue through three basic parameters, namely absorption, light scattering,
and emission.

As discussed in Chapter 4, light absorption by the oxy and

deoxyhemoglobin, water, and other molecules found in tissues [123, 124] is greatest
below 700nm, causing significant auto-fluorescence in the visible spectra [125] and
limiting the penetration depth to less than a few millimeters [126]. However, owing to
the small tissue absorption coefficient in the NIR window (700nm-900nm) of the
spectrum, light can penetrate much deeper into the tissues, enabling imaging deeper
imaging into the tissues in contrast to imaging with probes in the visible region of the
spectra [115].
In addition to the tissue properties which complicate in vivo imaging, the contrast
agent itself must be nontoxic and overcome certain challenges in vivo such as absorption,
distribution, metabolism, and excretion [127]. Furthermore, the contrast agent must be
able localize and remain at the site with enough fluorescent intensity to be imaged [127,
128].
Hence, the development of NIR contrast agents with appropriate biological
parameters is crucial for in depth optical imaging of living tissues. We have investigated
the performance of NIR-emissive porphyrin polymersomes, polymeric vesicles loaded
with porphyrin contrast agents, in both a biocompatible and bioresorbable formulation
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and demonstrated their ability to assist in diagnostic applications as well as drug
biodistribution studies.
Chapter 2 and Chapter 4 discuss the fabrication of the drug loaded polymersomes
and the drug loaded polymersome for imaging purposes, while Chapter 5 demonstrates
the potential of these vesicles in vitro. In addition to the use of polymersomes for in vivo
optical imaging in the NIR, this chapter will investigate use of drug loaded vesicles for in
vivo applications.
Currently many pharmaceutical agents exist whose systemic toxicity is too great
to be administered clinically. Other compounds, would be clinically beneficial, however
their hydrophobicity precludes them from being administered by conventional methods.
Hence, a delivery vehicle with the ability to deliver such toxic and hydrophobic
molecules at a high payload to the site of interest is imperative for advancing therapies.
Previously,

researchers

have

demonstrated

the

therapeutic

benefits

of

encapsulating pharmaceutical agents with low bioavailabilty or high systemic toxicity in
PEG-ylated lipid vesicles, termed liposomes [120, 129, 130]. As described throughout
this thesis, polymersomes, polymeric vesicles, have unique biological properties [4-6, 8]
to render them superior to liposomes for drug delivery applications. Hence considerable
effort has been made in developing polymeric vesicles for drug delivery tools [27, 43,
131, 132]. The in vivo performance of the fully bioresorbable PEO-b-PCL polymersome
for the delivery of doxorubicin, a chemotherapeutic agent known to causes cardiotoxicty
will be examined in this chapter. Lastly, the chapter will close by demonstrating the
potential for using polymersomes as both drug and imaging delivery agents.
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6.3EXPERIMENTAL METHODS
Nude athymic mice used in the studies discussed below were housed under
USDA- and AAALAC-approved conditions with free access to food and water. The
University of Pennsylvania Institutional Animal Care and Use Committee and Small
Animal Imaging Facility (SAIF) Animal Oversight Committee approved all experimental
procedures. All in vivo imaging was conducted at the SAIF in the Department of
Radiology at the University of Pennsylvania.
6.3.1 Preparation of Drug and Imaging Agent Loaded Polymersomes
Drug loaded vesicles, porphyrin loaded vesicles, as well as drug-porphyrin
vesicles were prepared as described in Chapter 2 and Chapter 4. Briefly, thin-film
hydration was used to assemble the ~200nm PEO-b-PCL copolymers into equilibrium
morphologies [10]. Polymersomes were incubated with doxorubicin in a ratio of 1:.4
polymer:drug (w/w) for ~9h at a temperature above their main gel to liquid-crystalline
phase transition temperature, trapping the drug in the aqueous core. Nonentraped DOX
was removed using HPLC; the solution was passed through two HiTrap desalting
columns and further removed using a Centricon tube to ensure the absorbance of drug in
the subnatant was undetectable at 480nm. The collected DOX polymersome suspension
was concentrated and passed through a 1um membrane prior to injection.
To determine the concentration of doxorubicin in the PEO-b-PCL polymersomes,
sample aliquots were removed from the concentrated stock solution, and lyophilized to
destroy the vesicle structure and release the encapsulated DOX from the core of the
polymersome. The freeze-dried powder was reconstituted in tertiary butanol:water 9:1,
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v/v containing 0.075N HCl or 90% isopropyl alcohol containing 0.075 M HCl. The
concentration of DOX was determined using Beer’s Law by measuring the absorbance at
480nm using a molar extinction coefficient of 12,5000cm-1M-1 in either solvent [70, 122].
6.3.2Preparation of Porphyrin Imaging Agent Loaded PEO-b-PBD and PEO-b-PCL
Polymersomes
Porphyrin loaded PEO-b-PCL and PEO-b-PBD polymersomes were prepared as
described in Chapter 4. Briefly, self-assembly via thin-film hydration followed by freeze
thawing and extrusion were used to yield small porphyrin PEO-b-PBD polymer vesicles
or porphyrin PEO-b-PCL polymersomes (~200nm diameter)[9]. The porphyrin dye is
localized to the vesicle membrane. The suspension was centrifuged using Millipore
Centricon Tubes to obtain a porphyrin concentration of 15uM as determined by
absorbance spectroscopy.

Prior to injection, vesicles were passed through a sterile

200nm membrane.
The concentration of the porphyrin vesicles in solution was determined by
measuring the absorbance at 794nm using a molar extinction coefficient of 1.29*105M1

cm-1 [9]. Polymer concentration was determined by a mathematical calculation, since

the ratio of porphyrin to polymer was set at 1:40 (molar ratio).
6.3.3 Cell Culture and Establishment of Tumors in Nude Mice
The T6-17 cell line which is derived from NIH-3T3 cells by over-expressing the
human erbB2 receptor was used for all in vivo studies; these cells are HER2-expressing
transformed tumor cells with the ability to develop tumors in nude mice [133].
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The T6-17 cells, were cultured in DMEM - high glucose 4.5 gm/L (base media),
10% fetal bovine serum (FBS), 1% Pen/Strep 100X (10000u/ml P - 10mg/ml S), and 1%
glutamine.

Cells were maintained in plastic culture flasks at 37◦C in a humidified

atmosphere containing 5% CO2 in air and subcultured at subcultivation ratio of 1:10
when the flasks were 70% to 90% confluent.

When cells were deemed 70%-90%

confluent, growth media was removed from the culture flask via aspiration and the flask
was washed with Phosphate Buffered Saline (PBS).

The PBS was removed and

0.25%trypsin-EDTA was added and the flask was returned to the incubator for 5min at
37 C and 5% CO2 in air. Post trypsin incubation, media was added to the flask and the
wall was washed in order to remove all cells. The cell suspension was then transferred to
a conical tube and centrifuged at 1000rpm for 5 minutes to pellet the cells.

The

supernatant was aspirated and the cells were resuspended in fresh growth media. When
cells were to be used for tumor studies, a cell count was performed.
6.3.4 In vivo Biodistribution and Diagnostic Studies Using Porphyrin loaded PEO-bPBD Polymersomes
To establish the tumor in vivo, T6-17 tumor cells (1x106) were injected s.c. into
the flank of athymic nude female mice. At least ten days after inoculation of tumor cells,
when tumors were visible and palpable, treatment with polymersomes commenced as
described.
In order to reduce background fluorescence for extended imaging studies, lasting
more than 12 hours, mice were switched from a fenbendazole-impregnated diet for
prophylaxis purposes to AIN-76A, a low-autofluorescence rodent diet (Research Diets,
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Inc.; New Brunswick, NJ). 5 to 7 days prior to imaging and remained on the lowfluorescence feed until the culmination of the study.
Once the tumors were visible and palpable, 100ul of the porphryin polymersome
solution (15uM porphyrin) was injected intravenously into the tail vein of a tumor
bearing (T6-17 cells) nude mouse. Fluorescent signal was measured prior to injection, as
well as at specific time points ranging from hours to days, post injection, using one of the
following small animal imagers: a) the GEART eXplore Optics, 2) the LICOR Pearl
Imager. At the culmination of the study, the mice were sacrificed according to protocol.
At the culmination of the extended study, sacrificed mice were carefully dissected and
their organs were excised for further analysis.
6.3.5 In vivo Intratumor Studies Using Porphyrin loaded PEO-b-PBD Polymersomes
To establish the tumor in vivo, T6-17 tumor cells (1x106) were injected s.c. into
the flank of athymic nude female mice. At least ten days after inoculation of tumor cells,
when tumors were at least visible and palpable, 100uL of a 15uM solution of porphyrin
PEO-b-PBD polymersomes was injected intravenously into the tail vein of the tumor
bearing nude mouse. Approximately eight hours post injection of vesicles, 100ul of
AngioSense-IVM 680 (VisEn Medical), a large fluorescence agent (250k MW) that
remains localized in the vasculature for extended periods of time (λex=680±10nm,
λex=700±10nm), was intravenously injected into the retro-orbital vein of the mouse.
Immediately following the injection of AngioSense-IVM 680, a full body scan of
the mouse in the prone position was taken using the GEArt. Subsequently, a small
portion the skin was removed from the tumor and the tumor was imagined using the
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Olympus IV-100. At the culmination of the study, the mice were euthanized as per
protocol. .
6.3.6 In vivo Therapeutic Study Using Doxorubicin Loaded PEO-b-PCL Polymersomes
To establish the tumor in vivo, T6-17 tumor cells (1x106) were injected s.c. into
the flank of athymic nude female mice. One week after inoculation of tumor cells, when
tumors were visible and palpable, treatment with polymersomes commenced as
described.
Once the tumors were visible and palpable, the mice were injected through the tail
vein with 200uL of (1) polymersomes loaded with DOX at a concentration of 1mg/ml,
(2) DOXIL (liposomal formulation of DOX) at a DOX concentration of 1mg/ml, (3) free
DOX (unencapsulated drug) at a DOX concentration of 1mg/ml, and (4) PBS. Each
group consisted of five mice. The concentration of DOX in all administrations was
1mg/ml and 200ul of solution was administered to each mouse, to yield a dose of 10mg
of drug/kg.
After the administration of treatment (i.e. post i.v. injection), tumors were
measured daily and mice were weighed every other day. Tumor volume was determined
by the equation, l*w*h. Nine days after the start of treatment, the mice were sacrificed,
bled from the retrooribital sinuses, and organs were harvested. Using a HEMAVET,
blood work was performed to be used as a metric for systemic toxicity resulting from
each of the treatment groups. Physical appearance and behavior were recorded as well.
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6.3.7 In vivo Theranostic Study Using Doxorubicin and Porphyrin Loaded PEO-b-PCL
Polymersome
To establish the tumor in vivo, T6-17 tumor cells (1x106) were injected s.c. into
the right flank of athymic nude female mice. Nine days after inoculation of tumor cells,
when tumors were visible and palpable, treatment with polymersomes commenced as
described in the following sections.
In order to reduce background fluorescence for extended imaging studies, lasting
more than 12 hours, mice were switched from a fenbendazole-impregnated diet for
prophylaxis purposes to AIN-76A, a low-autofluorescence rodent diet (Research Diets,
Inc.; New Brunswick, NJ). 5 to 7 days prior to imaging and remained on the lowfluorescence feed until the culmination of the study.
Once the tumors were visible and palpable, the mice were injected through the tail
vein with 250uL of:
(1) Doxorubicin-Porphyrin PEO-b-PCL polymersomes at a concentration of
0.122mgDOX/ml (4.65uM porphyrin and 2.6 mgPEO-b-PCL/ml as determined by
the porphyrin absorbance),
(2) Porphyrin PEO-b-PCL polymersome at a concentration of 2.6mgPEO-bPCL/ml (4.65uM porphyrin)
(3) PEO-b-PCL polymersomes without DOX or porphyrin at a concentration of
2.6mgPEO-b-PCL/ml
(4) free DOX drug at a DOX concentration of 0.122mg/ml.
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Each group consisted of four mice. The concentration of DOX delivered to the
mice in this study was approximately 10% of the concentration delivered in the
Therapeutic Study described above.

Furthermore the porphyrin concentration was

approximately 1/3 the concentration delivered in the Diagnostic Studies described above,
however, twice the volume of porphyrin vesicle suspension was delivered, making the
total porphyrin injected approximately 2/3 of the amount injected in previous studies.
Recall from Chapter 4, the loading of DOX into porphyrin vesicles is difficult and
inefficient; this is most likely the result of the large hydrophobic porphyrin molecules
hampering the diffusion of the DOX molecules across the hydrophobic bilayer.
Post treatment, tumors were measured daily and mice were weighed every day.
Tumor volume was determined by the equation, l*w*h.
Prior to treatment, mice that were to be administered porphyrin vesicles and
porphyrin-DOX vesicles were pre-scanned using the Licor Odyssey Infrared Imaging
System equipped with the Odyssey MousePOD In vivo Imaging Accessory. Mice were
then scanned at regular intervals using the Odyssey and MousePOD Accessory. Five
days after the start of treatment, the mice were sacrificed and carefully dissected. Organs
were imaged post excision using the LICOR Odyssey.

6.4 RESULTS AND DISCUSSION
6.4.1 In vivo Biodistribution Studies Using Porphyrin Polymersomes
When Porphyrin loaded NIR-emissive nanopolymersomes are injected into the
tail-vein of mice, the biodistribution of the nanoparticles can be tracked in vivo via noninvasive NIR fluorescence-based optical imaging. Figure 6.1 demonstrates the ability to
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track PEO-b-PBD polymer vesicles in tumor bearing mice over 12 h.

Additional

extended studies using porphyrin loaded PEO-b-PBD (Figure 6.2) and PEO-b-PCL
polymersomes demonstrated the ability to track vesicles in vivo for up to 9 days and will
be discussed in this section and in Section6.4.4. It is important to note that initial studies
were carried out using the biocompatible vesicle since it was known not to degrade in
vivo. Nonetheless, it is envisioned that the bioresorbable vesicles generated from PEO-bPCL diblock, might be able to link changes in fluorescence not only to the clearance of
the vesicle but also to degradation of the vesicle.
Porphyrin NIR- emissive polymersomes injected into the tail vein of a tumor
bearing mouse accumulated at the tumor site of non-necrotic tumors within four hours
and remain at the tumor site for at least 72hours.

Furthermore, these vesicles are

observed in vivo for at least 9 days and are cleared by organs of the reticuloendothelial
system (RES) as determined by imaging of fluorescence signals. Upon culmination of
the extended studies and excision of the organs, it was determined, though fluorescence
imaging of the organs, that there was significant vesicles accumulation in the spleen, and
liver.

Furthermore, even 7 days post treatment, a significant fluorescent signal is

observed from the tail.
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Figure 6.1- Tumor imaging by NIR-emmisive PEO-b-PBD polymersome.
Fluorescence images obtained using eXplore Optix instrument of the same mouse
taken prior to administration of NIR-emissive polymersomes, and at 4, 8, and 12 h
post tail-vein injection. (A) Prone position, (B) supine position (k = 785 nm, k =
830–900 nm). The arrows in the prone and supine positions suggest location of
organs. In the supine position, the arrow suggests the fluorescence emanating from
ex
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em

the lower portion of the mouse body is from the tumor; it may also be emanating
from the gut of the mouse due to break down of food.

Figure 6.2- Fluorescence images of the same mouse taken right after administration
of NIR-emissive PEO-b--PBD polymersomes, and at 4, 8,12, 48, 72, 144, 168, 192, and
216 hours post tail-vein
vein injection.
Images were acquired using the Licor Pearl Imager. (A) Prone Position (B) Supine
Position (λex
ex =785nm, λem=830
λem=830-900nm)
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6.4.2 In vivo Intratumor Studies Using Porphyrin loaded PEO-b-PBD Polymersomes
The Olympus IV-100, intravital laser scanning microscope for small animal
imaging, was used to examine the location of polymersome in relation to the tumor
vasculature. Prior imaging with the Olympus IV-100, the mouse was imaged using the
GEArt to confirm the distribution of porphyrin vesicles and AngioSense-IVM 680 in the
mouse’s body; furthermore the localization of porphyrin vesicles at the tumor site was
verified using the GEArt.
Once the distribution of dye and vesicles was confirmed using the GEArt, the
tissue on the tumor just below skin was imaged using the Olympus IV-100. Figure 6.3
clearly shows the co-localization of AngioSense IVM-680 in the vasculature and the
porphyrin PEO-b-PBD vesicles, confirming their location in the tumor vasculature. The
left hand panel of Figure 6.3 used the signal from AngioSense IVM-680 to show the
tumor vasculature (700 channel), while the middle panel shows the fluorescent signal
from the polymersomes in the same area (800channel); the right hand panel is an overlay
of the left and middle panels and clearly shows the localization of porphyrin vesicles
within the tumor vasculature.
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Figure 6.3- Intravital microscopy of the tumor tissue using the Olympus IV-100.
IV
Left hand pannel shows the tumor vasculature (using AngioSense IVM 680, 700
channel); Middle pannel shows the localization of porphyrin polymersomes (800
channel); Right pannel is the overly of the images from each channel clearly
showing the co-localizati
localization
on of porphyrin vesicles in the blood vessels.
6.4.3 In vivo Therapeutic Study Using Doxorubicin loaded PEO
PEO-b-PCL
PCL Polymersomes
Doxorubicin loaded bioresorbable PEO
PEO-b-PCL
PCL polymersomes were administered
in vivo to xenotransplanted (T6-17 cells) tumor-bearing mice and their therapeutic
capability to retard tumor growth was assessed using such metrics as tumor size and body
weight.
Error! Reference source not found.,
found. doxorubicin
As demonstrated in Figure 6.4Error!
loaded PEO-b- PCL polymersomes were able to retard tumor growth in mice on a par
with the commercially available agent DOXIL ® (a clinically administered liposomal
formulation of doxorubicin
doxorubicin),, and better than free drug and PBS alone. Further, mouse
weights remained within ±1.5 g of the initial weight, for all treatment groups throughout
the study.
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Figure 6.4- Anti-tumor
tumor effects of doxorubicin loaded PEO-b-PCL polymersome in
mice.
Mice were inoculated with tumor cells on day 0, were administered drug (free dox,
dox loaded polymersome, or DOXIL) or PBS on day 7, and sacrificed on day 16.
Images of tumor bearing mice administered PBS (A) and DOX polymersomes at the
culmination of the study, day 16. (B); (C
(C–E)
E) Average tumor Volume vs. Time,
Tumor volumes of the 5 mice per group averaged. Error bars are reported as
standard error.
A bloodd sampled was drawn from each mouse and analyzed using a HEMAVET
(Figure 6.5).
). White blood cell ((WBC) count and neutrophil (NE) count
ount are slightly
elevated in control mice receiving PBS only, but similar for the mice administered DOX
in any form. Since WBC is a measure of the body’s response to cytotoxic agents, the
results demonstrate that all DOX treatments have the same level of systemic toxicity.
RBC counts,
s, HB, HCT and PLT values are similar for the various treatment groups.
groups
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Figure 6.5- The effect of different treatments on the red blood cell (RBC) count (A),
platelet (PLT) count (B), white blood cell ((WBC)
WBC) count (C), neutrophil (NE) count
(D), hemoglobin (HB) count (E), and hematocrit (HCT) (F).
n=5. Error bars= ±S.E.
The tails
ails and bodies of mice administered Doxil (cage 1) turned pink one day
after drug was administered (Figure 6.6A,B) while those
hose administered polymersomes
polymerso
(cage 4) (Figure 6.6C)
C) and PBS or free DOX were no
not nearly as pink. Pictures of the
mouse bodies and tails were taken two days after drug administration. Infected, oozing
and/or scabbing tails were observed on 3/5 of the mice receiving free DOX (cage 3)
(Figure 6.6A,B) while the tails of mice receiving DOX polymersomes
polymersome as a treatment
(cage 4) showed only slight signs of irritation (Figure 6.7C,D). Images were obtained at
the culmination of the study. It should be noted that mice some of the mice that received
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Doxil treated mice exhibited aggressive behavior and were difficult to handle in
comparison to the mice re
receiving
ceiving other treatments suggesting that DOX polymersome is
better tolerated than DOXIL.

Figure 6.6- Images of mouse bodies and tails two days after administration of (A, B)
Doxil and (C) DOX polymersome
polymersomes.
Images were taken two days after treatment.
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Figure 6.7- Images of mouse tails post free DOX treatment (A,B) and
DOXpolymersomes (C,D).
Images were taken at the culmination of the study.
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6.4.4 In vivo Theranostic Study Using Doxorubicin and Porphyrin Loaded PEO-b-PCL
Polymersome
This study married the two main goals of this thesis linking drug delivery with
imaging.

As described, mice were administered one of the following treatments:

doxorubicin-porphyrin polymersomes, porphyrin polymersomes, unloaded polymersomes
or free doxorubicin in PBS, all at the same concentration of drug (doxorubicin), imaging
agent (porphyrin), and polymer where applicable.
Figure 6.8 demonstrates the ability to track bioresorbable PEO-b-PCL vesicles
loaded with porphyrin in vivo using an Odyssey Imager with MousePOD Accessory. It
should be noted that there was considerable background on many of the images due to
residual dye on the skin or skin distress; when the skin is distressed, the laser light gets
trapped in the nicks of the roughened skin, and is detected erroneously as fluorescent
signal.
Similar to the imaging study described in Section 6.4.1 using biocompatible PEOb-PBD vesicles, fully bioresorbable PEO-b-PBD vesicles localize to the tumor within 12
hours, and clear over the course of 120 hours, with the greatest accumulation occurring
24-48 hours post administration. At 24 hours post vesicle administration, signal was
observed in vivo from 100% of the mice administered porphyrin vesicles and 75% of the
mice administered doxorubicin-porphyrin vesicles.

At 120 hours post vesicle

administration, signal is observed ex vivo from 100% of the tumors of mice administered
porphyrin vesicles and porphyrin-doxorubicin vesicles (Figure 6.10).

As expected,

excised tumors of mice administered PEO-b-PCL polymersomes without porphyrin only
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showed fluorescent
uorescent signal in the 700 channel (red) due to auto fluorescence, but did not
show any fluorescent signal in the 800 channel (green) ((Figure 6.10).

Figure 6.8- Representative fluorescent images of a mouse administered porphyrin
PEO-b-PCL vesicles.
Left hand panel: two color images showing 700 channel (red, auto fluorescence) and
800 channel (green, porphyrin po
polymersomes).
lymersomes). Right hand panel: Pseudo-colored
Pseudo
rendering of the 800 channel showing the intensity of the signal from various
organs. Top (890 to 5000), Bottom (370
(370-472). Top- supine position; BottomBottom prone
position. Pink arrow- liver; Cyan arrow: sple
spleen;
en; Yellow arrow: tumor.
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Figure 6.9- White light image of mouse shown in Figure 6.8.

Figure 6.10- Ex vivo imaging of tumors excised 120 hours post administration of
vesicles.
A) Two color images showing 700 channel (red, auto fluorescence) and 800 channel
(green, porphyrin polymersomes); B) Pseudo
Pseudo-colored
colored rendering of the 800 channel
showing the intensity of the signal from various tumors (Range 300-140).
300
Row ATumors excised from mice administered porphyrin PEO
PEO-b-PCL vesicles; Row BB
Tumors excised from mice administered porphyrin
porphyrin-doxorubicin
doxorubicin PEO-b-PCL
PEO
vesicles; Row C- Tumors excised from mice administered PEO
PEO--b-PCL vesicles
without porphyrin.
Vesicle accumulation in the spleen and liver is apparent in the images in Figure
6.8 and Figure 6.11A.
A. Vesicles are cleared by the kidneys as evide
evidenced
nced Figure 6.11A as
well as the fluorescence emanating from the mouse paws and underbelly (observed in
Figure 6.8);
); this results from residual fluorophore on the skin from the urine. Figure 6.11
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B and C demonstrate that the accumulation of vesicles in the tumor is heterogeneous and
most likely dictated by the blood vesicles or lack thereof in portions of the tumor. Note
that after 120
20 hours, a majority of the vesicles have been cleared from the tumor and have
localized to the organs of the RES. Note that there is minimal accumulation of the
vesicles in the heart (Figure
Figure 6.11). Figure 6.12B
B shows vesicles sequestered in the tail at
the site of injection, while Figure 6.12A
A shows the tail almost entirely cleared of vesicles;
this difference is probably caused by variability in the tail vein injections. It appears that
sequestering of vesicles in the tail is predominan
predominantly
tly observed when multiple injections (as
evidenced by multiple fluorescent sites) are required to deliver the volume of vesicles.

Figure 6.11- Pseudo colored images from fluorescence in the 800 channel emanating
from A) excised organs (clockwise: liver, lungs, spleen, kidneys, and tumor. Center
position: heart) B) sliced tumor and C) whole tumor.
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Figure 6.12- Excised tails from two different mice imaged ex vivo. Top tail shows
clearance of the vesicles, while the bottom tail shows considerable accumulation of
the vesicles in the tumor at the sites of injection.
Figure 6.13 shows the tumor volumes in millimeters cubed for the mice
administered the different treatments. It is clear that mice administered porphyrin only
vesicles had larger tumors than mice administered doxorubicin
doxorubicin-porphyrin
porphyrin vesicles up to
four days after treatment. The tumors of the mice administered porphyrin-doxorubicin
porphyrin
vesicles were on par with mice administered vesicles only and larger than the tumors of
mice administered free DOX after four days of treatment. This most likely results from
fro
the fact that at the start of the administration of treatment two populations of tumor sizes
were present—large
large and small. We used mice with tumors in the “large population” for
the imaging-drug
drug studies and mice with tumors in the “small population” for the control
studies (free DOX and vesicles only). As such, the growth potential for tumors in the
“small population” was much less than that of the tumors in the “large population.
Hence, although mice administered doxorubicin
doxorubicin-porphyrin
porphyrin vesicles had tumors
tum
that were
on par or greater than mice administered vesicles only or free DOX, respectively, this is
probably the result of different tumor sizes at the beginning of the study. Additionally,
the amount of drug administered was approximately 10% of that administered in the
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therapeutic study. At such a low concentration of drug, variability in the success of the
t.v. injection can also lead to a significant variation in the amount of drug delivered.
After five days, there is a great increase in the si
size
ze of the tumors of the mice
administered free DOX, while the size of those administered DOX in vesicles does not
increase nearly as much even though they were larger. This is possibly due to the fact
that the free drug is cleared much more rapidly from tthe
he tumor site than the vesicles.

4
Figure 6.13- Tumor Volume (mm3) for mice administered porphyrin PEO-b-PCL
PEO
Vesicles (blue diamonds), Doxorubicin
Doxorubicin-Porphyrin PEO-b-PCL
PCL Vesicles (red
squares), PEO-b-PCL
PCL Vesicles (green triangles), and Free Doxorubicin (yellow
circles).
Four mice per group, error bars are reported as ±SEM
Results from this study demonstrate the possibility that with an increased
dosage and tumors of the same size at the start of the study
study,, a dramatic difference in
tumor size between mice administered porphyin
porphyin-DOX
DOX vesicles and all other
treatments could be observed.
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6.5 CONCLUSIONS
We have shown that porphyrin PEO-b-PBD and PEO-b-PCL polymersomes can
be used to non-invasively track the location of polymersomes, and may potentially be
applied for diagnostic studies. Porphyrin polymersomes will greatly decrease the number
of animals required for biodistribution since the location of the polymersomes can be
determined without sacrificing animals at multiple time points to perform histology on
the excised organs. Furthermore, the localization of the vesicles in the tumor vasculature
was confirmed using intravital microscopy.
The ability of doxorubicin loaded PEO-b-PCL polymersomes to retard tumor
growth on par with DOXIL® (the clinically administered liposomal formulation of
doxorubicin) and better than free DOX was confirmed. Multi-functional polymersomes
loaded with doxorubicin and porphyrin were tracked in vivo for 120 hours and were able
to retard tumor growth in comparison to porphyrin polymersomes. Due to tumor size
variation at the start of the study, the porphyrin-doxorubicin PEO-b-PCL polymersomes
did not did not perform as expected.

However, based on overall polymersome

performance, it is believed that with minor modifications which will be discussed in
Chapter 7, multimodal polymersomes hold promised for theranostic applications.
The ability to load components into the polymersome membrane and core shows
enormous promise for dual modality polymersomes which will allow for the continuous
noninvasive monitoring of drug-loaded nanopolymersomes in vivo, obviating the need to
sacrifice animals at each time point to determine basic pharmacokinetic and
biodistribution profiles, thereby greatly reducing animal load. Hence, polymersomes
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hold enormous potential to be nanostructured biomaterials for future drug delivery and
imaging applications.
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Chapter 7
SUMMARY, MAJOR FINDINGS, AND SUGGESTED FUTURE
RESEARCH FOR THE DEVELOPMENT OF FULLY BIORESORBABLE
MULTI-FUNCTIONAL POLYMERSOMES
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7.1 SUMMARY
The ability to deliver systemically toxic pharmaceutical agents or hydrophobic
therapuetics with low bioavailability is a major challenge in treating malignancies.
Combination therapies, consisting of either two different small molecules or a
combination of small molecules and biologically active ligands, are currently used for the
treatment of various cancers;

thus, the capability co-administer and simultaneously

deliver them is of great importance. In addition to treatment challenges, noninvasive
diagnostic tools for the screening, diagnosis, and post treatment monitoring, are of
particular clinical interest. The ability to coencapsulate drug and imaging agent, enabling
the “imaging of drug delivery”, can greatly enhance exploration into various treatment
options and elucidate the efficacy of these treatments. Liposomes are presently used in
various biotechnological and pharmaceutical applications to improve therapeutic indices
and enhance cellular uptake [4], but it appears that polymersomes can offer superior
advantages for future clinical therapeutic and diagnostic applications.
In this thesis, I develop, characterize, and evaluate in situ, in vitro, and in vivo,
polymersomes (polymeric vesicles):
a) with the ability to co-encapsulate doxorubicin, a chemotherapeutic, and
combretastatin, a vascaular disrupting agent, for the co-administration of two
different therapeutics, creating a tool for the eradication of both tumorigenic
cells and vascular cells.
b) and with the ability to co-incorporate doxorubicin and porphyrin, a highly
hydrophobic near infrared fluorophore, for the capability to simultaneously
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image and deliver pharamacetuical agents, essentially creating a tool for
therapy and diagnosis.

7.2 MAJOR RESULTS

WITH

RESPECT

TO THE

AIMS DELINEATED

IN

CHAPTER 1
7.2.1 Aim 1: To load physiologically relevant molecules and imaging agents into the
polymersome and characterize release kinetics
Doxorubicin was successfully loaded into the PEO-b-PCL polymersome, as well
as polymeric vesicles compromised of other diblock copolymers. The different loading
parameters were explored and it was determined that loading DOX into PEO-b-PCL
vesicles could be accomplished using only an ammonium sulfate gradient, but the loading
of DOX into PEO-b-PBD and PEO-b-PmCL required the generation of a pH gradient as
well as an ammonium sulfate gradient. This difference in loading environment was
attributed to the differences in hydrophobicity between the different hydrophobic
backbones. Combretastatin incorporation into PEO-b-PCL vesicles was also established.
The insight gained from loading doxorubicin into these polymeric vesicles,
enabled the successful encapsulation of doxorubicin into combretatstatin incorporated
vesicles and into porophyrin encapusulated vesicles. Similar to the encapsulation of
DOX into PEO-b-PBD and PEO-b-PmCL vesicles, these encapsulations required the use
of both a pH and ammonium sulfate gradient.
Doxorubicin release kinetics from the various vesicles and co-encapsulations was
characterized. The cumulative release of drug from the vesicles interior occur though the
diffusion of the amphiphilic molecule across the vesicle membrane and by degradation of
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the hydrophobic backbone of the vesicle. These release mechanisms depend upon both
the pH of the external solution and the polymer and hydrophobic encapsulant
composition of the vesicles. The

successful

co-encapsulation

of

DOX

and

combretastatin lead to the generation of a polymersome with the potential to treat tumors
by affecting both the vasculature and tumor cells. The encapsulation of DOX into
porphyrin incorporated vesicles lead to the creation of vesicles with therapeutic and
diagnostic capabilities.
7.2.2 Aim2 Load Doxorubicin into the Aqueous Core of Dendrosomes
Doxorubicin was successfully encapsulated into the aqueous core of
dendrosomes, vesicles self-assembled from various amphiphilic Janus-dendrimers. Due
to stability issues of the dendrosomes at low pH, doxorubicin was not actively loaded
across a gradient as it was for the case of polymersomes, but rather it was loaded
passively by incorporation in the hydration solution. Release studies were performed and
show a significantly higher release of drug at acidic pH than at physiological pH. Drug
release was observed to vary depending on both pH of the external solution and
dendrosome library.
The toxicity of the dendrosomes was evaluated in vitro on human umbilical vein
endothelial cells (HUVECs) using Cell Titer-BlueTM. The results indicate only minimal

toxicity as compared to polymersomes after four hours of incubation with vesicles.
The results of dendrosome studies establish their the potential use as of selfassembled dendrimeric vesicles for drug delivery purposes
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7.2.3 Aim 3: To study the in vitro effects of functional polymersomes using HUVECs
and SK-BR-3 tumorigenic cells
The effects of PEO-b-PCL vesicles on HUVECs and SK-BR-3 cells were
examined separately. It was determined that the HUVECs incubated with PEO-b-PCL
polymersomes remain 50% viable after 72 hours, even when incubated at the high
concentration of polymer. At short times, SK-BR-3 cells appear to tolerate the PEO-bPCL polymersomes, with viability as great as 50% after 12 hours. However toxicity is
observed at longer times, where after 72 hours only 50% of cells cultures in the lowest
polymer concentration are viable.
The cellular uptake of PEO-b-PCL by HUVECs and SK-BR-3 cells was
determined using porphyrin polymersomes. The uptake of vesicles by these cell types was
established over 5 hours and it was determined that the uptake is dependent upon both
vesicles concentration and incubation time.
Lastly, the cytotoxic effects of drug loaded polymersomes on cell viability were
investigated with cells cultured both separately and in co-culture. In general, toxicity was
a function of both drug concentration and incubation times. Preliminary co-culture assays
suggest that cells in co-culture appear to be less adversely affected initially by the drug
loaded vesicles.
These in vitro experiments establish the potential of using polymersomes loaded
with doxorubicin and combretastatin for the simultaneous (and independent) destruction
of tumorigenic and endothelial cells.
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7.2.4 Aim 4: To demonstrate the in vivo potential of polymersomes for imaging and
drug delivery applications using athymic nude mice with xenograft tumors
Using NIR-emissive porphyrin PEO-b-PBD polymersomes, the biodistribution of
vesicles was determined both at short times (up to 12 hours) and at long times (up to 9
days) using the eXploreOptix GEArt and LI-COR Odyssey, respectively. These studies
demonstrate accumulation of vesicles at the tumor site within 4 hours, with the greatest
accumulation after 24 hours. Furthermore, localization of the vesicles with the spleen
and liver were observed in vivo and ex vivo studies also demonstrate accumulation in the
kidneys and lungs. Subsequent studies carried out using NIR-emissive porphyrin PEO-bPCL polymersomes show similar results.
The anti-tumor effects of doxorubicin loaded PEO-b-PCL polymersomes on
tumor suppression in vivo were demonstrated using metrics such as tumor volume and
mouse weight.

Athymic nude mice were administered one of four treatments

(doxorubicin polymersomes, DOXIL®, unencapsulated doxorubicin, and PBS) and it was
determined that the DOX polymersomes was able to retard tumor growth in mice as well
as DOXIL®, and better than free DOX. Furthermore, physical behavioral disposition of
the treated mice, suggested that the polymersome may be a superior delivery vehicle for
the drug.
The potential to image drug delivery through the use of multi-functional
doxorubicin loaded porphyrin incorporated PEO-b-PCL polymersomes was highlighted.
Mice were administered one of four treatments (DOX-porphyrin polymersomes,
porphyrin polymersome, unloaded polymersomes, and free DOX). While the results of
the study are not nearly as promising as was desired, the study does demonstrate the
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ability to use bioresporbable vesicles loaded with drug for imaging and treating tumors
highlighting their potential for theranostic applications.

7.3 SIGNIFICANCE OF RESULTS
Through preliminary developmental studies, multi-drug loaded PEO-b-PCL and
multi-functional PEO-b-PCL polymersome were successfully generated. These multidrug loaded vesicles demonstrate potential utility for combination therapies where the
simultaneous co-localization of the drug is imperative for effective therapy, for example
when administering a vascular disrupting agent and a chemotherapeutic. If the antivascular agent is administered prior to the chemotherapeutic, the chemotherapeutic may
never reach the tumor site because of vasculature disruption.

The multi-functional

porphyrin-doxorubicin PEO-b-PCL polymersome enables the drug loaded vesicles to be
tracked in vivo. This novel ability is believed to prove exceedingly useful for monitoring
therapeutic outcomes of after administration of therapy. In addition, this combination
vesicle will greatly assist in drug biodistribution studies where the number of animals
required can be greatly reduced since location of the drug over time can be tracked
fluorometrically, obviating the need to sacrificing multiple animals at various time points
for histological assessment on the excised organs.

7.4 FUTURE WORK
OF

A

AND

CLINICALLY

INVESTIGATIONS TOWARDS
RELEVANT

THE

DEVELOPMENT

FULLY-BIODEGRADABLE

MULTI-

FUNCTIONAL POLYMERSOME FOR IN VIVO THERANOSTIC APPLICATIONS
As demonstrated throughout this thesis, bioresorbable polymersomes hold
considerable promise to be clinically relevant nanoparticles for the simultaneous delivery
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of dual therapeutics and imaging agents. However, a few key modifications to the
vesicles would enhance their clinical utility. Furthermore, additional experimentation is
required to bring theses nanoparticles from bench to bedside. This section will highlight
additional experiments deemed necessary to demonstrate the clinical applicability of
multi-modality vesicles, future surface modifications to the vesicles, and suggest
additional changes to experiments already performed.
7.4.1 Suggestions to Enhance Experiments Investigating the Anti-vasculature and
Anti-tumor Potential of Combretastatin and Doxorubicin Loaded PEO-b-PCL
Polymersomes on HUVECs and SK-BR-3 Cells in Co-culture
As discussed in Chapter 5, considerable sticking was observed when carrying out
stained co-culture cell viability assays to determine the effects of doxorubicin and
combretastatin separately or together on co-cultured cells.

At the time of the

experimentation, the dual color staining of cells using CellVue® stains from MTTI
appeared to be a proper course of action for these preliminary experiments. However,
post experimentation, considerable cell sticking was observed with HUVECs. It was
determined that this sticking increases as the amount of time the nonviable cells remain in
the wells increases; thus yielding false positive results (i.e. nonviable cells appear viable).
A dual-color fluorescence imaging based assay [38, 134], appears to be a
promising alternative to the current assay. In this assay, one type of cells in the coculture, the tumorigenic cells for example, will be transfected and selected such that they
express green fluorescent protein (GFP). The co-culture, comprised of HUVECs and
tumorigenic cells, will be exposed to the various polymersome treatments for a defined
period of time. After administration of drug-loaded polymersomes, the cells will be
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treated with propidium iodide to stain the nuclei and analyzed by dual-fluorescence
confocal microscopy to determine the extent of treatment efficacy by examining the
vascular network and survival of the tumor cells.
In addition to the dual-color fluorescent microscopy assay detailed above, if the
morphological markers of cell death vary between the cell types, investigating
morphological markers can be used to ascertain difference in cellular viability between
each cell type. In addition, the upregulation of various cellular markers on the cell can be
examined to further determine the cellular viability of each cell type.
Additionally, it may be advantageous to co-culture the endothelial and
tumorigenic on cells a three-dimensional Matrigel, as this will simulate the tumor
environment better than cell culture plates.
7.4.2 Suggestions for Future Surface Modifications to the Vesicles for Enhanced
Therapeutic and Diagnostic Efficacy and Related Experiments
Tumor vasculature varies greatly from that of normal tissues. The endothelial
cells lining the vessels of solid tumors, where angiogenesis is prevalent, upregulate αv
integrins, as well as receptors for various angiogenic growth factors [135].

These

proteins, however, are not present or are present at very low levels in established normal
blood vessels [135]. Thus, peptides directed at these upregulated proteins are good
targets for cancer therapeutics. Ruoslahti and colleagues showed that upregulated αvβ3
integrins on tumor vasculature are active, available for binding by circulating RGD
ligands, and expressed at levels sufficient for tumor targeting[135, 136]. Furthermore, αv
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integrins are expressed on many human carcinoma cells as well as tumor vasculature
[135].
Peptides for homing to tumors (that can direct therapeutics to the tumor site) can
enhance therapeutic efficacy and minimize adverse side effects [137]. This idea of
enhanced therapeutic index with tumor-homing peptides was examined by Ruoslahti and
coworkers who conjugated doxorubicin to an RGD peptide and administered the
conjugated drug and free drug to nude mice with human tumor xenografts [135]. In
addition to increased survival rate and decreased tumor size, nude mice treated with the
dox-RGD conjugates exhibited less cardiac and liver toxicity than those treated with free
DOX [135].
This data suggests that decorating the PEO brush surface of the fully-bioresobable
polymersome loaded with combretastatin and doxorubicin with an RGD peptide capable
of targeting tumor vasculature as well as cancer cells would enhance the localization of
the vesicles at the tumor site and ultimately improve therapeutic efficacy.
Peptides targeting upregulated αv-integrins can be conjugated to the PEO brush of
the polymersome via various covalent and modular chemistries. Currently, Joshua Katz
(Hammer and Burdick Laboratories) is working on the ability to functionalize the
polymer chain ends through amidation chemistry, where by the amine of the peptide is
conjugated to a carboxylic acid at the end of the PEO block to form an amide bond.
Furthermore, the biotin-avidin binding represents a method of modular chemistry for
peptide conjugation. A biotin molecule is attached to the PEO brush of the polymersome
surface and an additional biotin molecule is attached to the end of the peptide. The
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biotinylated polymersome and the biotinylated peptide are joined by an avidin molecule
[21]. It should be noted that the attachment of peptides to the vesicle surface has been
previously attempted by P. Peter Ghoroghichian [53] with limited success in maintaining
vesicular structure with peptide attachment. This is likely because the conjugation of
ligands to the polymersome surfaces can alter the composite polymer amphiphiles’
hydrophilic-block-to-total-mass ratio leading to a change in structural morphology (e.g.
from vesicles to micelles) [132]. Hence peptide attachment to polymer vesicles should be
confirmed using both cryo-TEM, to images the vesicles, and well as fluorescence
microscopy to confirm the presence of an aqueous reservoir.
Once peptide attachment to vesicles is confirmed, Enzyme-linked Immunosorbent
Assay (ELISA) can be performed to ensure binding of the RGD peptide-conjugated
polymersome with αv integrins and to determine binding properties of the αv integrin to
the conjugated polymersome.

Equilibrium binding of the RGD peptide-conjugated

polymersomes to purified αv integrins will be examined using an ELISA assay. RGD
peptide-conjugated polymersomes, scrambled RGD peptide-conjugated polymersomes,
and non-conjugated polymersomes will each be mixed with purified αv integrins. After
integrin binding, the sample will be purified to remove unbound integrin, and an antibody
for the integrin (but not function blocking) will be added to each sample. Again the
sample will be purified once binding had occurred. Lastly, a secondary antibody linked
to an enzyme such as horseradish peroxidase (HRP) will be added and allowed to bind to
the anti-integrin antibody.

The sample will be purified, and the enzyme will be

developed using a substrate solution.

After a period of time, the reaction will be

quenched and absorbance readings will be determined using an ELISA reader [53].
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Higher absorbance values will be seen with increased enzyme in sample, thus correlating
to increased integrin-RDG peptide binding.
Once these in vitro studies are completed, further in vivo work to demonstrate
increased therapeutic outcomes as well as increased localization to the tumor site are
necessary. Anti-tumor potential of the peptide-decorated drug loaded polymersomes can
be assayed as a measure of tumor volume and mouse survival. The localization of these
peptide conjugated vesicles can be demonstrated through vesicle tracking with the
porphyrin fluorophore as shown in Chapter 6.
These enhancements and confirming studies can lead to the generation of a fullybioresorbable vesicle with potential to directly and simultaneous effect tumor cells and
the endothelial cells which grow up to support their existence.
7.4.3 Suggestions for Future Work and Experiments to Enhance In Vivo Component
of this Thesis
Through the work described in this thesis, considerable advancements have been
made in marrying the drug delivery and imaging applications of polymersomes.
However, there are still challenges which must be overcome. First and foremost, the
sizing of the vesicles is an extremely labor and time intensive task and a system to
automate the extrusion process is essential if vesicle preparation is to be scaled up for
clinical use.
In addition, the loading efficiency of DOX, when loaded into porphyrin
incorporated vesicles, must be further enhanced and better controlled so that a substantial
amount of drug can be delivered to the tumors. Currently, the loading is quite poor and
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as such, only 1% of the dose deliver in the Therapeutic Studies was delivered in the
Theranostic Studies. The addition of a targeting agent to the vesicle should enhance the
localization of vesicles to the tumor site, decrease systemic delivery of the drug, and
thereby increase the amount of drug delivered to the tumor. Once the loading efficiency
of DOX in porphyrin-incorporated vesicles has been increased, the Theranostic Study
described in Chapter 6 should be repeated as the potential to demonstrate the “imaging of
drug delivery” has been demonstrated, and could be confirmed with an increase in drug
concentration at the tumor site.
As eluded to in Chapter 6, it is envisioned that the bioresorbable vesicles
generated from PEO-b-PCL diblock, might be able to link changes in fluorescence not
only to the clearance of the vesicle, but also to degradation of the vesicle. While PEO-bPBD vesicles are biocompatible, they are not known to be biodegrable. Thus, changes in
fluorescence associated with the non-degradable PEO-PBD vesicles, would provide
information about biodistribution and in vivo clearance of the vesicles while changes in
fluorescence of the degradable PEO-PCL vesicles should provide information about
clearance and biodistribution, as well as vesicle breakdown and subsequent drug delivery.
Data in Chapter 4 demonstrated a decrease in porphyrin fluorescence as doxorubicin is
released from the vesicle interior.

To carry out this experiment, mice should be

administered, PEO-b-PBD and PEO-PCL vesicles with porphyrin incorporated into the
bilayer. The in vivo fluorescence should be tracked over time, and organs examined for
fluorescence upon culmination of the study to determine vesicle location and breakdown.
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Once these studies establish the ability to demonstrate vesicle degradation in vivo
through changes in fluorescence, the drug delivery component should be added by
administering doxorubicin loaded vesicles in both the biocompatible and biodegradable
formulation. Post treatment, tumor volumes and fluoresce should be monitored in vivo at
regularly established time points. At the culmination of the study, organs should be
harvested and fluorescence measured.

In addition to imaging whole organs for

fluorescence signal from the porphyrin in the vesicles, these tumor should be sectioned,
and sections should imaged for both DOX florescence [28] and porphyrin fluorescence.
Ex vivo imaging of visible fluorophores is possible at sub-millimeter depths [114]. These
studies will assist in fully capturing the essence of polymersomes for imaging drug
delivery.
Lastly, in an effort to further develop multi-drug vesicles for clinical in vivo
applications for the simultaneous delivery of drug to two different cell types, namely
endothelial cells and tumorigenic cells, once clearance is granted for in vivo studies, in
addition to demonstrating increased tumor suppression when combretastatin is delivered
in combination with DOX, the tumor vasculature post delivery of the VDA should be
examined. Mice should be administered chemotherapeutic vesicles with and without
combretastatin, as well as blank vesicles to compare the therapeutic effects of the dual
drug loaded vesicles against single drug vesicles and control (non-drug loaded) vesicles.
Tumor volumes should be monitored daily, and mouse weights recorded every other day.
At the culmination of the study, prior to sacrificing mice, if possible, mice should be
administered Angiosense 680 IVM and the tumor vasculature examined using the
Olympus IV-100 described in Chapter 6 for invasive in vivo examination of the tumor
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vasculature. Once the vasculature dye has cleared, the mice should be sacrificed, tumors
harvested, sectioned, and stained for vWf, CD34, CD31, which are known markers of
blood vessels in order to get a better understanding of the effects of combretastatin on
tumor vasculature.

7.5 CONCLUDING REMARKS
Considerable progress was made in establishing the utility of polymer vesicles for
drug delivery and diagnostic applications. In vitro work was performed to characterize
the effects of these vesicles on endothelial and tumorigenic cells. However, the ultimate
experiments in establishing the significance of these vesicles in clinical biological
applications were performed in vivo through collaboration with Dr. Murali. For future
clinical use of the theranostic polymersomes, however, the efficiency of loading
doxorubicin into porphyrin vesicles must be greatly enhanced, so that a significant dose
of drug can be delivered to the tumor site. Furthermore, to fully realize the potential of
multi-drug vesicles, the attachment of a vascular homing peptide to target the vesicles to
the tumor would probably enhance therapeutic efficacy of the drug loaded vesicles. As a
final permutation, to provide both dual therapeutic action as well as imaging capability, a
vascular targeting peptide with known therapeutic value could be attached to the PEO
brush surface of doxorubicin-porphyrin PEO-b-PCL vesicles, enabling the simultaneious
imaging of drug delivery to both endothelial and tumorigenic cells.
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